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Abbreviations 
 
A2780  a human ovarian carcinoma cell line 
A2780R cisplatin-resistant human ovarian carcinoma cell line 
A498  a renal cancer cell line 
Boc  tert-butoxy carbonyl 
CD  circular dichroism 
CDCl3  chloroform 
CDDP  cisplatin 
cHpz  cis-dichloro(isopropylamine)(pyrazole)platinum(II)  
CH1  ovarian carcinoma cell line 
CH1R  resistant ovarian carcinoma cell line 
cMeim  cis-dichloro(isopropylamine)(1-methylimidazole)platinum(II) 
cMepz  cis-dichloro(isopropylamine)(1-methylpyrazole)platinum(II) 
CT DNA calf thymus DNA 
d  doublet 
dach  diaminocyclohexane 
DMEM Dulbecco's Modified Eagle Medium 
DMF  dimethylformamide 
DMSO  dimethylsulfoxide  
DPP  differential pulse polarography 
D2O  deuterium oxide 
edta  ethylendiaminetetraacetate 
EtBr  ethidium bromide 
exc  excess 
EVSA-T a breast cancer cell line 
FAAS  flame atomic absorption spectroscopy 
GMP  guanosine 5’-monophosphate 
GSH  glutathione 
H226  non-small cell lung cancer 
HMG  high-mobility group 
HPLC  high performance liquid chromatography 
HPMA  N-(2-hydroxypropyl)methacrylamide 
Hpz  pyrazole 
HSC  hepatic stellate cells 
IGROV an ovarian cancer cell line 
ICL(s)  interstrand cross-link(s) 
iPram  isopropylamine 
IR  infrared spectroscopy 
KCs  kupffer cells 
LCMS  liquid chromatography and mass spectrometry 
M19  a melanoma cell line 
M6P-HSA mannose 6-phosphate human serum albumin 
m  multiplet 
MCF7  a breast cancer cell line 
Meim  1-methylimidazole 
Mepz  1-methylpyrazole 
MS  mass spectrometry 
MT  metallothionein 
7 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide 
NMR  nuclear magnetic resonance 
PAM 212 murine keratinocytes cell line 
PAM212-ras transformed murine keratinocytes cell line overexpressing the H-ras oncogen 
PBS  phosphate buffered saline 
ptx  pentoxifylline 
quint  quintuplet  
RF  resistant factor, IC50 (resistant cell line)/IC50 (parent cell line) 
SECs  sinusoidal endothelial cells 
SRB  sulforhodamine B 
sbr  broad singlet 
sept  septuplet 
Su  succinimide 
sx  sextuplet 
t  triplet 
TAE  tris-acetate/edta buffer 
TEAA  triethylammonium acetate 
TDDP  trans-diamminedichloroplatinum(II), transplatin 
Tris  tris(hydroxymethyl)aminomethane 
tHpz  trans-dichloro(isopropylamine)(pyrazole)platinum(II) 
tMeim  trans-dichloro(isopropylamine)(1-methylimidazole)platinum(II) 
tMepz  trans-dichloro(isopropylamine)(1-methylpyrazole)platinum(II) 
UV  ultraviolet 
WIDR  a colon cancer cell line 
XL  number of interstrand cross-links per one molecule of the linearized DNA 
duplex 
σ  superhelical density of the plasmid DNA 
Φ unwinding angle 
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1.1 Cancer 
Malignant tumors are a major cause of mortality all over the world. Although great strides 
are currently being made in unraveling the molecular, cellular, and genetic processes that give 
rise to cancer, this knowledge has not been translated into effective new cures for the disease.1 
Cancer is based on the uncontrolled growth of the affected cells in an organism, overrun and 
damage tissues and organs.  At the most simple level, it can be considered that cancer cells 
have lost contact with their environment, which means they do not respond to the control 
signs and interactions that normally take place in healthy tissue.2 Advances in detection, 
surgery, radiotherapy and chemotherapy are needed to improve the curability of cancer. 
Chemotherapy was first defined by Paul Ehrlich (Nobel Prize in medicine in 1908). 
Introduction of the classical alkylating agents and antimetabolites to the clinic led to a marked 
improvement in the treatment of lymphomas and leukemias. A great variety of many different 
drugs possessing different spectra of activity is currently used in the treatment of cancer. This 
PhD thesis is focused on the treatment of cancer and on the development of new drugs based 
on cisplatin and its analogues.   
 
1.2  Discovery and use of cisplatin 
Cisplatin (cis-diamminedichloroplatinum(II), CDDP) was chemically described in 1845,3 
but its antitumor properties were only found accidentally by Rosenberg in 1965.4,5 While 
investigating the influence of an electric field on the growth of the E.coli bacteria, Rosenberg 
found that cells stopped dividing and displayed strong filamentous growth. This phenomenon 
appeared to be caused by the presence of small amounts of compounds, like cis-[PtCl4(NH3)2] 
and cis-[PtCl2(NH3)2], formed by slowly dissolving Pt electrodes in the ammonium chloride 
electrolyte.6 Following this discovery a large number of platinum complexes were tested for 
their antiproliferative effect. The complexes having cis geometry were found to be antitumor 
active and cisplatin the most active. The trans isomer of cisplatin, transplatin, showed no 
antitumor activity.7 The structures of cisplatin and transplatin are shown in Figure 1.1. 
 
 
Figure 1.1. Structure of the antitumor drug, cisplatin, and its inactive trans isomer, transplatin. 
Cisplatin successfully entered into clinical trials in 1971,8 the first clinical test was 
performed by Hill et al. and was approved by the United States FDA in 1978. Cisplatin is 
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routinely used in the clinic, appearing the most effective against testicular and ovarian 
cancer.9-11 The response rates of other solid malignances, such as head, neck, small-cell lung, 
oesophageal, can be improved with cisplatin treatment, although this effect appears to be 
temporary.12 In combination with other antitumor drugs, such as vinblastine and bleomycin, a 
synergistic effect has been achieved. With testicular cancer, when recognized in an early 
stage, curing rates exceed 90 %. 
Common problems associated with cisplatin in the clinic include nephrotoxicity, 
ototoxicity and myelosuppresion.13-15 Procedures such as forced diuresis16-21 and 
pharmacological interventions with S-containing chemoprotectants22,23 have helped to 
alleviate the dose-limiting nephrotoxicity. In addition to the serious side effects, inherent or 
treatment-induced resistant tumor cell sub-populations also limit the therapeutic efficacy of 
cisplatin (details of the mechanism are discussed in section 1.5).24,25 These toxic side effects 
of cisplatin limit the dose that can be administrated to patients; typical doses are 100 mg/m2, 
which is usually given at a three-weekly schedule.26  
The most significant advantage in obviating the side effects of cisplatin has come from the 
process of analogues development, i.e. the search for structural analogues of cisplatin that 
fulfill one or all of the next criterions: 
1. Development of new selectivities, including an activity spectrum wider than 
cisplatin and, especially, activity in cisplatin-resistant tumors. 
2. Modification of the therapeutic index, that is to say, a higher clinic efficacy to 
reduce toxicity, with activity at least in the same range as cisplatin. 
3. Modification of the pharmacological properties, such as solubility, which 
could result in improved ways of administration. 
 
1.3  Structure-Activity Relationship (SAR) 
The ligand exchange kinetics of Pt compounds is largely determined by the nature of the 
leaving groups (i.e. the group that first leaves the Pt under the used reaction conditions). 
Complexes with strongly coordinating leaving groups do not have antitumor activity, also 
very weakly coordinating leaving groups do not lead to high activity.27,28 This inactivity can 
be caused by either the low reactivity or the very high reactivity of these compounds. In 
addition, the trans effect of the strongly coordinating group would cause the release of the 
amine ligand. Pt complexes with weakly coordinating ligands are not active, because they 
show too much reactivity, the most probable being a rapid reaction with other intracellular 
components (see section 1.5).  
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The nature of the non-leaving groups also influences the reactivity of platinum 
compounds. For drugs of general formula cis-[PtCl2(amine)2] with several ligands as non-
leaving groups have shown antitumor activity. These can be monodentate ligands (NH3) or 
didentate ligands, like diethylenediamine (en) or diaminocyclohexane (dach). The activity of 
the platinum complexes decreases along the series NH3>RNH2>R2NH>R3N (R is an alkyl 
subtituent).29 Steric hindrance and hydrogen-bonding ability of the ligands are important 
factors in determining the reactivity.30 The amines can act as hydrogen donor to the O6 atom 
of a guanine and to a 5’ phosphate group in DNA, thus stabilizing Pt-G binding.31 These 
interactions are important for the thermodynamics (by stabilizing the Pt-d(pGpG) adduct) and 
for the kinetics of the reaction (by driving the Pt complex to the N7 of guanine). So all these 
observations resulted in a list of requirements for the structure of platinum complexes 
exhibiting antitumor activity, the so-called Structure Activity Relationships (SARs):  
 
1. A cis geometry is required with the general formula cis-[PtX2(amine)2] for 
Pt(II), and for Pt(IV) the formula cis-[PtX2Y2(amine)2]. Monofunctional 
binding cationic complexes are inactive. 
2. The X ligands (leaving groups) should be of intermediate strength (Cl-, SO42-, 
carboxylate ligands). For Pt(IV) complexes the Y ligands should have a trans 
orientation and can be Cl-, OH-, or [O(CO)CnH2n+1]-. 
3. The non-leaving group amine ligands should contain at least one NH moiety, 
necessary for hydrogen-bonding interactions with DNA (H-bonding to the O6 
of guanine and to the 5’ phosphate group). 
 
1.4  New platinum drugs 
As mentioned in section 1.2, the design and synthesis of more effective and less toxic 
platinum complexes constitutes a broad area of research with the aim of overcoming the 
problems associated with cisplatin in chemotherapy.32 Toxicity can be decreased by 
exchanging the labile chloro ligands for comparatively more stable didentate leaving groups, 
thereby slowing down the hydrolytic activation of the drugs.33 Cleare and Hoeschele, who 
summarized the structure-activity relationships, demonstrated that the diaqua form of cisplatin 
is highly toxic and that toxicity decreases by decreasing the lability of the leaving ligand, 
while more stable didentate leaving ligands can still give rise to active complexes and activity 
is only lost when very tightly bound ligands are used.34 When the chloride leaving groups are 
substituted by more stable ligands, such as 1,1-cyclobutanedicarboxylate, the renal effects are 
decreased, while the antitumor activity remains.35 Three of the “second-generation” platinum 
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drugs fulfilling the requirements mentioned above are currently used in cancer chemotherapy: 
carboplatin, nedaplatin and oxaliplatin, Figure 1.2.33  
Cis-diammine-1,1-cyclobutane-dicarboxylatoplatinum(II) (carboplatin),36 the most 
successful of these second-generation platinum complexes,  and cis-diammine(glycolato)-
platinum(II) (nedaplatin)37 are cisplatin derivatives that show less renal and gastrointestinal 
toxicity than cisplatin as well as reducing the nephrotoxicity and vomiting.36-38 Carboplatin 
has gained worldwide approval and steadily increasing acceptance as a less toxic alternative 
to cisplatin, while nedaplatin has received only limited regional approval.33  
Changing the ammines of carboplatin for dach results in (1R,2R-diaminocyclo-
hexane)oxalatoplatinum(II), (oxaliplatin, l.OHP), Figure 1.2. This compound was first 
reported in Japan;39,40 and entered the clinic in France.41 It has been approved for secondary 
treatment of lung and ovarian cancers and it is first line combination therapy for colon cancer. 
It shows a different range of activities compared with cisplatin,42 and it overcomes cisplatin 
resistance, i.e it is active in cisplatin-resistant cell lines.43 
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Figure 1.2. Structure of antitumor drugs in clinic, carboplatin, nedaplatin and oxaliplatin. 
 
Cisplatin and all the “second-generation” drugs are administrated by intravenous injection 
or infusion. Orally available drugs would give higher flexibility in the dosage and this could 
increase the potential for the use of platinum drugs. For cisplatin oral administration is not 
possible, due to its low levels of absorption.44  
 
1.5 Mechanism of action 
1.5.1 Uptake of cisplatin in the cell 
Although a variety of known carrier-mediated transport systems influence cellular 
accumulation of cisplatin, there is little evidence for an active carrier-mediated uptake 
mechanism.1 Because cisplatin accumulation is neither saturable, nor competitively inhibited 
by structural analogues, it has been suggested that the drug enters in the cell through passive 
diffusion.45-48 Involvement of high-capacity facilitated diffusion via gated channels has been 
also proposed,49 but the steric demands of cisplatin prohibit entrance through most of the 
Chapter 1 
14 
well-characterized ion channels. Recently it has been reported that the copper transporter Ctr1 
is involved in the uptake of cisplatin, since it has been demonstrated that deletion of the yeast 
homologue of the Ctr1 gene, which encodes a high-affinity copper transporter, results in 
increased cisplatin resistance and reduces the intracellular accumulation of cisplatin.50,51 
Once cisplatin enters the cell, where the chloride concentration is much lower than in 
plasma (~ 4 mM) the drug undergoes hydrolysis to form positively charged active species for 
subsequent interaction with cellular nucleophiles.52 The ultimate target for cisplatin inside the 
cell is DNA. The exact interaction mode between cisplatin and DNA and the cellular 
distribution are not known yet. However, inside the cell there are many competitors for DNA 
binding present, as well as in the nucleus, such as small molecules and ions which compete 
for cisplatin binding [Cl-, (HPO4)2-, OH-, H2O], amino acids, peptides, proteins, and 
polyphosphates.31,53,54 Pt-protein binding is thought to play an important role in the toxicity 
and the mechanism of cisplatin-resistance; this will be discussed in section 1.6. 
 
1.5.2 DNA binding 
Because platinum belongs to the group of “B”-type metals, its ion reacts preferentially 
with N atoms rather than O atoms. In fact, the preferred binding site in DNA is the N7 atom 
of purines nucleobases.50,55 At physiological pH the N3 atom of thymine is protonated, the N3 
of purines are sterically hindered and aromatic nitrogens without a σ lone pair are excluded 
for platinum coordination. The N1 of adenine and the N3 atom of cytosine are suitable 
positions for platinum binding. In Figure 1.3 a scheme with all the potential binding positions 
is represented. All four positions can be platinated, but the preferred binding step is the N7 
atom of guanine, which shows a strong kinetic preference.31,54 This tendency results from the 
strong basicity of that position and from hydrogen bond interactions between ammine protons 
of cisplatin with O6 in guanine and their accessibility for the platinum complexes.30 
The reaction of cisplatin with DNA leads to the formation of six major categories of 
Pt-DNA adducts, the most important ones schematically depicted in Figure 1.4. The major 
adduct formed by cisplatin was found to be the 1,2-intrastrand d(GpG) cross-links on adjacent 
purine bases, followed by  1,2-intrastrand d(ApG) cross-links between an adjacent adenine 
and guanine, 1,3-intrastrand d(GXG) and 1,4-intrastrand d(GXXG) cross-links between 
purines separated by one or two intervening bases, respectively. A small percentage of 
cisplatin was found to be involved in interstrand cross-links, linking the two strands of the 
DNA double helix, or in monofunctional adducts coordinated to a single purine and protein-
DNA cross-link, in which cisplatin coordinates a protein molecule and a nucleobases.56-61  
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Figure 1.3. Possible platinum binding sites on DNA. 
 
The consequences of these cross-links to the cell and how they lead to cell death are 
largely unknown. Results to date, obtained in numerous cell lines, suggest that cisplatin-
damaged DNA causes cell cycle perturbation, and arrest in the G2-phase to allow repair of the 
damage, and in the case of inadequate repair, the cells eventually undergo an abortive attempt 
at mitosis that results in cell death via an apoptotic mechanism.61-64  
Transplatin is not able to form 1,2-intrastrand cross-links, because of the steric 
hindrance of the two ammine groups in trans position; instead it may form 1,3-intrastrand 
cross-links between two G residues, or between a G and a C residue, separated by at least one 
base. The amount of monofunctional adducts and protein-DNA cross-links formed is much 
higher for transplatin than for cisplatin. Another difference between the two isomers is that 
interstrand cross-links formed by transplatin are between complementary G and C residues, 
whereas cisplatin forms only G interstrand cross-links.65 It was reported that under 
physiological conditions the major adducts are the monofunctional adducts, allowing the 
formation of protein-DNA cross-links. In vivo transplatin interstrand cross-links might not 
form because of the slow rate (t1/2 ≈ 24 hr) of the cross-linking reaction, and the trapping of 
the monoadduct species by thiol-containing proteins.66,67 
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 Figure 1.4. Main adducts formed in the interaction of cisplatin with DNA. (a) 1,2-intrastrand 
cross-link; (b) 1,3-intrastrand cross-link; (c) interstrand cross-link; (d) protein-DNA cross-link 
(Figure modified from ref1). 
 
1.5.3 3D structures of Pt-DNA adducts 
DNA binding of platinum complexes is considered to be responsible for their 
cytotoxic effect. DNA containing platinum-DNA adducts is structurally distorted with respect 
to normal B-DNA, resulting in a loss of helix stability. The structural aspects of DNA-binding 
platinum complexes have been studied, using NMR spectroscopy,68-72 X-ray 
crystallography,73-75 and gel electrophoresis.76  
The 1,2-intrastrand GG adduct of cisplatin (Figure 1.5). This is the most stable and 
abundant DNA adduct of cisplatin. The local conformational aspects of this DNA adduct are: 
(i) Bending of the duplex with a kink of 40-70º towards the major groove. All the 
complementary base-pairing interactions, even within the G-C base pairs directly involved in 
the Pt-binding, remain intact, (ii) The conformation of the 5’ sugar shows a change from the 
C2’ endo (S) conformation, normally found in B-DNA, to a C3’ endo (N) conformation 
common in A-DNA, (iii) Unwinding of the helix by about 20º. This unwinding is 
accompanied by compression of the minor groove. 
The 1,3-intrastrand adducts of cisplatin and transplatin. An early NMR study77 
showed that the duplex in the cisplatin 1,3-intrastrand d(GXG) adduct is more distorted than 
in 1,2-d(GG) adduct. The 5’G is reported to adopt an N-type conformation and the central 
thymine was found bulging out. Gel electrophoresis experiments indicated that the DNA 
duplex is bent 23-35º.78-80 Additional chemical probing experiments confirmed the following: 
(i) the 5’G side of the lesion is more distorted than the 3’side, (ii) the base pairing is disrupted 
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for the 5’G*-C and the central T-A base pairs, and (iii) that the central thymine is oriented 
towards the solvent.78  
 The structure of the transplatin 1,3-adduct has not been solved yet, but a molecular 
modeling study of the trans-adduct suggests a similar destacking of the central base pair; the 
central base being extruded from the helix and situated in the minor groove. This study 
reported a bending of the helix of only 18º, differing greatly from the angle of 60º determined 
by gel electrophoresis.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Ribbon representation of the NMR-solution structure of 
d(CCTG*G*TCC)·d(GGACCAGG) containing the 1,2-d(GpG) intrastrand cross-link.69 The bending 
of the DNA towards the major groove is clearly illustrated. The arrowhead indicates the possible 
hydrogen bonding between the ammine of cisplatin and the 5’ phosphate. 
 
1.5.4 Protein recognition of platinum-DNA adducts 
The mechanism of killing cells by cisplatin-induced DNA damage is beginning to be 
disentangled. In the past, it was thought that cisplatin cytotoxicity was the result of inhibition 
of DNA synthesis. However, DNA-repair deficient cells die at concentrations of cisplatin that 
do not inhibit DNA synthesis. Moreover, DNA repair-proficient cells survive at 
concentrations of cisplatin high enough to inhibit DNA synthesis and arrest the cells in S 
phase of the cell cycle (Figure 1.6).62 Thus cisplatin-induced cell death does not always 
correlate with inhibition of DNA synthesis. More recently, considerable evidence indicates 
that cisplatin can kill cells via apoptosis.63,64 Apoptosis is an ubiquitous, genetically regulated 
mechanism of active cell death that is conserved in multicellular organisms.82-84 It has unique 
morphological and biochemical features, including cell shrinkage, blebbing of cell surface, 
loss of cell-cell contacts, chromatin condensation and fragmentation, recognition by 
phagocytic cells, characteristic DNA degradation, and dependence on the energy supplied by 
ATP, as well as an active protein synthesis.85 The process of apoptosis will be explained in 
more detail in section 1.7.  
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Figure 1.6. The cell cycle perturbations that occur as a consequence of DNA damage induced by 
cisplatin. The gray box represents the time period during which cells arrest at various phases of the 
cell cycle with the intent to repair the damage. Drawn after modification of ref 1. 
 
The specific mechanism(s) that trigger apoptosis in response to cisplatin have not yet 
been defined. Logically, such mechanisms must include ways to detect damage, and to 
determine whether the damage is sufficiently severe to be lethal. Much attention has been 
focused on identification and characterization of proteins that recognize cisplatin-induced 
DNA damage.6 At present, several families of proteins are implicated: (1) nucleotide excision 
repair (NER) proteins; (2) mismatch repair (MMR) proteins; (3) DNA-dependent protein 
kinase (DNA-PK); and (4) high-mobility group (HMG) proteins. 
(1) Nucleotide excision repair (NER) proteins. The NER pathway is responsible for 
the repair of cisplatin-DNA adducts and it is an important factor in cisplatin resistance.86,87 
NER has a broad substrate specificity,88 it involves more than 20 proteins and in a concerted 
reaction it is able to recognize and remove the lesion by a dual incision in the damaged DNA 
strand, in the removal of the damaged oligonucleotide and gap-filling replication using the 
opposite strand as a template.32,89 Many different NER proteins, like the xeroderma 
pigmentosum genes XPC, XPA and XPE, are involved in the recognition and play an 
important role in the repair.90 Clearly, upregulation of NER activity would lead to Pt 
resistance. In fact, increased expression of XPE was found in some cisplatin-resistant cell 
lines. Therefore, amplification of XPE or other factors involved in damage recognition may 
be partly responsible for the resistance encountered in the clinic. 
(2) Mismatch repair (MMR) proteins. MMR is a post-replication repair system that 
corrects unpaired or mispaired nucleotides. The relationship between DNA damage 
cisplatin 
DNA 
G1 phase S phase G2 phase
p53+ 
p53+ or p53-
Cell cycle arrest
and repair
recovery 
Cell survival 
 
Apoptosis 
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recognition by MMR proteins and cytotoxicity is not completely defined. The human 
mismatch repair complex h-MutS-α detects but does not remove cisplatin-DNA adducts. This 
protein has been shown to recognize specifically a single cisplatin intrastrand adduct between 
two adjacent guanines within a double-strand oligonucleotide.91 As for the molecular 
pharmacology of cisplatin-DNA adduct repair, it is currently questioned whether NER is 
more important than MMR in repairing the DNA. However, at least in ovarian cancer and 
colon cancer, MMR is a comparatively small contributor to the cisplatin resistance phenotype, 
because an intact MMR system seems to be essential for linking DNA damage with the 
initiation of apoptosis.92 
(3) DNA-dependent protein kinase. DNA-PK also interacts with cisplatin-DNA 
lesions.93 Binding of DNA-PK via Ku subunits is essential in vitro to activate the kinase 
activity of DNA-PK to phosphorylate itself. It has been shown in apoptotic ovarian cancer 
cells that the presence of cisplatin-DNA adducts serves to inhibit the ability of the Ku 
subunits of DNA-PK to translocate into a duplex DNA substrate. As a result, the kinase 
activity is increased and the ability of the Ku subunits to bind DNA is decreased.94 
(4) High mobility proteins (HMG) are a family of small, non-histone chromatin-
associated proteins involved in gene regulation and maintenance of chromatin structure. 
Binding to DNA is associated with recognition of the structural distortion of the DNA helix.95 
It was reported that several HMG-domain proteins, including HMG1 and HMG2, 
preferentially bind to the 1,2-intrastrand and interstrand DNA adducts generated by 
cisplatin,96 but not the 1,3-intrastrand adduct97 and the DNA lesions induced by the 
therapeutically inactive transplatin98 and [Pt(dien)Cl]+.99 The resulting protein-bound 1,2-
interstrand DNA adducts accompanies further significant bending and unwinding of the 
double helix (Figure 1.7).100,101  
It still remains unclear how the binding of HMG protein to the 1,2-intrastrand adducts 
influences the cytotoxic effect of cisplatin. Two different hypotheses have been postulated: 
 
1. The HMG-domain proteins recognize and shield the major cisplatin-DNA adducts 
from excision repair,102,103 resulting in sensitization of cancer cells to cisplatin. 
2. The HMG-domain proteins are hijacked from their normal binding site by the Pt-DNA 
adducts, disturbing normal DNA transcription.104 
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Figure 1.7.Ribbon representation of the X-ray structure of the complex of HMG1 domain A 
with d(CCTCTCTG*G*ACCTTCC)·d(GGAAGGTCCAGAGAGG).109 
 
However, the cytotoxicity of cisplatin cannot be satisfactory explained with either of 
these two hypotheses, because: 
a) Detection of the yeast IXR1 gene (encoding the HMG1 protein) only results in 
a marginally rescue of the Pt sensitivity.105 
b) HMG proteins are not essential in the recognition of 1,2-intrastrand and 
interstrand DNA adducts. 
 
1.6 Inactivation and drug resistance 
Both inherent and acquired resistance to platinum chemotherapeutic agents limits the 
curing rates.106 Several mechanisms for cisplatin resistance have been proposed and most 
likely a combination of these factors play an important role. Changes in membrane 
properties,107 upon which cisplatin transport and/or efflux may change, could result in 
resistance to the drug. A P-glycoprotein, found in multidrug-resistant cell lines, acts as a 
pump, which results in a decrease of drug accumulation in the cell.45,52,108,109  
The presence of thiol-containing groups in the cell, such as the intracellular peptide 
glutathion (GSH) and metallothionine (MT), is another cause of cisplatin resistance.110 Since 
cisplatin may react with these species, the amount of platinum binding to DNA decreases. 
Elevated levels of GSH have been observed in some cisplatin-resistant cells.52,111 MT, a 
protein of 61-62 amino acids, containing 20 cysteins residues112 involved in metabolizing 
heavy metals such as zinc, cadmium, and copper, is also believed to be involved in the 
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mechanism of resistance. Elevated levels of MT have indeed been found in some cisplatin-
resistant cells.113-115 Other studies, however, have shown no causal relationship between 
cisplatin resistance and MT expression.116,117 
Increase in DNA repair may also contribute to cisplatin resistance. Enhanced DNA repair 
was observed in some cisplatin-resistant cell lines.118-120 
   
1.7 Apoptosis and necrosis 
One potentially important mechanism of translation of cisplatin-DNA damage into the cell 
death is apoptosis, as mentioned in section 1.5.4. Considerable evidence indicates that 
cisplatin can kill cells through the induction of apoptosis.64 In this section the different phases 
of apoptosis are presented in more detail. To help understand apoptosis it is necessary to 
consider three different stages (Figure 1.8). 
1. Initiation phase, in which a stimulus is received, followed by engagement of any one 
of several possible pathways that respond to the stimulus.  
2. Effector phase, where all the possible initiating signals are integrated and where a 
decision to live or die is made. 
3. Execution phase. Some proteins autodigest and DNA is cleaved.64 
Bcl-2 is an oncogene that seems to be at the convergence of many apoptotic pathways 
and the ratio of Bcl-2 to Bax protein121 might be the final determinant of whether a cell enters 
the execution phase (Figure 1.8). Bax is a gene that encodes a dominant inhibitor of Bcl-2.122 
A conserved feature of the execution phase of apoptosis is the specific degradation of a series 
of proteins by the cystein-aspartate-specific proteases, or caspases. Caspases are activated 
when an apoptotic stimulus induces the release of cytochrome C from mitrochondria.123 
However, little is known about what initiates activation of the first caspase and what 
constitutes the critical substrate for caspase cleavage.  
The apoptotic death is accompanied with defined and consecutive signs in the morphology 
of the cells. These changes in the morphology are useful to determine whether the cells die by 
apoptosis or by necrosis. 
Necrosis is caused because of digestion and denaturation of cellular proteins largely by 
release hydrolytic enzymes from damage lysosomes and it is an uncontrolled cell death, 
characterized by:  
(i) Cell swelling and mitochondrial damage leading to rapid depletion of 
energy levels;  
(ii) A breakdown of homeostatic control and  
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(iii) Cell membrane lyses and releases of the intracellular contents, 
leading to an inflammatory response. 
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caspases endonucleases
Initiation Effector Execution
 
Figure 1.8. A diagrammatic representation of the converging pathways leading to apoptosis in 
mammalian cells.124  
 
1.8 Recent and “Non-classical” platinum complexes 
1.8.1 Introduction 
Recently an increasing amount of reports describing platinum complexes, which seem 
to violate the previously mentioned structure activity relationship rules (SARs) (section 1.3), 
appears in the literature and examples of these “non-classical” platinum complexes are listed 
below, also new derivatives will be shown, like ZD0473. 
 
1.8.2 Platinum(IV) complexes 
Pt(IV) complexes as antitumor drugs appear as a consequence of a search of more 
soluble compounds than cisplatin and therefore they can often be orally administrated. The 
absence of cross-resistance to cisplatin of some Pt(IV) compounds with general formula 
cis,trans,cis-[PtCl2(OCOR1)2(NH3)(RNH2)] have increased the interest in the study of such 
Pt(IV) compounds. These Pt(IV) complexes show even higher activity than cisplatin in 
several cisplatin-sensitive and resistant cell lines.125,126  
The most successful Pt(IV) complex bis(acetato)amminedichloro(cyclo-
hexylamine)platinum(IV) (satraplatin, JM216) (Figure 1.9 (a))48 entered clinical trials in 
1992127 and is undergoing Phase-III evaluation as an oral drug,128,129 since satraplatin posseses 
in vivo oral antitumor activity against a variety of murine and human subcutaneous tumor 
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models, broadly comparable to parenterally administrated cisplatin or carboplatin. In addition, 
it has a relatively mild toxicity profile with myelosuppression being dose limiting.  
An oral drug must be a neutral compound, lipophylic, water soluble and stable enough 
to survive in the grastrointestinal media.125 
Iodo complexes of Pt(IV) (Figure 1.9 (b)) are a new type of compounds with 
promising antitumor activity, since it was observed that their cytotoxicity against tumor cells 
is potentiated by visible light.130,131 
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Figure 1.9. Structural formula of the orally antitumor active Pt(IV) compounds. 
 
1.8.3 Sterically hindered platinum(II) complexes 
 One of the main mechanisms of cisplatin-resistance is an increased intracellular thiol-
mediated detoxification by peptide and proteins, like GSH and MT (see Section 1.6). Cis-
amminedichloro(2-methylpyridine)platinum(II) (ZD0473) (Figure 1.10) exhibits no cross-
resistance to cisplatin132 and its steric hindrance makes it less reactive towards thiol-
containing molecules than cisplatin.133,134 ZD0473 is in Phase-I clinical trial, and 
myelosuppression is the dose liming toxicity.134-138 
 
Pt
Cl
Cl
H3N
N
ZD0473  
 
Figure 1.10. Structural formula of the sterically hindered Pt(II) complex that circumvents 
cross-resistance to cisplatin.133 
 
1.8.4 Polynuclear platinum(II) complexes 
Polynuclear platinum(II) complexes with amine ligands acting as bridges between 
platinum centers, represent a new type of antitumor agents with higher antitumor activity in 
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vitro and in vivo. Farrell et al. have synthesized a series of multinuclear platinum(II) 
complexes, which form DNA adducts that differ markedly in structure, sequence specificity, 
and formation kinetics from those generated by cisplatin and its mononuclear analogues 
(Figure 1.11).139  
Both isomeric dinuclear platinum(II) complexes, [{cis-PtCl(NH3)2}2{μ-
(H2N(CH2)n(NH2)}]2+ (1,1/c,c) and [{trans-PtCl(NH3)2}2{μ-(H2N(CH2)n(NH2)}]2+ (1,1/t,t) are 
antitumor active, but their activity in resistant cell lines is different. 1,1/t,t, geometry 
overcomes the cross-resistance, while 1,1/c,c does not.140 Binding studies of both complexes 
show that the trans isomer binds in a different way from cisplatin, as illustrated by the 
increase of the formation of interstrand cross-links.141-143 
The trinuclear platinum(II) complex, [{trans-PtCl(NH3)2}2{μ-trans-
Pt(NH3)2(H2N(CH2)6(NH2)}]4+ (1,0,1/t,t,t, BBR3464) was found to be highly cytotoxic and 
effective against cisplatin-resistant tumor cells.144 Unfortunately, due to its severe side effects 
Phase II trials were abandoned. 
 The complex [{cis-Pt(NH3)2}2(μ-OH)(μ-pyrazolate)]2+ (ampz) was developed a few 
years ago145 and it was found to have a very high activity against several cell lines.146 With 
the goal of inducing minimal distortions when binding to the DNA, the complex was designed 
with pyrazole as a rigid bridging. The DNA-adducts, formed by this type of complex, cannot 
be recognized by repair systems. The crystal structure of the complex with two ethylguanine 
model bases has been solved and it shows that the orientation of the nucleobases is similar to 
the normal configuration of the nucleobases in DNA.147 
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Figure 1.11. Selection of polynuclear platinum(II) complexes. 
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1.8.5 Trans-platinum(II) complexes 
The trans isomer of cisplatin, trans-[PtCl2(NH3)2] or transplatin, was found to be 
inactive in vivo7 and to be less active than cisplatin in vitro. Divergent explanations, based on 
experimental findings, have been presented. 
Stronger inhibition of DNA replication148 and transcription149 by cisplatin than by 
transplatin adducts, without differences in rates and removal150 or, in contrast, more rapid 
repair of transplatin adducts,151,152 consistent with the inability of the high-mobility group 
protein HMG1 to recognize transplatin adducts.97 Moreover, the slower closure of 
monofunctional to bifunctional transplatin adducts and therefore higher susceptibility to 
destabilization by gluthathione has been also proposed as a contributing factor.153,154 In each 
case, structural differences of the DNA adducts have been found responsible for these 
observations. The most obvious difference in this respect is the inability of transplatin to form 
1,2-intrastrand cross-links, which are the most frequent adducts formed by cisplatin. From 
another point of view, it has been argued that transplatin is generally more reactive than 
cisplatin and therefore more susceptible to rapid inactivation.155-157 
However, substitution of the ammine ligands of transplatin by amines resulted in a 
number of antitumor active trans complexes with equivalent, or even higher activity 
compared to their cis analogues both in vitro and in vivo.155,158-160 One class of active trans 
complexes contains planar aromatic amines, such as pyridine, N-methylimidazole, thiazole or 
quinoline (Figure 1.12, (1, 2)). Remarkably, several of these complexes retain their activity in 
cells with acquired resistance to cisplatin and show an activity pattern in the cell line panel of 
the NCI, which is distinctly different from cisplatin.161,162 Reduced reactivity with 
biomolecules, such as glutathione, and thus reduced susceptibility to inactivation as a 
consequence of steric hindrance towards associative ligand exchange by the bulky planar 
groups has been put forward as an explanation for the remarkable activity of these compounds 
in comparison with transplatin.155 Furthermore, the formed adducts by these complexes may 
be more effective to cure cancer than those produced by transplatin. A higher portion of 
interstrand cross-links relative to total DNA adducts163-165 and formation of bifunctional DNA 
adducts and DNA-Pt-protein adducts similar to those produced by cis-configured 
complexes,155 may account for the higher activity and for lack of cross-resistance with 
cisplatin. In the case of transplatin, model calculations and experimental evidences suggest 
the formation of pseudo-bifunctional adducts, i.e. basically monofunctional adducts which 
induce bending of DNA due to intercalation with the nitrogen bases of the DNA.164  
A second series of active trans-Pt complexes contains iminoethers (Figure 1.12 
(3)).166,167 Like aromatic amines contained in the complexes mentioned above, iminoethers 
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have a planar geometry and introduce steric hindrance to ligand exchange reactions. They 
bind to DNA slower compared to cisplatin, but persist for a longer time, thus eventually 
resulting in similar levels of DNA platination.167 These trans-Pt(II) complexes are more 
active than their corresponding cis analogues both in vitro and in vivo and lack cross-
resistance with cisplatin in vivo.166,168,169 In contrast to trans complexes containing aromatic 
amines, the complexes containing two trans-located iminoether ligands show a much lower 
interstrand cross-linking efficiency than cisplatin and transplatin, both in cellular and isolated 
DNA.162 On the other hand, they produce higher numbers of monofunctional adducts which 
do not evolve DNA cross-links,169,170 but are much more resistant to destabilization by sulfur-
donor ligands than adducts formed by transplatin.171 
 
Pt
N
Cl
Cl
N
Pt
N
Cl
Cl
S
O
Pt
NH
Cl
Cl
HN
H3CO
OCH3
Pt
H2
N
Cl
Cl
NH
1 2 3
4
Pt
NH3Cl
NH2 Cl
OH
OH
5  
Figure 1.12. Antitumor active trans-Pt(II) complexes. 
 
A series of platinum(IV) complexes containing axial hydroxide ligands and one bulky 
aliphatic amine trans to ammine are also active in vivo (Figure 1.12 (4)), whereas their cis 
analogues have been found not to be active.172,173 The latter finding was of fundamental 
importance, because it is known platinum(IV) complexes require reduction to platinum(II) 
species in order to exert their antitumor affects. Trans-
ammine(dichlorocyclohexylamine)dihydroxoplatinum(IV), JM335, is capable of forming 
DNA interstrand cross-links, and it induces single-strand breaks, but only in one cell line.174  
The most recently discovered class of active trans-complexes are platinum(II) 
complexes with mixed aliphatic amines, described by the general formula trans-
[PtCl2(isopropylamine)(amine)] (Figure 1.12, (5)).175,176 Higher cytotoxic activity in ras-
transformed than in normal keratinocytes in vitro, provides evidence for a higher therapeutic 
index than cisplatin. The activity in vivo shows that the Pt(IV) complex where amine is 
Introduction 
27 
dimethylamine shows promising level of in vivo antitumor activity against human tumor 
xenograft in comparisdon with it cis counterpart.177 Their cis analogues were found inactive in 
several cell lines, sensitive and resistant to cisplatin (Chapter 2).178 
 
1.9 Platinum-drug targeting 
1.9.1 Introduction 
Most patients treated with platinum drugs experience only incomplete response with 
systemic toxicity preventing administration of higher doses. Strategies to modify drugs in 
such a way that they are selectively accumulated and/or activated in tumor tissue would make 
it possible to generate higher drug concentrations in the tumor without enhancing their toxic 
side effects and would therefore be of great benefit. 
In the context of platinum drugs, strategies based on the so-called enhanced 
permeability and retention (EPR) effect have recently proceeded to the early clinical stage of 
development. According to the EPR effect, biocompatible macromolecules accumulate at 
much higher concentrations in tumor tissues than in normal tissues, organs, or plasma.179,180 
The EPR effect leads to enhanced extravasation of macromolecules and particles of similar 
size and their accumulation in the solid tumors as a consequence of several factors. This 
happens because of the defective architecture of the vascular endothelium (large gaps in 
endothelial cell-cell junctions, lack of smooth muscle layer, etc), impaired lymphatic drainage 
and increased production of permeability mediators (nitric oxide, prostaglandins, etc) in 
neovascularized tumor tissue in contrast to healthy tissue. Consequently, conjugation of drugs 
to a large diversity of biological and synthetic polymers carriers and encapsulation of drugs in 
microparticles such as liposomes has extensively been explored. The EPR effect, originally 
described for serum proteins has been confirmed for several polymer-conjugated 
antineoplastic agents.181,182 Attempts to deliver platinum drugs involve liposomal or synthetic 
polymer carriers, but also extend to appropriate biological carrier molecules such as albumin 
and other proteins.183 Therefore, the enhanced permeability and retention effect is the basis for 
selective targeting of macromolecular drugs to the tumor, and the EPR effect is used for the 
selective delivery of macromolecular anticancer drugs. 
Alternative approaches to drug targeting involve the use of low-molecular-weight 
carriers with specific affinity for structures which are associated with certain tumor tissues.184 
However, due to the rapid washout by the capillarity blood flow of low-molecular-weight 
drugs, the EPR effect cannot explain their transport in the body.  
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1.9.2 Liposomal platinum drugs 
An advanced liposome technology, which overcomes the problem of instability of 
other liposomal preparations of cisplatin and which prevents rapid removal of liposomes by 
reticuloendothelial system by means of incorporation of methoxypolyethyleneglycol, has been 
applied to encapsulate cisplatin.185 This formulation (SPI-77), which has undergone several 
Phase I and Phase II clinical trials,186-193 has been designed to increase delivery to tumor cells 
by retarding renal excretion and prolonging retention in the circulatory system, to reduce 
toxicity in comparison to free cisplatin and to render hydration and antiemetics unnecessary. 
However, cases of severe hypersensitivity reactions to liposomal constituents have 
necessitated extended prophylaxis using corticosteroids and antihistamines.192 Using novel 
encapsulation methods it is possible to form nanocapsules of cisplatin in a lipid bilayer with 
very high drug-to-lipid ratio.194 These show promising in vitro activity and are currently 
investigated in vivo. 
 
1.9.3 Polymer-conjugated platinum drugs  
AP5280 (Figure 1.13 (a)) is the product of another approach aiming at accumulation 
of a platinum complex in tumor tissue by means of the EPR effect. It contains platinum 
moieties linked by peptide spacers to N-(2-hydroxypropyl)methacrylamide (HPMA).  
Promising results obtained with a similar HPMA-doxorubicin conjugate in Phase I studies 
have stimulated the study of this kind of polymer-conjugate applied to other chemotherapeutic 
agents, including platinum compounds.195 The polymer is designed with a size large enough 
to take advantage of the EPR effect and small enough to ensure renal elimination of the drug 
fraction remaining in the circulatory system; the peptide spacer is designed to be largely 
stable throughout the whole process of delivery to tumor cells, but to be cleaved by lyposomal 
proteases inside the cells. 
Studies on a series of HPMA copolymer platinates preceding the selection of AP5280 
for clinical development have explored different modes of linking the platinum-containing 
moiety to the peptide spacer. This spacer may terminate either (i) in an amino species such as 
ethylenediamine, which is supported to form a stable bond to cis-dichloroplatinum(II) moiety, 
or (ii) in a carboxylate, which is supposed to form a hydrolytically labile bond to the cisplatin 
moiety. In vivo experiments suggest that only the former type of conjugate, which is largely 
stable to hydrolysis and designed to release the platinum-containing moiety only upon 
endocytotic uptake and intracellular enzymatic degradation, shows distinct advantages over 
free cisplatin in therapeutic index.196 Nevertheless, AP5280 is more closely related to the 
latter type of conjugate, as the peptide spacer ends in a malonate group. This may serve as a 
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didentate ligand and thus be less susceptible to hydrolysis than a single carboxylate 
ligand.196,197 It has been proven that the binding of the platinum center to other possible sites 
in the peptide spacer, such as amide nitrogen, cannot take place.198,199 Recently, AP5280 has 
entered Phase I studies.199 
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Figure 1.13. Structure of the polymer-conjugate AP5280 (a), the osteotropic phosphonate 
complexes KP735 (b) and KP1363 (c). 
 
1.9.4 Platinum drugs containing low-molecular-weight carriers 
The majority of mammary, endometrium and prostate carcinomas expresses steroid 
hormone receptors. Although a high percentage of these tumors progress from hormone-
dependent to hormone-independent growth, steroid receptor expression is often retained. 
Therefore, development and study of these receptors as a target is being performed nowadays 
in order to achieve selectivity of platinum drugs for these tumors.200,201 Platinum complexes 
with low affinity for the oestrogen receptor have been designed by coordination to 
diphenylethylenediamine ligands. Several of these complexes inhibit growth of hormone-
dependent rat mammary tumors. (Anti)oestrogenic effects seem to remain over a DNA 
damaging mode of action in those compounds which exhibit selectivity for hormone-sensitive 
tumors,202-204 whereas a lack of endocrine effects is mostly associated with either a loss of 
selectivity or even a total loss of activity.205,206 
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Several ligands containing aminophosphonic acid groups have been used in order to 
produce platinum drugs with selective activity in primary and secondary bone tumors (Figure 
1.13 (b, c)). Phosphonic ligands have a high affinity for calcium; as a consequence, an 
accumulation of this kind of drugs on the bone will take place. These complexes are currently 
used in various bone disorders, such as Paget’s disease, osteoporosis and tumor-induced 
osteolysis and hypercalcaemia.207,208 Current studies with this kind of carriers attempted to 
optimize therapeutic effects involved in both modification of the phophonate-containing 
leaving group and modification of the non-leaving amine group in order to produce a drug 
which lacks cross-resistance to cisplatin.209 
 
1.10 Aim and scope of this thesis 
New platinum anticancer drugs with cis geometry, similar to cisplatin, have been 
developed with the aim of decreasing the severe side effects of cisplatin. Platinum complexes 
with trans geometry, however, have been less studied, due to the inactivity of transplatin, 
although a new area of research with these complexes have been opened the last years as 
described in section 1.8.5. In this PhD thesis project new asymmetric trans-platinum(II) 
complexes have been explored, with the general formula trans-[PtCl2(iPram)(azole)]. These 
new complexes circumvent cross-resistance to cisplatin. A comparative study with their cis 
analogues is described and their cytotoxic properties and their interaction with model bases is 
studied. 
In Chapter 2, synthesis, cytotoxic activity and interaction with GMP of cis-Pt(II) 
complexes with general formula cis-[PtCl2(iPram)(amine’)] (amine’ = dimethylamine, 
methylamine, propylamine and butylamine) are shown in comparison with their trans 
isomers. In Chapter 3, cytotoxicity and interaction with GMP of asymmetric trans-
[PtCl2(iPram)(azole)] complexes (azole = pyrazole, 1-methylimidazole and 1-methylpyrazole) 
are presented. These complexes overcome cisplatin-resistance. Also a comparison with their 
cis analogues is introduced and performed as presented in Chapter 4. In Chapter 5, the 
interaction of the trans-[PtCl2(iPram)(azole)] complexes with double-stranded DNA is 
presented. Chapter 6 presents platinum-drug targeting systems, where small organic drugs 
and carriers are bound to the platinum in trans geometry, allowing to be transported and bind 
to specific tissues. Chapter 7 presents a general evaluation and discussion of the results 
obtained in this study. 
Parts of this thesis have been published or have been submitted for publication.178,210, 211  
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New cis-[PtCl2(isopropylamine)(amine’)] compounds: 
cytotoxic activity and reactions with GMP compared with 
their trans isomers∗ 
 
Abstract 
The synthesis and characterization of four new cis-platinum compounds of structural formula 
cis-[PtCl2(iPram)(amine’)] (iPram= isopropylamine; amine’= methylamine, dimethylamine, 
propylamine and butylamine), 2a-2d, are described. Cytotoxicity tests in tumor cell lines 
sensitive to cisplatin (CH1 and Pam 212) and resistant to cisplatin (CH1cisR, and Pam 212-
ras) indicate that only compound 2d possesses cytotoxic activity in the cisplatin-sensitive cell 
line CH1, albeit much lower than CDDP and also lower than the corresponding trans-
platinum compounds with mixed aliphatic amines. The interaction of cis- (2a-2d) and trans- 
(3a-3d) [PtCl2(iPram)(amine’)] compounds with GMP in dilute NaClO4 (10 mM) was 
investigated by 1H NMR spectroscopy, and the progress of the reactions was followed 
overnight. In all cases two product peaks are observed for the bisadduct product in the cis 
complexes, because of their asymmetry. Temperature-dependent studies have been 
performed, but no significant variation in product structure is observed. With this study, it 
was concluded that platinum complexes with trans geometry were more cytotoxic than their 
cis analogues, changing the structure-activity relationship rules. 
 
                                                 
∗ Based on the paper: E. Pantoja, et al.; Inorg. Chim. Acta 2002, 339, 525. 
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2.1 Introduction 
cis-Diamminedichloroplatinum(II), generally referred to as cisplatin, or CDDP, was 
chemically described in 1845 by Peyrone,1 but its anticancer properties were discovered only 
a few decades ago by Rosenberg.2 Early structure-activity studies showed that a cis 
configuration of the two leaving groups is essential for antitumor activity of simple Pt(II) 
derivatives and has later been confirmed for several groups of compounds.3,4 Thus, CDDP is 
endowed with cytotoxic properties, while its trans analogue (TDDP) does not show activity.5,6  
However, several classes of Pt(II) complexes, that violate this structure-activity rule, have 
been reported in the last decades, examples being: (i) trans-PtCl2(L)(L’) with L and L’ planar 
heterocyclic ligands,7,8 (ii) dinuclear compounds of the type [trans-{PtCl(NH3)2}2{μ-NH2-
(CH2)n-NH2}]2+ (with n = 2-6), or trinuclear complexes containing two trans-PtCl(NH3)2 units 
linked by a  NH2(CH2)6NH2-(trans-Pt(NH3)2)-NH2(CH2)6-NH2 chain,9-12 designated as 
BBR3464, (iii) trans-PtCl2 complexes with imino ether ligands as inert groups,13-16 and  (iv) 
trans-[PtCl2(amine’)(isopropylamine)], where amine’ may be methylamine, dimethylamine, 
propylamine, or butylamine.17 
Recently, several trans-platinum(II) compounds with mixed aliphatic amines exhibiting 
remarkable cytotoxic activity against tumor cell lines, both sensitive and resistant to cisplatin 
were reported.17 Because of these interesting biological properties, it was decided to compare 
the cytotoxicity of these trans-Pt(II) compounds with their corresponding cis analogues.18 
Therefore, several cis-Pt(II) complexes of general formula cis-[PtCl2(iPram)(amine’)] were 
synthesized and characterized. In these complexes the unchanged amine is isopropylamine 
while amine’ can be methylamine, dimethylamine, propylamine, or butylamine resulting in 
the four complexes: cis-[PtCl2(iPram)(methylamine)] (2a), cis-[PtCl2(iPram)(dimethylamine)] 
(2b), cis-[PtCl2(iPram)(propylamine)] (2c) and cis-[PtCl2(iPram)(butylamine)] (2d) (iPram= 
isopropylamine). The results reported in this chapter show that these complexes show lower 
cytotoxic activity than both cisplatin and their corresponding trans isomers (Figure 2.1).  
The consensus of opinion is that genomic DNA is the primary pharmacological target of 
cisplatin and related analogues.19,20 In addition, it is also generally accepted that the cytotoxic 
activity of platinum complexes may be a consequence of the formation of DNA adducts. 
Although, cisplatin may form several types of DNA adducts, the 1,2-d(GG) intrastrand cross-
link is the major one and therefore has been  considered as the main DNA lesion responsible 
for the biochemical mechanism of cytotoxic activity of the drug.19-22 The N7 atom of guanine 
in the major groove has been described as the most electronegative site in double-stranded 
DNA23 and is the most reactive site towards the positively charged, aquated cisplatin 
intermediates. In order to shed light on the differences observed in cytotoxic activity between 
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cis- and trans-[PtCl2(iPram)(amine’)] complexes, the kinetics of formation of the reaction 
products of these compounds with GMP was compared. The Pt binding to GMP has been 
studied by proton nuclear magnetic resonance (1H NMR) in dilute solution, using a four-fold 
excess of GMP. With this technique the Pt-GMP interaction can be followed, because it is 
possible to observe simultaneously the formation and disappearance of any platinum-GMP 
species present in the reaction mixture. The chemical shift of the H8 proton of GMP 
fortunately is very sensitive to the geometry and the composition of the complex24-26 and is a 
very useful signal to monitor. To mimic biological conditions, experiments were performed in 
neutral aqueous solutions. Rather low concentrations of the reactants were used to allow ready 
dissolution of the platinum chloride compounds. These conditions also prevent the 
polymerization reactions and precipitation, as found earlier for more concentrated solutions.26  
 
Pt
NH2CH(CH3)2Cl
Cl amine'
Pt
NH2CH(CH3)2Cl
amine' Cl
2a, amine'= NH2CH3
2b, amine'= NH(CH3)2
2c, amine'= NH2CH2CH2CH3
2d, amine'=  NH2CH2CH2CH2CH3
3a, amine'= NH2CH3
3b, amine'= NH(CH3)2
3c, amine'= NH2CH2CH2CH3
3d, amine'=  NH2CH2CH2CH2CH3trans-[PtCl2(iPram)(amine')
cis-[PtCl2(iPram)(amine')
 
Figure 2.1. General structure of cis- and trans-[PtCl2(iPram)(amine’)] complexes. 
 
2.2 Experimental section 
2.2.1  Materials 
K2PtCl4 was provided by Johnson & Matthey (Reading, UK). Isopropylamine, 
methylamine, dimethylamine, propylamine and butylamine were obtained from Fisher 
Scientific Nederland B.V. Guanosine-5’-monophosphate (GMP) was obtained from Aldrich-
Sigma. Trans-[PtCl2(iPram)(amine’)] compounds were provided by the group of Prof. Dr. 
Carmen Navarro Ranninger. 
 
2.2.2 Synthesis of the cis-[PtCl2(iPram)(amine’)] complexes 
The synthesis has been accomplished in four steps, as presented in Scheme 2.127,28 
and is described in detail below. 
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Scheme 2.1. Synthesis of cis-[PtCl2(iPram)(amine’)] compounds; details are in the text below (exc= 
excess).  
 
cis-[PtI2(iPram)2] 
K2PtCl4 (2.0 g, 4.82 mmol) was dissolved in 100 ml of water and treated with 8.0 g (47 
mmol) of KI. The solution was stirred for 1.5 hr at room temperature. Two equivalents of 
isopropylamine (0.57 g, 9.64 mmol) were added quickly to the K2PtI4 solution. The reaction 
mixture was stirred for 3 hr. The yellow precipitate was washed with water, methanol and 
diethyl ether. The final product cis-[PtI2(iPram)2] was dried in air. Yield: 2.61 g (95 %). 1H 
NMR (acetone-d6): δ (ppm): 4.37 (4H, sbr); 3.57 (2H, sept, 6.69 Hz), 1.37 (12H, d, 6.5 Hz). 
195Pt NMR (acetone-d6): δ (ppm): -3342. (sbr: broad singlet, d: doublet, sept: septuplet) 
 
[PtI2(iPram)]2 
A suspension of cis-[PtI2(iPram)2] (2.61 g, 4.60 mmol) in 24 ml of water and 74 mL of 
ethanol was treated with 4.67 ml of HClO4 (70 %) over a period of 9 days. During the 
reaction the yellow precipitate turned into a red brown precipitate. The suspension was 
filtered and the precipitate washed with water and dried in air. Yield: 2.18 g (93 %). 1H NMR 
(acetone-d6): δ (ppm): 4.47 (4H, s); 3.24 (2H, sept, 6.46 Hz); 1.38 (12H, d, 6.46 Hz). 195Pt 
NMR (acetone-d6): δ (ppm): -4201.9 and  -4213.8.  
 
cis-[PtI2(iPram)(amine’)] 
A suspension of cis-[PtI2(iPram)]2 (2.16 g, 2.14 mmol) in 4.5 ml of water was mixed with 
2 equiv. of amine’ [4.28 mmol of methylamine (a), dimethylamine (b), propylamine (c), and 
butylamine (d), respectively]. The reaction mixture was stirred for 2 days at room 
temperature. The yellow precipitate was filtered, washed with water, and dried in air. Yield: 
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(1a) 0.84 g (73 %); (1b) 1.0 g (85 %); (1c) 1.13 g (93 %); (1d) 1.02 g (83 %). 1H NMR 
(acetone-d6): δ (ppm): (1a) 4.43 (4H, sbr, NH2CH(CH3)2 and NH2CH3), 3.51 (1H, sept, 6.5 Hz, 
NH2CH(CH3)2), 1.4 (6H, d, 6.5 Hz, NH2CH(CH3)2), 2.62 (3H, t, 6.35 Hz, NH2CH3), 195Pt 
NMR (acetone-d6): -3547.2 ppm; 1H NMR (acetone-d6): δ (ppm): (1b): 4.44 (2H, sbr, 
NH2CH(CH3)2), 3.39 (1H, sept, 6.7 Hz, NH2CH(CH3)2), 1.28 (6H, d, 6.7 Hz, NH2CH(CH3)2), 
4.93 (1H, sbr, NH(CH3)2), 2.64 (6H, d, 5.9 Hz, NH(CH3)2); 195Pt NMR (acetone-d6): -3546.3 
ppm; 1H NMR (acetone-d6): δ (ppm): (1c) 4.41 (4H, sbr, NH2CH(CH3)2 and NH2(CH2)2CH3), 
3.52 (1H, sept, 6.5 Hz, NH2CH(CH3)2), 2.95 (3H, quint, 7.4 Hz, NH2CH2CH2CH3), 2.24 (3H, 
t, 7.4 Hz, NH2CH2CH2CH3), 1.69 (2H, sx, 7.4Hz, NH2CH2CH2CH3), 1.39 (6H, d, 6.5 Hz, 
NH2CH(CH3)2): 195Pt NMR (acetone-d6): -3548.2 ppm; 1H NMR (acetone-d6): δ (ppm): (1d) 
4.42 (4H, sbr, NH2CH(CH3)2 and NH2(CH2)3CH3), 3.54 (1H, sept, 6.5 Hz, NH2CH(CH3)2), 
2.99 (4H, m, NH2CH2CH2CH2CH3), 1.66 (2H, quint, 7.6 Hz, NH2CH2CH2CH2CH3), 1.39 
(6H, d, 6.5 Hz, NH2CH(CH3)2), 0.99 (3H, t, 7.6 Hz, NH2CH2CH2CH2CH3): 195Pt 
NMR(acetone-d6): -3547.1 ppm. (sbr: broad singlet, d: doublet, quint: quintuplet, t: triplet, sx: 
sextuplet, sept: septuplet) 
 
cis-[PtCl2(iPram)(amine’)]  
A suspension of cis-[PtI2(iPram)(amine’)] in 80 ml of water was treated with 1.85 equiv. of 
AgNO3 for 1 day in the dark. Precipitated AgI was filtered off and 4 equiv. of KCl was added 
to the filtrate. The reaction mixture was stirred for 10 hr at 40 ˚C and allowed to stay 1 day at 
4 ˚C. When the mixture was cooled a yellow solid precipitated. The solid was filtered, washed 
with water, and dried in air. A second fraction was obtained by evaporating half of the 
solvent, and filtering off the precipitate. The characterization of the final compounds and the 
structural formula can be observed in Table 2.1 and Figure 2.2, respectively. Yield: (2a) 
0.1907g (42 %), (2b) 0.248 g (41 %), (2c) 0.4121 g (60 %), (2d) 0.4368 g (68 %). 
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Table 2.1. 1H and 195Pt NMR Parameters δ (ppm) and mass spectrometry of compounds 2a-2d  (for 
numbering see Figure 2.2). The numbers in parentheses corresponds to J(1H—1H) in Hz; ; s, singlet; 
d, doublet; t, triplet; sx, sextet; sept, septuplet; m, multiplet; sbr, broad singlet; solvent DMSO. bThis 
value corresponds to the J(15N—1H); n.o, not observed. 
 iPram 2a 2b 2c 2d 
H1 2.95 sept 1H  
J (6.2) 
3.02 sept 1H 
J (6.5) 
3.05 sept 1H 
J (6.5) 
3.04 sept 1H 
J (6.5) 
3.04 sept 1H
J (6.5) 
H2 0.92 d 6H  
J (6.2) 
1.20 d 6H 
J (6.5) 
1.22 d 6H 
J (6.5) 
1.20 d 6H 
J (6.5) 
1.20 d 6H 
J (6.5) 
NH2 2.10 sbr 2H  4.73 sbr  2H 4.81 sbr 2H 4.79 sbr 2H n.o. 
H1’  2.49 t 3H 
 J (6.35)b 
2.67 d 6H 
J (6.0) 
2.48 t 2H 
J(7.4) 
2.55 m 2H 
J (7.6) 
H2’    1.33 sx 2H 
J(7.4) 
1.5 q 2H 
J (7.6) 
H3’    0.85 t 3H 
J(7.4) 
1.5 sx 2H 
J (7.6) 
H4’     0.85 t 3H 
J (7.6) 
δ (195Pt), ppm  -2529.2 -2509.3 -2528.7 -2529.1 
m/z  356.12 370.18 384.05 398.07 
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Figure 2.2. Structural formula of cis-[PtCl2(iPram)(amine’)] compounds and numbering used 
in the characterization. 
 
2.2.3 Physical measurements 
Elemental analysis of the complexes was performed in the microanalytical laboratory 
of the Servicio Interdepartamental de Investigación (SIDI, Universidad Autónoma de Madrid, 
Spain), using a Carlo Erba Strumentazione element analyzer (Model 1106). 1H, 13C and 195Pt 
NMR spectra (in DMSO-d6 and acetone-d6), for the characterization of the complexes, were 
recorded on a Bruker DPX-300 spectrometer operating at a frequency of 300, 75.5 and 64.52 
MHz, respectively; in SIDI. Mass spectrometry was performed in SIDI in a VG AutoSpec. 
NMR spectra, for the GMP reactions, were recorded on a Bruker DPX 300 spectrometer with 
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a 5-mm multi-nuclei probe. The temperature was kept constant at 310 K by a variable 
temperature unit. The GMP reactions were performed in the Gorlaeus Laboratories at Leiden 
University. 
 
2.2.4 Biological methods. Reagents and compounds 
 The 100-mm culture and microwell plates were obtained from NUCLON (Roskilde, 
Denmark). MTT, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)], was 
purchased from Sigma Chemical Co. FCS was supplied by GIBCO- BR; cisplatin was 
purchased from Sigma Chemical Co. Stock solutions of the compounds at a concentration of 
1 mg/ml in PBS were freshly prepared before use. 
 
2.2.5  Cell lines and culture conditions 
Pam 212, a normal murine keratinocytes cell line, Pam 212-ras, a transformed murine 
keratinocytes cell line overexpressing the H-ras oncogen, CH1 human ovarian tumor cells and 
CH1cisR resistant human ovarian tumor cells,29 were all cultured in DMEM, supplemented 
with 10% FCS, 2 mM glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 
ºC in an atmosphere of 95% air and 5% CO2. All cultures were passaged twice weekly 
showing a doubling time between 16-24 hr.30,31 
 
2.2.6 Drug cytotoxicity 
Cells, which survive in cultures treated with the compounds, were evaluated by using 
the so-called MTT method.32 Compounds were added to microwells containing the cell 
cultures at final concentrations of 0-200 μM; 24 hr later, cell survival was evaluated by 
measuring the absorbance at 520 nm, using a Whittaker microplate reader 2001. The IC50 
values (i.e. the concentration of the complex which restricts cell growth to 50% of that 
compared to the control) were calculated from curves constructed by plotting cell survival (%) 
versus compound concentration (μM). All experiments were performed in triplicate. 
 
2.2.7 Reactions with GMP 
  Reactions of compounds 2a-d, 3a-d (1 mM) with a four-fold excess of GMP (ratio 
Pt:GMP = 1:4) were carried out in 10 mM NaClO4 within the NMR tube. The samples were 
dissolved at 90 °C, but not in all cases clear solutions have been obtained, and dissolution 
took place while reacting with GMP. The reaction mixtures were maintained thermostated at 
310 K in an oven. 1H NMR spectra were measured at different time intervals (30 min) at 
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310K. Subsequently, the reactions were carried out at different temperatures (310 K, 323 K, 
333 K, 338 K). 
 
2.3 Results and discussion 
2.3.1 Synthesis and characterization of the cis-[PtCl2(iPram)(amine’)] compounds 
The synthesis takes place in four steps as it is shown in Scheme 2.1.27,28 Preparation of 
the cis-Pt(II) compounds involves obtaining the iodine-bridged dimer with isopropylamine 
and the subsequent breaking of the bridge with the different aliphatic amines.27 Elemental 
analysis, infrared spectra and 1H, 13C and 195Pt NMR spectra and mass spectrometry confirm 
the formation of the desired compounds. The microanalytical data are consistent with the 
empirical formulas PtCl2C4H14N2 (2a), PtCl2C5H16N2 (2b), PtCl2C6H18N2 (2c), and 
C7H20N2PtCl2 (2d), which support the structure [PtCl2(iPram)(amine’)]. The assignment of 
the cis geometry is supported by IR spectral data (two bands at 323 and 317 cm-1, 338 and 
320 cm-1; 323 and 314 cm-1; and 322 and 318 cm-1, assigned to Pt—Cl stretching; in 
compounds 2a, 2b, 2c and 2d, respectively), which agrees with the cis geometry of the 
chloride ligands. The IR spectra also show bands at 435, 513, 432, and 431 cm-1, respectively, 
tentatively assigned to the asymmetric Pt—N stretch.33 In this case no splitting due to a cis 
orientation is observed. 
The 1H and 13C NMR data confirm the structures of the complexes proposed by IR 
data. The 1H NMR data for compounds 2a-2d are shown in Table 2.1. The signal 
corresponding to the amine group of isopropylamine appears deshielded in the complexes 
(Δδ= 2.63-3.55), and integrates as two protons. The aliphatic protons are also shifted to low 
field with respect to the free amine. 13C NMR shows the same effect (Table 2.2). 
 
Table 2.2. 13C NMR Parameters δ (ppm) of compounds 2a-2d (for numbering see Figure 2.2). 
 iPram 2a 2b 2c 2d 
C1 43.0 48.05 48.2 48.5 48.6 
C2 26.1 28.30 23.4 24.1 24.1 
C1’  52.70 42.1 47.95 46.16 
C2’    23.74 23.82 
C3’    11.23 19.48 
C4’     13.82 
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2.3.2 Cytotoxic activity of the synthesized cis-Pt(II) compounds and comparison with their 
trans analogues 
The cytotoxic activity of the synthesized complexes cis-[PtCl2(iPram)(amine’)] has 
been tested in cell lines sensitive (Pam 212: murine keratinocytes and CH1: ovarian 
carcinoma) and resistant (Pam 212-ras: transformed murine keratinocytes and CH1R: 
resistant ovarian carcinoma) to cisplatin. The results shown in Table 2.3 indicate that the    
cis-[PtCl2(iPram)(amine’)] compounds show a cytotoxic activity significantly lower than that 
of cisplatin. In fact, the only compound which shows comparable cytotoxicity in the cisplatin-
sensitive cell line CH1 is 2d. It shows an IC50 of 38.4 μM, similar to the IC50 value of its trans 
analogue, although this value is still 2.9 times higher than the IC50 value of cisplatin. Table 
2.3 also shows the differences between the trans-Pt(II) and cis-Pt(II) isomers and cisplatin. 
The results indicate that, in general, the trans-Pt(II) isomers exhibit cytotoxic activity in the 
micromolar range, similar to that of  cisplatin. On one hand, the cis-Pt(II) isomers do not have 
significant cytotoxic properties against the panel of cell lines tested, because, with the 
exception of compound 2b and 2d in CH1 cells, the IC50 values  shown by compounds are all 
≥100 μM (Table 2.3). On the other hand, it should be pointed out that amongst the trans-
Pt(II) isomers, compound 3c is the most active one. In fact, at a concentration of 50 μM it 
inhibits nearly 100 % of the growth of the Pam 212-ras cells, while compounds 3a, 3b and 3d 
inhibit 60%, 70% and 32% of the growth of the Pam 212-ras cells, respectively. Therefore, 
the presented cytotoxicity results in Table 2.3 indicate that the trans-[PtCl2(iPram)(amine’)] 
isomers have better antitumor properties than the cis-[PtCl2(iPram)(amine’)] isomers. 
 
Table 2.3. IC50 Mean values obtained for cis- and trans-[PtCl2(iPram)(amine’)] complexes against 
several tumor and normal cell lines (trans data are taken from ref. 17.). 
 IC50 (μM) ± DS, cell lines 
Compound CH1 CH1cisR Pam 212 Pam 212-ras 
2a > 100 >100 >100  >100 
2b 69.5 ± 2.3 >100 >100 >100 
2c > 100 >100 >100 >100 
2d  38.4 ± 1.5 90± 2.0 >100 >100 
Cisplatin 13 ± 1.3 50 ± 1.3 114 ± 3.0 156 ± 6.0 
3a 19 ± 1.2 15 ± 1.5 56 ± 2.0 6 ± 0.5 
3b 43 ± 2.5 39 ± 3.4 50 ± 3.0 32 ± 1.0 
3c 16 ± 1.7 > 100 71 ± 4.0 21 ± 2.0 
3d 53 ± 1.3 16 ± 0.1 39 ± 4.1 17 ± 2.8 
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2.3.3 Reactions of cis- and trans-platinum isomers with GMP 
Because most platinum compounds show a preference for the N7 atom of guanine 
when binding to DNA,34 the reactions of the cis and trans isomers with the nucleotide GMP 
were studied by NMR spectroscopy. Thus, overnight reactions of cis- and trans-
[PtCl2(iPram)(amine’)] complexes with GMP at a molar ratio of 1:4 were monitored by 1H 
NMR at 310 K. 1H NMR spectra were recorded again 24 hr after the overnight experiment 
and no further spectral variations were observed. Reaction schemes for both sets of 
compounds are depicted in Scheme 2.2.  
For the 1:1 adduct of the cis-Pt(II) complexes two H8 resonance peaks would be 
expected in the 1H NMR spectra, as the GMP in each intermediate has a slightly different 
chemical and magnetic environment. On the other hand, the 1:1 adducts of the trans-Pt(II) 
complexes should produce a unique guanine H8 signal, because for the trans isomers the 
chemical and magnetic environments are equivalent. In the final products again the cis 
products have two different GMP’s, whereas the trans products have only one kind of GMP 
bound. Furthermore, the rotation around the Pt bond is slower in the cis-Pt(II) complexes than 
in the trans isomers, because the steric effect is larger in the cis isomers, where the iPram and 
amine’ ligands are located at the same side; this implies that the rotation around the Pt–iPram 
and Pt–amine’ bonds is likely to be slower than in the trans isomers. Consequently, the H8 
atoms of the GMP’s can be distinguished as trans for both amines; so the result is that two 
bis-adduct product peaks are observed in the 1H NMR. This splitting does not occur in the 
trans complexes, where the iPram and amine’ locations make the H8’s of GMP equivalent. 
Table 2.4 shows the values of chemical shift observed for the guanine H8 signal in the final 
reaction products of the cis and trans isomers with GMP. 
 
Table 2.4. Chemical shifts values from the H8 proton of the GMP in bisadduct products. 
 Free  
GMP 2a 2b 2c 2d 3a 3b 3c 3d 
Free  
GMP 8.16 8.16 8.16 8.16 8.16 8.15 8.15 8.15 8.15 
Peak 1  8.52 8.33 8.5 8.54 8.45 8.86 8.75 8.96 
Peak 2  8.44 8.44 8.44 8.43     
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Scheme 2.2. Scheme of the reaction of the cis- and trans-platinum(II) compounds with GMP. 
  
As mentioned above, in the case of the cis-platinum compounds, two resonance peaks 
for the final product would be expected, and this is indeed observed. However, for all cis-
Pt(II) compounds, 2a-2d, only one signal is observed for the 1:1 intermediates. For all the cis-
Pt(II) complexes, the intermediates 1:1 are observed after 11 hr from the start of the reaction. 
With time the intensity of the peak corresponding to the monofunctional adduct decreases, 
while the peaks corresponding to the 1:2 product increase until the end of the reaction, 
starting to appear after 2 hr from the beginning of the reaction. For all the complexes, 2a-2d, 
the reactions were completed after 24 hr after the start of the reaction. The time-dependent 
formation and disappearance of the 1:1 product is shown in detail in Figure 2.3.  
The reactions of trans-platinum compounds with GMP were performed in the same 
way as the cis-platinum isomers. In all the compounds the same progress in the reaction is 
observed. Directly upon mixing the products 1H NMR spectra were recorded and the H8 of 
the free GMP appeared to be the only observed signal. At the beginning of the reaction only 
one new peak is appearing gradually, corresponding to the mono-adduct product; the intensity 
of this peak increases up to 3 hr after the reaction started in all the compounds. As for the cis-
Pt(II) compounds in Figure 2.3 one of  the trans-Pt(II) complexes (3a) is shown as an 
example of its time dependence. The only case where the 1:1 intermediate is still observed 
after 14 hr, is compound 3b, where the amine’ is dimethylamine. In the next phase the peak 
starts to decrease until 6 hr of reaction during which period another peak appears, 
corresponding to the bisadduct product. It should be noted that even after 14 hr not all 
products have reacted. Also after 2 hr some minor impurities or side products becomes visible 
at 8.7 ppm and 8.3 ppm, which have not been assigned, due to the very small amounts. 
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Figure 2.3. Time-dependent 1H NMR for reaction of compounds 2a and 3a with an excess of GMP at 
310 K. The symbols show the H8 signals of GMP ligands in the products, 1:1 intermediate (●), 1:2 
intermediate (■), free GMP (▲). (*) Corresponds to traces of DMF used to predissolve the complex.  
 
In summary the following differences between the cis- and trans-platinum complexes, 
originating from their different geometry, are observed.  
1. In the cis-Pt(II) products, two intermediate 1:1 adducts can be observed in all cases; 
however, only in compound 2b, these peaks remain for prolonged reaction times. In the 
trans-Pt(II) product only one 1:1 adduct peak is observed in all cases, and it is only in 
compound 3b, where this peak remains for longer time. 
2. In cis-Pt(II) compounds two product peaks are found from the bisadduct product as the H8 
of the both GMP are magnetically not equivalent; in trans-Pt(II) complexes only a single 
adduct peak is observed, because in this case magnetic equivalence exists.  
3. An interesting observation is that the bisadduct product peaks in cis-platinum complexes 
have a lower chemical shift than their corresponding trans-platinum isomers. 
 
 
2a 3a
***
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2.4 Concluding remarks 
The results described and discussed above have clearly shown that both cis- and trans-
isomers of complexes of general formula PtCl2(L1)(L2) with L1 = isopropylamine and L2 = 
another secondary amine, do react with comparable rates with GMP. On the other hand the 
antitumor activity of the cis isomers is significantly lower than that of the trans isomers. This 
could be explained by the fact that the cis complexes react slower with the DNA and therefore 
they can be deactivated by S-donor ligands, present in the cells, not being able to form the 
1,2-intrastrand cross-links, which are supposed to give the antitumor activity to platinum 
complexes with cis geometry. In the case of trans complexes it does not happen. 
 In the following chapters similar studies with other N-donor ligands L2 will be 
reported and discussed whether or not this observation has a more general value. 
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_________________ 3 
 
New asymmetric trans-platinum(II)  complexes that 
overcome cisplatin resistance∗ 
 
Abstract   
Three new asymmetric trans-platinum(II) complexes have been synthesized and 
characterized by elemental analysis, 1H, 195Pt NMR spectroscopy and IR spectroscopy. In 
addition the X-ray crystal structures for all three complexes have been determined. The three 
complexes crystallize in the monoclinic space group P21/c, and all have a normal molecular 
trans arrangement of the Cl- ligands. In the case of complex tHpz only one orientation of the 
isopropylamine ligand is observed, while for the complexes tMeim and tMepz two different 
orientations for the same ligand are observed.  
Overnight reactions of tHpz, tMeim and tMepz with guanosine 5´-monophosphate 
(GMP) in NaClO4 (0.1 M) at 310 K have been monitored by 1H NMR spectroscopy. It was 
found that all three complexes react with GMP, but that the reaction of tMepz is slower than 
the reaction of tHpz and tMeim in the formation of the bis(GMP) adduct. Preliminary kinetic 
parameters for the complex tMeim were obtained, and it was found that the reaction between 
tMeim and GMP mainly proceeds via direct substitution of the Cl- ligand by the N7 of GMP. 
Cytotoxic assays of tHpz, tMeim and tMepz have been performed on a variety of human 
tumor cell lines. In general, tHpz and tMeim are only slightly less cytotoxic than cisplatin, 
and show IC50 values within the micromolar range. The complex tMepz shows cytotoxicity 
within the same range as cisplatin, although it is significantly less cytotoxic than cisplatin, 
tHpz or tMeim. The complexes tHpz and tMeim were found to be as cytotoxic as cisplatin 
in the EVSA-T and IGROV cell lines. Cytotoxicity was also studied in the cisplatin-sensitive 
and cisplatin-resistant A2780 cell lines. It was found that all three complexes do overcome 
cisplatin resistance in this cell line. These results are of fundamental importance showing that 
certain platinum complexes having a trans geometry can display improved cytotoxic activity, 
and even overcome cisplatin resistance. 
 
                                                 
∗ The results of this chapter will be  (in part) included in E. Pantoja et al.; ms. in preparation for publication 2005 
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3.1 Introduction. 
Cisplatin (CDDP), cis-[PtCl2(NH3)2] has received worldwide acceptance as a clinical 
drug for the treatment of various neoplastic diseases, including testicular, ovarian, and neck 
and head cancers.1,2 Unfortunately, it exhibits some important dose-limiting toxicity, such as 
nephrotoxicity. Also drug resistance development has been reported as major clinical 
limitation of the drug.3-5 While CDDP is endowed with cytotoxic properties, its congener 
transplatin (TDDP) is therapeutically inactive.6,7 This observation agrees with the original 
structure-activity relationship of a series of platinum amine compounds.8 Cisplatin, a 
bifunctional DNA-binding agent, forms intrastrand cross-links with only small amounts of 
interstrand adducts (< 6%),9-11 although the contribution of each binding mode to the overall 
cytotoxic effect remains unknown.  
The major adduct formed by cisplatin is the 1,2-intrastrand cross-link between guanines 
of adjacent base pairs.12,13 Steric reasons prevent the formation of such intrastrand cross-links 
with transplatin in double-helical DNA between adjacent residues.14 The inability to form 1,2-
intrastrand cross-links and the structural differences in the different cross-links are used to 
explain the inactivity of transplatin.15-17 In fact the initially formed monofunctional adduct of 
transplatin slowly transforms into interstrand adducts involving guanine-N7 and the 
complementary cytosine-N3 of the same base pair.18 While the geometry requirements 
expressed in the structure-activity relationship rules applied to complexes that contain NH3 or 
aliphatic amines as non-leaving groups, they appeared not valid for compounds in which 
platinum carries planar N-heterocyclic amines or aromatic amines are presented as non-
replaceable ligands.19,20  
It has been previously shown that the trans isomers of some complexes, where one or 
both NH3 ligands of trans-[PtCl2(NH3)2] have been replaced with planar ligands (such as 
pyridine, thiazole, quinoline, imidazole) have enhanced cytotoxicity compared to the cis 
analogues.21-23 Such non-classical trans-platinum antitumor complexes show quite an altered 
range of biological activity in vitro, compared to the clinically used cisplatin, including 
increased cytotoxicity in cisplatin-resistant tumor cells. To explore and identify new trans-
platinum complexes potentially endowed with biological activity, it was decided to study new 
asymmetric trans-platinum complexes, having a planar ligand and an aliphatic amine, where 
iPram is maintained as the aliphatic amine and the planar ligand is an azole ligand with or 
without H-bond donor capacity (pyrazole, 1-methylimidazole, 1-methylpyrazole) as presented 
in Figure 3.1.  
In this chapter, it will be shown that these three new asymmetric trans-Pt(II) complexes 
display improved cytotoxic activity compared to cisplatin in several human tumor cell lines, 
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and especially in the cisplatin-resistant cell line, A2780R. In addition to the cytotoxicity data, 
the reactions with model base GMP are reported. 
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Figure 3.1. Structural formula and numbering scheme of the new asymmetric trans-Pt(II) complexes. 
 
3.2 Experimental section 
3.2.1 Materials 
K2PtCl4 was provided by Johnson & Matthey (Reading, UK). Pyrazole, 
isopropylamine and guanosine 5’-monophosphate were obtained from Sigma-Aldrich.          
1-methylimidazole and 1-methylpyrazole were obtained from Fisher Scientific Nederland 
B.V.  
 
3.2.2 Synthesis and characterization of the trans-[PtCl2(iPram)(azole)] complexes 
A suspension of cis-[PtCl2(iPram)2] (0.2 g, 0.521 mmol) in 8 ml of water was treated 
with 1.9 equiv. of pyrazole (Hpz), 1-methylimidazole (Meim) and 1-methylpyrazole (Mepz), 
respectively. The mixture was stirred and heated at 70 ºC until a clear yellow solution was 
obtained, which was brought to reflux for 1 hr. Subsequently, the solution was cooled to room 
temperature, and hydrochloric acid (12 M, 0.364 ml) was added. The solution was heated to 
reflux for 6 hr and then cooled down in an ice bath and stored at 4 ºC overnight, to increase 
the yield of the reaction. The product was collected by filtration and washed with water 
(Scheme 3.1), obtaining the pure desired complexes: trans-[PtCl2(iPram)(Hpz)] (tHpz), 
trans-[PtCl2(iPram)(Meim)] (tMeim) and trans-[PtCl2(iPram)(Mepz)] (tMepz) (Figure 3.1). 
Yield: (tHpz) 0.127 g (60 %), (tMeim) 0.164 g (75 %), (tMepz) 0.157 g (72 %).24 The three 
complexes were characterized by 1H and 195Pt NMR (Table 3.1), IR, X-ray crystal analysis 
and by elemental analysis. Data are as follows: (tHpz) Theory % (PtCl2C6H13N3): C: 18.33, 
H: 3.33, N: 10.69; Found %: C: 18.62, H: 3.20, N: 10.01; (tMeim) Theory % (PtCl2C7H15N3): 
C: 20.65, H: 3.71, N: 10.32; Found %: C: 20.74, H: 3.90, N: 10.53; (tMepz) Theory % 
(PtCl2C7H15N3): C: 20.65, H: 3.71, N: 10.32; Found %: C: 20.54, H: 3.80, N: 10.43. In the 1H 
NMR (CDCl3) spectra for all the platinum complexes the signals corresponding to the azole 
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ligands and to the iPram are shifted downfield, compared to each of their free ligands. The 
chemical shifts observed for 195Pt NMR (in CDCl3) are -2168, -2118 and -2119 ppm for tHpz, 
tMeim and tMepz, respectively; these values agree with a trans environment of 2Cl and 2N 
around the platinum atom.25,26 The trans geometry is also supported by IR spectral data (one 
band at 342, 335 and 334 cm-1 for complex tHpz, tMeim and tMepz, respectively, assigned 
to the stretching of the Pt—Cl bonds).27 The structure for the three complexes has been 
depicted schematically in Figure 3.1 
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Scheme 3.1. Synthetic scheme for the asymmetric trans-platinum(II) complexes (exc= excess).  
 
 
 
 
 
Table 3.1. 1H and 195Pt NMR Data for the trans-Pt(II) complexes (solvent: CDCl3) (see Figure 3.1 for 
numbering).  
Complex Azole, δ(1H), ppm iPram, δ(1H), ppm δ(195Pt), ppm 
tHpz 
11.69 [H1’(s)], 8.13 [H3’(d)], 
6.38 [H4’(t)], 7.59 [H5’(d)] 
3.41 [H1(sept)], 1.38 
[H2(d)] 
-2168 
tMeim 
3.7 [H6’(s)], 8.02 [H2’(s)], 
6.79 [H4’(d)], 7.42 [H5’(d)] 
3.43 [H1(sept)],  
1.37 [H2(d)] 
-2118 
tMepz 
4.13 [H6’(s)], 7.58 [H3’(s)], 
6.35 [H4’(d)], 7.95 [H5’(d)] 
3.10 [H1(sept)],  
1.16 [H2(d)] 
-2119 
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3.2.3 Physical measurements  
Elemental analysis was performed in a Perkin-Elmer series II CHNS/O Analyzer 
model 2400. NMR spectra were recorded on a Bruker DPX 300 spectrometer. The 
temperature was kept constant (at 310 K for the GMP reactions, and at 298 K for the other 
cases) by a variable temperature unit. 1H and 195Pt NMR was measured in D2O (for GMP 
reactions) and CDCl3 (for the characterization of the remaining complexes). FTIR spectra 
were obtained on a Perkin Elmer Paragon 1000 FTIR spectrophotometer equipped with a Golden 
Gate ATR device, using the diffuse reflectance technique in the range 4000-300 cm-1 (resolution 
4 cm-1). Mass spectrometry was performed in a Finnigan TQS700 instrument. 
 
3.2.4 X-ray structural determinations 
Single crystals of complexes tHpz, tMeim and tMepz were obtained by slow 
evaporation of their saturated CDCl3 solutions, directly from the NMR tube. X-ray intensities 
were measured on a Nonius KappaCCD diffractometer with rotating anode (λ = 0.71073 Å) at 
a temperature of 150(2) K. The structures were solved with automated Patterson methods 
(compounds tHpz and tMeim, DIRDIF-9728) and Direct Methods (compound tMepz, 
SHELXS-86129) and refined with SHELXL-9730 against F2 of all reflections. Non-hydrogen 
atoms were refined freely with anisotropic displacement parameters; hydrogen atoms were 
refined as rigid groups. Molecular illustration, structure checking and calculations were 
performed with the PLATON package.31 All structural drawings and geometrical calculations 
were performed with PLATON.32 The details of the crystal structure determinations are given 
in Table 3.2. 
 
3.2.5 Reactions of tHpz, tMeim and tMepz with GMP monitored by NMR 
GMP was reacted with tHpz, tMeim and tMepz by using excess (1:4) and 
stochiometric (1:2) amounts of GMP in 250 μL 0.1 M NaClO4/D2O in a NMR tube. The three 
complexes were first pre-dissolved in 30 μL of DMSO-d6 for complex tHpz and DMF-d7 for 
complex tMeim and tMepz, respectively; because of the poor solubility of the complexes in 
water; this was followed by the addition of 480 μL of NaClO4/D2O. The reactions were left to 
incubate at 310 K in the dark. The reactions were monitored by recording 1H NMR spectra at 
time intervals of 30 min during the overnight reaction, and after every 24 hr until no further 
changes were observed. Subsequently, at the end of the reactions 195Pt NMR was recorded 
from the same solution in the same NMR tube and mass spectrometry was recorded from this 
tube as well.   
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Table 3.2. Crystal data for trans-[PtCl2(iPram)(Hpz)] (tHpz), trans-[PtCl2(iPram)(Meim)] (tMeim) 
and trans-[PtCl2(iPram)(Mepz)] (tMepz). 
 
 tHpz tMeim tMepz 
Chemical formula [PtCl2C6H13N3] [PtCl2C7H15N3] [PtCl2C7H15N3] 
Formula weight 393.17 407.2 407.2 
Crystal system monoclinic monoclinic monoclinic 
Space group P21/c P21/c P21/c 
a [Å] 8.2538(10) 8.7902(1) 10.4091(8) 
b [Å] 7.7014(10) 24.5227(2) 8.1146(6) 
c [Å] 16.8804(10) 11.1475(1) 16.9424(15) 
α [deg] 90 90 90 
β [deg] 99.9560(10) 97.1514(3) 125.424(6) 
γ [deg] 90 90 90 
V [Å3] 1056.9(2) 2384.26(4) 1166.15 
Z 4 8 4 
ρcalc [g/cm3] 2.471 2.269  2.319 
μ [mm-1] 13.735 12.181  12.453 
Transmission 0.35-0.66 0.11-0.45 0.20-0.43 
Crystal color Colorless Colorless Colorless 
Crystal size [mm3] 0.30 x 0.08 x 0.18 0.30 x 0.15 x 0.15  0.15 x 0.06 x 0.06 
No. refl. measured 27690 36053 25084 
No. unique refle. 2409 5485 2284 
No. Parameters 111 241 151 
R1 (all refl.) 0.0245 0.0232 0.0339 
R1 (obs. refl.) 0.0171 0.0206 0.0237 
WR2 (all refl.) 0.0314 0.0453 0.0565 
WR2 (obs. refl.) 0.0299 0.0444 0.0525 
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3.2.6 Cytotoxic studies 
In vitro cytotoxicity test in human tumor cell lines  
In vitro cytotoxicity tests in human tumor cell lines were performed at the Dr. Daniel 
den Hoed Kliniek (Rotterdam Cancer Institute), Department of Medical Oncology 
(Rotterdam, The Netherlands). Cell lines WIDR, M19, A498, IGROV and H226 belong to the 
currently used anticancer screening panel of the National Cancer Institute, USA.33 The MCF7 
cell line is estrogen (ER)+/ progesterone (pgR)+ and the cell line EVSA-T is (ER)-/(PgR)-. 
Prior to the experiments a mycoplasma test was carried out on all the cell lines and 
found to be negative. All cell lines were maintained in a continuous logarithmic culture in 
RPMI 1640 medium with Hepes and phenol red. The medium was supplemented with 10% 
FCS, penicillin 100 IU/ml and streptomycin 100 μg/ml. The cells were mildly trypsinized for 
passage and for use in the experiments. On day 0, 150 μl of trypsinized tumor cells (1500-
2000 cells/well) were plated in a 96-well flatbottom microtiter plate (Falcon 3072, BD). The 
plates were preincubated 48 hr at 37 ºC, 8.5 % CO2 to allow the cells to adhere. On day 2, a 
three-fold dilution sequence of ten steps was made in full medium, starting with the 250000 
ng/ml stock solution (1 mg of each complex, tHpz, tMeim and tMepz). Every dilution was 
applied in quadruplicate by adding 50 μl to a column of four wells. On day 7, the incubation 
was finished and the plates were washed twice with PBS. Subsequently, the cells were fixed 
with 10 % trichloroacetic acid in PBS and placed at 4 ºC for 1 hr. After five washings with 
water, the cells were stained for at least 15 min with 0.4 % SRB dissolved in 1 % acetic acid. 
After staining, the cells were washed with 1 % acetic acid to removed the unbound stain. The 
plates were air-dried and the bound stain was dissolved in 150 μl 10 mM 
Tris(hydroxymethyl)aminomethane buffer (Tris-base). The absorbance was read at 540 nm 
using an automated microplate reader (Labsystems Multiskan MS). Cytotoxicity was 
estimated by the microculture sulforhodamine B (SRB) test.34 Data were used for construction 
of response curves and determination of the IC50 values by use of the Prism software, version 
3.0, 2000. 
 
In vitro cytotoxicity test in A2780 cell lines sensitive and resistant to cisplatin 
A2780 and A2780R human ovarian cell lines were obtained from Prof. Dr. Carmen 
Navarro Ranninger’s group (Universidad Autónoma de Madrid, Spain). The cell lines A2780 
and A2780R, i.e. ovarian cancer cell lines derived from untreated patient cells,35 which 
survive in cultures treated with the compounds, were evaluated using the so-called MTT 
method.36 This method is based on the mitochondrial reduction of the tetrazolium salt MTT 
(2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) by actively growing cells 
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to produce blue insoluble purple formazan crystals. Both cell lines were cultured in McCoy’s 
5a medium, supplemented with 10 % fetal Calf serum (Gibco, Paisley, Scotland); penicillin 
(100 units/ml): Duchefa, Netherlands) and streptomycin (100 μg/ml: Duchefa, Netherlands). 
For the cell-growth assay, cells (5·104/ml) were pre-cultured in 96 multi-well plates for 24 hr 
at 37 ºC, 5 % CO2. Compounds were added in microwells containing the cell culture at final 
concentrations of 0-200 μM; 48 hr later, cell survival was evaluated by measuring the 
absorbance at 590 nm, using a BIO-RAD microplate model 550. The IC50 values (i.e. the 
concentration of the complex that restricts cell growth to 50% of that compared with the 
control) were calculated from curves constructed by plotting cell survival (%) versus 
compound concentration (μM). All experiments were performed in triplicate. Data were used 
for construction of response curves and determination of the IC50 values by use of GraphPad 
Prism software, version 3.0, 2000. 
 
3.3 Results and discussion 
3.3.1 X-ray crystal structures  
The three compounds, tHpz, tMeim and tMepz, were fully characterized by 
spectroscopic and analytical methods, as described in section 3.2.2. For further proofs and 
details of the interatomic distances a 3D-structure determination with X-Ray analysis was 
performed for each of the complexes.  
Complex tHpz was found to crystallize with only one independent molecule in the 
asymmetric unit. A molecular plot is presented in Figure 3.2; selected bond distances, angles 
and torsion angles are presented in Table 3.3. The environment of the Pt atom is slightly 
distorted square planar with the following bond length values: Pt—N2 = 2.019(2) Å, Pt—N6 
= 2.041(2) Å, Pt—Cl1 = 2.30(8) Å and Pt—Cl2 = 2.29(8) Å. These values are comparable 
with those found in other trans-Pt(II) complexes with planar amines.22 The Pt—N(azole) 
bonds were found to be slightly shorter than Pt—N(amine) bonds. Since the Pt—N2 bond for 
the Hpz ligand is almost in the same plane as the ideal plane of this ligand, the torsion angle 
Cl1—Pt1—N2—C3 can be used to gauge the inclination of the ligand with respect to the 
equatorial plane around the Pt. This angle is 159.0(3)º. This value indicates that the ligand 
Hpz is not very twisted with respect to the plane formed by Cl1, Pt1, Cl2 and N6.  This small 
twist can be due to the fact that the H on the N next to the coordination position forms 
hydrogen bonds with both Cl- ligands located in the equatorial plane. Also, the                 
Cl1—Pt1—N6—C7 torsion angle is close to the dihedral angle between the Pt1—N6—C7 
plane of the iPram ligand and the equatorial plane around the Pt (Cl1, N2, Cl2, N6). The fact 
that the torsion angle is -104.21(29)º shows that the ligand adopts the configuration that 
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places the methyl groups as far as possible from the Cl- ligands. This deviation is also related 
to the formation of hydrogen bonds between the H of the amine group and the Cl- ligands. 
The lattice structure of complex tHpz consists of a one-dimensional zig-zag chain, build up 
by hydrogen bonds. A plot of the hydrogen bonds in the chain is displayed in Figure 3.3. The 
details for the hydrogen-bonds geometry are given in Table 3.4. 
 
Figure 3.2. Molecular structure of the complex trans-[PtCl2(iPram)(Hpz)] (tHpz). 
 
 
 
Figure 3.3. Intramolecular hydrogen bonding between N-H and Cl in trans-
[PtCl2(iPram)(Hpz)]. C-H hydrogen atoms have been omitted for clarity.  
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Table 3.3. Selected bond distances (Å), angles, and relevant torsion angles (deg) for trans-
[PtCl2(iPram)(Hpz)] (tHpz). 
 
 
 
Table 3.4. Hydrogen-bonding parameters and short contacts for trans-[PtCl2(iPram)(Hpz)] (tHpz), 
Symmetry operations: i: -x, 1/2+y, 1/2-z, ii: -x, -1/2+y, 1/2-z, iii: -x, -y, 1-z, iv: x, 1/2-y, z. 
D-H...A D-H [Å] H...A [Å] D...A [Å] D-H...A [deg.] 
N1-H1...Cl1 0.88 2.60 3.087(3) 116 
N1-H1...Cl1iii 0.88 2.81 3.391(3) 125 
N6-H6A...Cl2ii 0.92 2.66 3.534(3) 158 
N6-H6B...Cl1i 0.92 2.54 3.451(2) 170 
C3-H3…Cl2 0.95 2.80 3.226(3) 108 
C5-H5…Cl2iv 0.95 2.69 3.610(3) 162 
 
Complex tMeim was found to crystallize with two independent molecules in the 
asymmetric unit. A molecular plot of the two molecules is presented in Figure 3.4; bond 
distances angles, and torsion angles are presented in Table 3.5. In both residues a slightly 
distorted square planar geometry is observed for complex tMeim. 
 
 
Atoms Distance and angles 
Pt1-N2 2.019(2) 
Pt1-N6 2.041(2) 
Pt1-Cl1 2.3027(8) 
Pt1-Cl2 2.2905(8) 
N2-Pt1-N3 176.39(10) 
Cl1-Pt1-Cl2 174.69(3) 
N2-Pt1-Cl1 90.96(7) 
N2-Pt1-Cl2 90.32(7) 
N6-Pt1-Cl1 90.90(7) 
N6-Pt1-Cl2 88.11(7) 
Cl1-Pt1-N2-C3 159.0(3) 
Cl1-Pt1-N6-C7 -104.21(19) 
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Figure 3.4. Displacement ellipsoid plot (50% probability) for both independent molecules of the 
trans-[PtCl2(iPram)(Meim)] complex (tMeim), showing the different conformations of the iPram 
ligands.  
Both distances and angles are comparable for both independent molecules. The torsion 
of the Meim ligand is slightly different with Cl11—Pt1—N13—C12 of -155.1(3)º in residue 
A and Cl21—Pt2—N23—C33 of -139.0(3)º in residue B. In both residues the Meim ligand is 
almost in the same plane as the equatorial plane formed by Cl11, N12, Cl12, N13 and Cl21, 
N22, Cl22, N23 for residues A and B, respectively. The major difference is in the 
conformation of the iPram ligand with Pt1—N12—C17—H17 of 53.27º in residue A and 
Pt2—N22—C27—H27 of -48.65º in residue B. Therefore, these values of torsion angles 
show that the iPram ligand is orientated out of the equatorial plane around the platinum atom. 
The Pt—N(azole) bonds with values of 2.029(3) and 2.011(3) Å are slightly shorter than the      
Pt—N(amine) bonds  (2.039(3) Å) in both residues. The Pt—Cl bonds lengths are in the 
expected range; similar distances were found in the crystal structure of other platinum 
complexes with the same Pt donor atom environment.25,26,37-39 
 
 
Table 3.5. Selected bond distances (Å), angles, and relevant torsion angles (deg) for trans-
[PtCl2(iPram)(Meim)] (tMeim). 
Residue A Residue B 
Pt1-N12 2.039(3) Pt2-N22 2.039(3) 
Pt1-N13 2.029(3) Pt2-N23 2.011(3) 
Pt1-Cl11 2.312(7) Pt2-Cl21 2.2967(8) 
Pt1-Cl12 2.297(7) Pt2-Cl22 2.2988(8) 
N12-Pt1-N13 177.49(10) N22-Pt2-N23 178.43(10) 
Cl11-Pt1-Cl12 175.72(3) Cl21-Pt2-Cl22 178.58(3) 
N12-Pt1-Cl11 87.62(7) N22-Pt2-Cl21 90.35(8) 
N12-Pt1-Cl12 88.66(7) N22-Pt2-Cl22 88.83(8) 
N13-Pt1-Cl11 92.42(8) N23-Pt2-Cl21 91.14(8) 
N13-Pt1-Cl12 91.39(8) N23-Pt2-Cl22 89.70(8) 
C12-N13-Pt1-Cl11 -155.1(3) C22-N23-Pt2-Cl21 -139.0(3) 
C17-N12-Pt1-Cl11 -74.8(2) C27-N22-Pt2-Cl21 -103.5(2) 
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The two independent molecules are linked by intermolecular hydrogen bonds with the 
amine hydrogen atoms as hydrogen bond donors and the chloride ligands as acceptors. 
Thereby a zig-zag one-dimensional chain is formed in the direction of the crystallographic a 
axis, with the chain consisting of both independent residues. A plot of the hydrogen-bonding 
pattern in the chain is displayed in Figure 3.5. The details for the hydrogen bonding geometry 
are given in Table 3.6. 
 
 
Table 3.6. Hydrogen-bonding parameters for trans-[PtCl2(iPram)(Meim)] (tMeim). Symmetry 
operations: i: 2-x, y-0.5, 1.5-z, ii: 1-x, y-0.5, 1.5-z, iii: 1-x, y+0.5, 1.5-z, iv: 2-x, y+0.5, 1.5-z 
D-H...A D-H [Å] H...A [Å] D...A [Å] D-H...A [deg.] 
N12-H12A...Cl22i 0.92 2.37 3.257(3) 161 
N12-H12B...Cl21ii 0.92 2.61 3.437(3) 150 
N22-H22A...Cl12iii 0.92 2.73 3.589(3) 156 
N22-H22B...Cl11iv 0.92 2.56 3.470(3) 172 
 
 
 
 
Figure 3.5. Intramolecular hydrogen bonding between N-H and Cl in trans-[PtCl2(iPram)(Meim)]. 
Hydrogen atoms have been omitted for clarity. 
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Complex tMepz, albeit similar to complex tMeim, crystallizes with only one 
molecule in the asymmetric unit. The iPram ligand appears to be disordered over two 
conformations and it shows, as the other two complexes, a slightly distorted square planar 
geometry around the platinum center. A molecular plot of the x-ray structure for complex 
tMepz is presented in Figure 3.6; bond distances, angles, and torsion angles are presented in 
Table 3.7. 
 
Figure 3.6. Molecular structure of the complex trans-[PtCl2(iPram)(Mepz)] (tMepz). 
 
As in complex tHpz and tMeim, complex tMepz contains Pt—N(azole) bond of 
2.019(4)Å, which is slightly shorter than the Pt—N(amine) bond of 2.035(4) Å. The Pt—Cl 
bonds lengths are in the expected range.25,26,37-39 In this case the pyrazole ligand in completely 
perpendicular to the equatorial plane formed by Cl1, N2, Cl2 and N3 around the Pt atom, with 
a torsion angle Cl1—Pt1—N2—N1 of 91.19º. This is due to the steric hindrance of the 
methyl group in the N next to the coordination position of the Mepz ligand. The iPram ligand 
has different torsion angles -99.17ºand -70.82º according to its different conformations. These 
values of torsion angles show a perpendicular disposition of the iPram ligand respect the 
equatorial plane. 
By hydrogen bonding a zig-zag one-dimensional chain is formed in the direction of 
the crystallographic b axis. As expected, the Mepz ligand itself is not involved in hydrogen 
bonding. A plot of the hydrogen-bonding pattern in the chain is displayed in Figure 3.7. The 
details for the hydrogen bonding geometry are given in Table 3.8. 
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Table 3.7. Selected bond distances (Å), angles, and relevant torsion angles (deg) for trans-
[PtCl2(iPram)(Mepz)] (tMepz). 
Atoms Distances and angles 
Pt1-N2 2.019(3) 
Pt1-N3 2.036(3) 
Pt1-Cl1 2.294(7) 
Pt1-Cl2 2.304(7) 
N2-Pt1-N3 179.02(10) 
Cl1-Pt1-Cl2 178.23(3) 
N2-Pt1-Cl1 89.85(7) 
N2-Pt1-Cl2 91.48(7) 
N3-Pt1-Cl1 89.87(8) 
N3-Pt1-Cl2 88.92(8) 
Cl1-Pt1-N2-N1 91.19(5) 
Cl1-Pt1-N3-C5A -99.17(5) 
Cl1-Pt1-N3C5B -70.82(6) 
 
Table 3.8. Hydrogen-bonding parameters for trans-[PtCl2(iPram)(Mepz)] (tMepz). Symmetry 
operations: i: 1-x,-1/2+y,1/2-z, ii: 1-x, 1/2+y, 1/2-z. 
D-H...A D-H [Å] H...A [Å] D...A [Å] D-H...A [deg.] 
N3-H32A...Cl2i 0.92 2.49 3.388(5) 165 
N3-H32B...Cl1ii 0.92 2.63 3.390 141 
 
 
 
Figure 3.7. Intramolecular hydrogen bonding between N-H and Cl in trans-[PtCl2(iPram)(Mepz)]. C-
H hydrogen atoms have been omitted for clarity.  
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3.3.2 Stability of complexes tHpz, tMeim and tMepz in aqueous solution 
The stability of complexes tHpz, tMeim and tMepz in solution has been followed as 
a function of time in D2O/H2O (80/20) by 1H NMR spectroscopy. The three complexes were 
pre-dissolved in DMSO-d6 for complex tHpz and DMF-d7 for complexes tMeim and tMepz, 
respectively. The aromatic resonances of the complex tMeim remained unchanged over 2 
weeks at 310 K, and no new signals appeared, indicating that this complex is inert to 
hydrolysis under these conditions. However, for complexes tHpz and tMepz, following the 
aromatic resonances of such ligands over time, the appearance of a new set of aromatic 
signals, is evident after 8 hrs. These new signals can be assigned to the hydrolyzed species 
trans-[Pt(iPram)(Hpz)(D2O)2]2+ and trans-[Pt(iPram)(Mepz)(D2O)2]2+.  
 
3.3.3 Reactions of complexes tHpz, tMeim and tMepz with GMP 
To understand the reactivity studied of this series of compounds towards DNA, the 
reaction with an excess of GMP (1:4) was monitored. The 1H NMR spectra of the reactions 
and the reaction scheme are shown in Figure 3.8 and Scheme 3.2, respectively. As the 
reaction proceeds, the H8 signal of the free GMP at 8.18 ppm decreases in intensity, while 
new signals appear downfield. In all three complexes it was observed that the chemical shifts 
of the protons of the azole ligands were sensitive to the formation of different species. 
For complex tHpz, the signals at 8.90 and 8.72 ppm, which appear simultaneously, 
were assigned to the monoadduct and monoadduct of the hydrolysed product, respectively, 
i.e. I-(GMP)Cl and I-(GMP)(OD2). These signals increase with time. The formation of such 
intermediate species have been reported previously during the reaction of platinum(II) 
complexes with GMP.40-44 After 1 hr of reaction, the monoadduct signal increases less than 
the hydrolysed one. 3 hr after the beginning of the reaction, at 8.88 ppm the signal assigned to 
the 1:2 product, I-(GMP)2, starts to appear and increases in intensity until the end of the 
reaction. After 96 hr of reaction, no further changes were observed and neither a change in the 
pH was seen, so it was concluded that the reaction had finished. The H8 proton of I-(GMP)2 
appears 0.7 ppm at lower field (310 K) than free GMP at pH = 7.20, which is comparable to 
that of cisplatin-bound GMP at this pH. This implies less stacked guanine ligands and 
allowance of relatively free rotation about the Pt—N7 bonds.40 The value for J1’-2’ is found to 
be 5.96 Hz, indicating a sugar puckering with similar N/S population, as that of a free 
GMP.45-47 For confirmation of the formation of the bisadduct product, I-(GMP)2, 195Pt NMR 
was measured and a single signal was found at -2507 ppm, which agrees with a 4N 
environment around the platinum atom.48 
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Figure 3.8. 1H NMR spectra in the aromatic region on the reaction of complexes tHpz, tMeim and 
tMepz with 4 equiv. of GMP in 0.1 M NaClO4/D2O solution measured at 310 K as a function of time. 
The symbols show the H8 signals of GMP ligands in the products: I, II, III-(GMP)Cl (●); I, II, III -
(GMP(D2O) (◣ );  I, II, III -(GMP)2 (■); free GMP (▲). (*) corresponds to traces of DMF used to 
predissolve the complex. 
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Scheme 3.2. Proposed reaction scheme of tHpz, tMeim and tMepz with an excess of GMP in 
aqueous solution. 
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For complex tMeim, the signal at 8.76 ppm assigned to the monoadduct product, II-
(GMP)Cl, increases in time up to 5.5 hr from the beginning of the reaction. After 1.5 hr a new 
signal appeared at 8.84 ppm, which was assigned to the bisadduct product, II-(GMP)2, and it 
increased in intensity until 48 hr of reaction, when only the signal for this species was 
observed and shows no further changes. For this reaction, the pH was also followed in time, 
and it was found to behave similar to that in tHpz. During the first hour of reaction significant 
changes were observed in the pH, i.e. a decrease the values from 7.98 to 7.26, but for the 
remaining 24 hr the variation of the pH was small; i.e. ΔpH < 0.3. For the final product 195Pt 
NMR was also measured and a single peak at -2377 ppm was observed. This 195Pt resonance 
appears about 100 ppm downfield from values that are usually observed for mixed 4N 
coordination of Pt2+ in aqueous solution. A solvent dependence of 195Pt shifts is held 
responsible for this difference, and such effects have been reported before.49,50  
The formation of the bisadduct product was confirmed with mass spectrometry. A 
peak corresponding to the molecular weight of this bisadduct was seen, II-(GMP)2 (m/z= 
531.1). The reaction with an excess (4 equiv.) of GMP yields the same products as those 
resulting from stoichiometric conditions. The value for J1’-2’ was found to be 13.8 Hz, 
implying a sugar puckering with S conformation, i.e. different from that of the free GMP. In 
this case the different conformation of the sugar moiety compared with the reaction of tHpz 
may be due to a steric effect resulting from the methyl group in the imidazole ring. 
  For complex tMepz, the 1H and 195Pt NMR profiles of the bisadduct species, III-
(GMP)2, are similar of that of II-(GMP)2. However, complex tMepz reacts slower than 
complexes tHpz and tMeim. The origin for this difference must be related to the methyl 
substituent in the N next to the coordination position of the pyrazole ring. Like in complex 
tHpz, the monoadduct hydrolysed species was observed, III-(GMP)(OD2). The 195Pt NMR 
spectrum of the product III-(GMP)2 was measured and a single peak at -2380 ppm was 
observed,49,50 which agrees with a 4N environment around the platinum centre. In this 
reaction, mass spectrometry was used to confirm that the product was present and a peak 
assigned to the molecular weight of the bisadduct product, III-(GMP)2 (m/z= 531.8) was 
detected. The value for J1’-2’ was found to be 6.15 Hz indicating a sugar puckering mostly 
with S conformation, but also with some degree of N conformation.45-47 
The relative rates of the reaction for complexes, tHpz, tMeim and tMepz, with GMP 
were first studied in a qualitative manner. In tHpz and tMeim the monoadduct product 
appears 15 min after the beginning of the reaction, while for complex tMepz it appears only 
after 1 hr under identical conditions, probably due to the steric hindrance of the methyl group 
next to the donor atom in the pyrazole ring. This fact was confirmed, since the bisadduct 
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product for tMepz appeared only 7 hr after the start of the reaction, while for complexes tHpz 
and tMeim this species appears after 3 and 1.5 hr, respectively. For the reaction of complexes 
tHpz and tMepz also the hydrolyzed monoadduct I-(GMP)(OD2) and III-(GMP)(OD2), were 
clearly observed as intermediates, but not for complex tMeim.  
To confirm the bifunctional behaviour of these asymmetric trans-Pt(II) complexes in 
their interaction with GMP; the interaction of them with stoichiometric amount of GMP, ratio 
1:2, was also studied (Figure 3.9) for the three complexes. The behaviour of the three 
complexes was found to be the same as in the reaction with an excess (1:4) of GMP, albeit 
somewhat slower. Bifunctional species were observed and in complex tMeim now also the 
monoadduct of the hydrolysed species was observed, which had not been detected in the 
reaction when an excess of GMP was used.  
 
 
 
 
 
 
 
 
 
 
Figure 3.9. 1H NMR spectra in the aromatic region on the reaction of complexes tHpz, tMeim and 
tMepz with 2 equiv. of GMP in 0.1 M NaClO4/D2O solution measured at 310 K as a function of time. 
The symbols show the H8 signals of GMP ligands in the products: I, II, III-(GMP)Cl (●); I, II, III-
GMP(D2O) (◣ );  I, II, III-(GMP)2 (■); free GMP (▲). (*) corresponds to traces of DMF used to 
predissolve the complexes. 
 
3.3.4 Kinetic aspects of complex tMeim in its reaction with excess of GMP 
The details of the kinetics will be presented below only for complex tMeim, where 
clearly isolated (non-overlapping) NMR signals have been observed. The kinetics of the 
reaction for tMeim has been followed with an excess of GMP (1:4) in 0.1 M NaClO4/D2O 
solution. The variation of percentage of disappearance for the free GMP has been analyzed in 
detail (Figure 3.10), together with the appearance of the mono- and bifunctional adducts. 
After 5 hr from the beginning of the reaction the mono- and bifunctional adducts appear to be 
present in about the same concentration, beyond this point the monofunctional adduct starts to 
decrease. The time of disappearance of 25% (t1/4) of free GMP was found to be 3 hr (180 min) 
and the time of formation (t1/4) of 25% of (II-(GMP)2) was found to be 4 hr (240 min). These 
values were determined graphically based on the relative integration values of the H8 proton. 
** 
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The reaction rate is proportional to the starting concentrations of GMP; which indicates that 
the reaction of tMeim with GMP mainly proceeds via direct substitution of a Cl- ligand by the 
N7 of GMP. It should be noted that for cisplatin, the rate-determining step for binding to a 
nucleic acid is known to be the hydrolysis of a Pt—Cl bond.51 Steric factors might also affect 
the reaction rate.  
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Figure 3.10. Percentage of reacted GMP in the reaction of complex tMeim with excess of 
GMP (1:4) (Conditions: 37 ºC, in NaClO4 (0.1 M)). 
 
3.3.5 Cytotoxicity. In vitro cytotoxicity assay in human tumor cell lines and on A2780 cell 
lines sensitive and resistant to cisplatin  
In vitro cytotoxicity assay in human tumor cell lines  
To investigate the antitumor activity, the cell growth of several cell lines was followed 
in the presence of compounds tHpz, tMeim and tMepz. Cisplatin was used as a reference 
compound under the same conditions. The IC50 values of tHpz, tMeim, tMepz and cisplatin, 
in several human tumor cell lines, MCF7 and EVSA-T (breast cancer), WIDR (colon cancer), 
IGROV (ovarian cancer), M19 (melanoma), A498 (renal cancer), and H226 (non-small cell 
lung cancer), have been summarized in Table 3.9. The three complexes appear to be active in 
the micromolar range in all used cell lines. Complexes tHpz and tMeim show a remarkable 
cytotoxicity profiles with a high specify for the EVSA-T and IGROV cell lines, and to lesser 
extent the H226 cell line. In the rest of cell lines the activity is comparable with cisplatin. 
However, although complex tMepz shows IC50 values in the micromolar range as cisplatin, it 
does not show an interesting activity in any of these cell lines. So, it can be concluded that 
complexes tHpz and tMeim complexes are about equally active as cisplatin.  
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Table 3.9. In vitro cytotoxicity assay of the asymmetric trans-Platinum(II) complexes and cisplatin on 
human tumor cell lines. 
IC50 (μM) 
Test 
compound 
MCF7 EVSA-T WIDR IGROV M19 A498 H226 
tHpz 4.21 1.56 7.74 1.88 6.41 9.79 12.76 
tMeim 5.52 2.86 10.69 3.66 7.4 19.31 18.81 
tMepz 18 8.4 25.4 10.3 19 55.2 28.7 
Cisplatin 1.42 1.42 1.78 0.43 1.84 5.75 4.53 
 
In vitro cytotoxicity assay on A2780 cell lines sensitive and resistant to cisplatin 
The cytotoxicity results of the trans-Pt(II) complexes and cisplatin in cisplatin-
sensitive and cisplatin-resistant ovarian cancer cell lines, A2780, are shown in Table 3.10. 
The resistant cell line A2780R was selected, because it displays all known major mechanisms 
of resistance to cisplatin: i.e. decreased uptake, enhanced DNA repair, increased DNA 
damage tolerance, and elevated glutathione (GSH) levels. In the parental cell line, the three 
complexes show cytotoxicity comparable to cisplatin, albeit less cytotoxic than cisplatin, but 
still within the active range. However, the three complexes are more potent than cisplatin in 
the resistant cell line, which includes some of the known major mechanisms of resistance to 
cisplatin, as said above. The so-called resistance factor (RF), defined as the relative ratio of 
IC50 values in both cell lines (A2780R/A2780), is found to be much lower for tHpz, tMeim 
and tMepz than for cisplatin. So it can be concluded that the three asymmetric trans-
platinum(II) complexes can overcome cisplatin resistance, since all exhibit an increased 
cytotoxicity in the resistant cell line compared to cisplatin.  
 
Table 3.10. In vitro cytotoxicity assay of the trans-Platinum(II) complexes and cisplatin on 
A2780 ovarian cancer cell lines sensitive (A2780) and resistant (A2780R) to cisplatin.  
IC50 (μM) 
Test 
compound 
A2780 A2780R RF 
tHpz 28 11 0.40 
tMeim 21 14 0.66 
tMepz 49 21 0.43 
Cisplatin 3 24 8 
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3.4 Concluding remarks 
In the results presented above, three new asymmetric trans-Pt(II) complexes with formula 
trans-[PtCl2(iPram)(azole)], where azole is pyrazole (tHpz), 1-methylimidazole (tMeim) and 
1-methylpyrazole (tMepz), have been discussed. For all three complexes the X-ray structure 
has been determined to confirm the structure.  The data of the crystal structures for the three 
complexes, tHpz and tMeim and tMepz, trans-[PtCl2(iPram)(Hpz)], trans-
[PtCl2(iPram)(Meim)] and trans-[PtCl2(iPram)(Mepz)], respectively, show that the square-
planar geometry around the trans-Pt(II) center is only slightly distorted. For complex tMeim, 
the slightly different orientations of the iPram and Meim ligands result in two different 
residues, A and B. Complex tMepz also presents slightly different orientations of the iPram 
ligand, however, only one molecule was found to crystallize in the asymmetric unit. All the 
three crystal structures exhibit NH—H…Cl hydrogen bonding. In tHpz, both the pyrazole 
and iPram acidic hydrogen atoms are involved in hydrogen bonding, and result in the 
formation of sheets in the bc plane. In tMeim and tMepz, the hydrogen bonds are from the 
hydrogen atoms in the iPram as expected, and join the molecules together into zig-zag chains, 
parallel to the a axis in tMeim and b axis in tMepz. 
In this chapter it is also shown how the planar ligands enhance the antitumor properties of 
the trans-platinum(II) complexes, showing a good cytotoxicity mostly in the same range as 
cisplatin. In fact, complexes tHpz and tMeim exhibit cytotoxic properties similar to those of 
cisplatin in several human tumor cell lines, and they specially show a high specificity for the 
EVSA-T and IGROV cell lines. Complex tMepz, although with a cytotoxicity in the active 
range of cisplatin, does not show a special activity in any of the human tumor cell lines tested. 
But even more importantly, the three complexes do not exhibit cross-resistance to cisplatin as 
shown in the cisplatin-resistant cell line A2780. The three complexes, tHpz, tMeim and 
tMepz, react with GMP with rates comparable to that of cisplatin, albeit with a slightly 
different mechanism, at least for tMeim. In the case of tMeim when it reacts with an excess 
of GMP, the reaction appears to proceed primarily with an associative mechanism, which is a 
substitution without experiencing hydrolysis of the Cl- ligand by the N7 of the GMP, whereas 
the rate-determining step for cisplatin is known to be the hydrolysis.52 However, when a 
stoichiometric amount of GMP is used, complex tMeim follows the same mechanism as 
cisplatin, and a monoadduct-hydrolyzed species can be observed. The mechanism of the 
reaction of tHpz and tMepz with GMP appears to be slightly different, as the monoadduct-
hydrolyzed species could be observed using both excess and a stoichiometric amount of 
GMP, probably due to the fact that the hydrolysis species for complex tHpz are stabilized by 
the formation of hydrogen bonds between the proton of the pyrazole ring and the N next to 
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the coordination position and the H2O bound to platinum after the hydrolysis of the second Cl, 
allowing their observation in 1H NMR, and in the case of complex tMepz, steric effects may 
be related to the observation of those species. So it is suggested that complexes tHpz and 
tMepz follow the same mechanism as cisplatin. Regretfully a detailed kinetic analysis was 
not possible, due to a disturbing overlap of the NMR signals. 
The results shown here are of fundamental importance, because complexes structurally 
different from cisplatin and its analogues may display clinically important differences in 
activity or toxicity. The study of these new trans complexes with the model base guanosine 
5’-monophosphate has shown that the three cases they may indeed behave as bifunctional 
DNA-binding species. 
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Comparison of antitumor activity and interaction with 
DNA model bases of cis-[PtCl2(iPram)(azole)] complexes 
with their trans analogues* 
 
Abstract 
 Asymmetric cis-platinum(II) complexes (cMeim and cMepz) were synthesized and 
characterized by elemental analysis, 1H and 195Pt NMR and IR. For one of the complexes 
(cMeim) the X-ray structure was also determined. Cytotoxicity tests in several human tumor 
cell lines including the cisplatin-sensitive cell line A2780 and its cisplatin-resistant analogue, 
were performed with the aim of comparing their antitumor activity with their trans isomers 
and to establish a relation between the structure and the activity. It is found that complexes 
with a cis geometry are less active than their trans analogues in the resistant cell line A2780R. 
However, it was found complex cMeim to overcome cisplatin resistance with a RF value 
lower than 2. In the case of the trans analogues, tMeim and tMepz, both circumvent the 
cisplatin resistance, as reported in Chapter 3. In the interaction with GMP, the asymmetric 
cis-Pt(II) complexes were found to react with similar rates as their trans analogues, forming 
bisadduct species within 24 hr. 
 
                                                 
* The results of this chapter will be (in part) included in E. Pantoja et al.; J. Inorg. Biochem. 2005 (submitted) 
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4.1 Introduction 
Cisplatin is a potent anticancer drug for the treatment of testicular and other solid tumors,1 
but its clinical use is limited by the non activity against a number of cancers, which has been 
ascribed to the acquired resistance developed by many tumors as well as severe side effects. 
Therefore, the search continues for improved platinum antitumor agents and in this search the 
clinical inactivity of transplatin was considered up to recently a paradigm for the classical 
structure-pharmacological activity relationships of platinum drugs.2 A large body of 
experimental evidences has shown that the success of platinum complexes in killing tumors 
cells is a consequence of the formation of different structures with DNA.3,4 Cisplatin reacts 
preferentially by coordination to the N7 position of the purine nucleobases in the major 
groove of B-DNA.5 As detailed in Chapter 1, the major DNA adduct of cisplatin is the 
intrastrand cross-link formed between two neighboring purine bases (1,2-GG or AG 
intrastrand cross-link).6,7 The minor adducts are monofunctional lesions, 1,3-GXG intrastrand 
cross-links (X= A, C, T) and GG interstrand cross-links.8 The study of the interactions of 
antitumor complexes with nucleosides or nucleotides is an important contribution to the 
elucidation of their modes of action. 
Both cis and trans geometries of platinum complexes as antitumor agents have been 
reported. The most of the complexes are symmetric where one or both ammine groups of 
cisplatin or transplatin have been replaced or asymmetric complexes where only one ammine 
group of cisplatin or transplatin was replaced by another amine ligand, such as thiazole, 
piperidine, piperazine, 4-picoline, and cyclohexylamine.9-11 However, examples where both 
ammine groups are replaced by other amines are not too much studied.12 
In this chapter, two new asymmetric cis-Pt(II) complexes of formula cis-
[PtCl2(iPram)(azole)] with isopropylamine (iPram) and an azole ligand, i.e. 1-
methylimidazole (Meim) and 1-methylpyrazole (Mepz) are reported (Figure 4.1), including 
the X-ray structure of one of them.  
 
Pt
NH2CH(CH3)2Cl
Cl N
N
Pt
NH2CH(CH3)2Cl
Cl N
N
cMeim cMepz
1 12 2
1' 1'2'
2'3'
3'4' 4'5'
5'
6'
6'
 
 
Figure 4.1. Structural formula and used atom numbering of the new asymmetric cis-Pt(II) complexes. 
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Cytotoxicity studies in several human tumor cell lines were carried out for both 
complexes and compared to their trans analogues and cisplatin. It was found that both 
asymmetric cis-platinum(II) complexes show strongly reduced cytotoxicity compared to their 
trans analogues and compared to cisplatin. Only the complex cMepz shows a comparable 
cytotoxicity to cisplatin in the human cell line EVSA-T with an IC50 value of 6.5 μM. 
Cytotoxicity was also studied in the cisplatin-sensitive and cisplatin-resistant (ovarian 
carcinoma) A2780 cell lines. It was found that both complexes, cMeim and cMepz, are active 
in the same range as cisplatin, both in sensitive and in resistant cell lines. However, the trans 
isomers show improved antitumor properties in the cisplatin resistant cell line, A2780R. 
These results are of interest, showing that complexes with trans geometry can indeed display 
improved cytotoxic activity compared to their cis analogues (see Chapter 3). However, 
although these new asymmetric cis-platinum(II) complexes have been found to be less active 
than cisplatin in several human tumor cell lines, in the cisplatin-sensitive and cisplatin-
resistant A2780 cell lines they show antitumor activity comparable to cisplatin; they may 
even display less side effects than cisplatin itself, being an advance in the search of new 
antitumor cis-platinum complexes. 
 
4.2 Experimental section 
4.2.1 Materials 
K2PtCl4 was provided by Johnson & Matthey (Reading, UK). Isopropylamine and 
guanosine 5’-monophosphate were obtained from Sigma-Aldrich. 1-methylimidazole and      
1-methylpyrazole were obtained from Fisher Scientific Nederland B.V.  
 
4.2.2 Synthesis and characterization of the cis-[PtCl2(iPram)(azole)] complexes 
The synthesis of both complexes was accomplished in four steps as presented in 
Scheme 4.1. The different steps of the reaction have been explained in detail in Chapter 2. 
The structural formula of the synthesized complexes is shown in Figure 4.1, and the yield of 
the reactions was found 34 % and 36 % for complexes cMeim and cMepz, respectively. 
The intermediate complexes, cis-[PtI2(iPram)(Meim)] (cI2Meim (D, in Scheme 4.1)) 
and cis-[PtI2(iPram)(Mepz)] (cI2Mepz (E, in Scheme 4.1)), were isolated and characterized 
by 1H and 195Pt NMR (Table 4.1). For the species B and C, their characterization has been 
presented in Chapter 2. 
The resulting complexes, cis-[PtCl2(iPram)(Meim)] (cMeim) and                        
cis-[PtCl2(iPram)(Meim)] (cMepz), were characterized by 1H and 195Pt NMR (Table 4.2), IR 
and by elemental analysis. Data for elemental analysis are: (cMeim) Theory % 
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(PtCl2C7H15N3): C: 20.65, H: 3.71, N: 10.32; Found %: C: 20.54, H: 3.80, N: 10.43; (cMepz) 
Theory % (PtCl2C7H15N3): C: 20.65, H: 3.71, N: 10.32; Found %: C: 20.74, H: 3.90, N: 
10.53. IR spectra support the cis geometry of both complexes, as seen from the appearance of 
two different bands assigned to the Pt—Cl stretching bond13 at 330 and 324 cm-1, 333 and 321 
cm-1, for cMeim and cMepz, respectively. The IR spectra also show bands at 435, 414 cm-1, 
respectively, which can be assigned to the asymmetric Pt—N stretch.13 In this case splitting 
due to the cis orientation is unresolved.  
 
 
K2PtCl4  +  KI exc
2 NH2CH(CH3)2
K2Ptl4 Pt
NH2CH(CH3)2I
I NH2CH(CH3)2
HClO4 (70%)
9 days
RT
Pt
II
(H3C)2HCH2N I
Pt
NH2CH(CH3)
I
Pt
NH2CH(CH3)2I
I azole
Pt
NH2CH(CH3)2Cl
Cl azole
A B
C
D: azole= Meim
2 azole
E: azole= MepzG
F: azole= Hpz
AgNO3
KCl
 
 
Scheme 4.1. Synthesis of cis-[PtCl2(iPram)(azole)] compounds; details of the reaction conditions are 
given in Chapter 2.  
 
 
 
Table 4.1. 1H and 195Pt NMR data for the cis-[PtI2(iPram)(azole)] complexes (solvent: acetone-
d6) (see Figure 4.1 for numbering). 
 iPram cI2Meim cI2Mepz 
H1 2.88 sept 1H 3.00 (1H, sept) 3.10 (1H, sept) 
H2 0.85 d 6H 1.27 (6H, d) 1.35(6H, d) 
NH2 2.13 2H sbr 4.74 (2H, sbr) 4.85 (2H, sbr) 
H6’  3.88 (3H, s) 4.34 (3H, s) 
H2’  8.18 (1H, s)  
H3’   7.82 (1H, s) 
H4’  7.28 (1H, d)  6.48 (1H, d) 
H5’  7.8 (1H, d) 7.98 (1H, s) 
δ (195Pt), ppm  -3238 -3332 
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Table 4.2. 1H and 195Pt NMR data for the cis-[PtCl2(iPram)(azole)] complexes (solvent: DMSO-d6) 
(see Figure 4.1 for numbering). 
 iPram cMeim cMepz 
H1 2.95 sept 1H 
 
2.57 (1H, sept) 
 
Under H2O 
(from DMSO) 
H2 0.92 d 6H 1.11 (6H, d) 1.27(6H, d) 
NH2 2.10 2H sbr 4.74 (2H, sbr) 4.85 (2H, sbr) 
H1’  3.71 (3H, s) 4.34 (3H, s) 
H2’  8.10 (1H, s)  
H3’   7.89 (1H, s) 
H4’  7.26 (1H, d)  6.45 (1H, d) 
H5’  7.16 (1H, d) 8.10 (1H, s) 
δ (195Pt), ppm  -2090 -2126 
 
4.2.3 Attempted synthesis of cis-[PtCl2(iPram)(Hpz)] 
The synthesis of the asymmetric cis-Pt(II) complex with the unsubstituted pyrazole 
ligand appeared not possible. Following the same reaction conditions as for the complexes 
with ligands Meim and Mepz, oligomeric species were obtained in the case of the Hpz ligand. 
This oligomeric structure was evident from the 1H NMR spectrum, since broad signals for all 
the proton signals of Hpz and iPram were observed. In addition, 195Pt NMR of a concentrated 
sample was measured and no signal was observed, another fact that confirms the formation of 
oligomers. 
The formation of oligomers is likely in case of the unsubstituted pyrazole ligand, since 
it is a ligand that may also behave as a bridging ligand between two metal centres after loss of 
H+ (Figure 4.2).14,15 To form the asymmetric cis complex with isopropylamine and pyrazole, 
the dinuclear platinum compound has to be first synthesized (species C in Scheme 4.1), just 
as in the other asymmetric cis-Pt(II) complexes cMeim and cMepz. To be able to form the 
asymmetric cis-diiodo complex F with iPram and Hpz, pH < 6 is necessary to avoid the 
deprotonation of the N in the pyrazole ring. However, the dinuclear precursor platinum 
complex C is stable under acidic conditions; it is formed at pH = 4-5, conditions required to 
avoid the pyrazole ligand to behave as a bridging ligand. 
 When 2 equiv. of Hpz ligand were added to C with the aim to form F, the pH of the 
reaction was ca. 7. Under these conditions, the form pz- of the Hpz ligand is easily accessible 
in the presence of a metal and it may behave as a bridging ligand, resulting in the formation of 
oligomers (Figure 4.2). When the pH is decreased to more acidic conditions, the Hpz 
predominates, but then the dinuclear complex C is stable, therefore the reaction between C 
and Hpz to yield F does not occur.  
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Pt
N
X X
N
Pt
N
X X
N
Pt
X X
X= isopropylamine  
Figure 4.2. Possible oligomeric structures formed when Hpz ligand acts as bridging ligand. 
 
The synthesis was also tried by synthesizing the dinuclear platinum complex with the 
Hpz ligand instead of with iPram; however, again the formation of oligomers was observed. 
Therefore, no further attempts were under taken. 
 
4.2.4 Physical measurements 
Elemental analysis was performed on a Perkin-Elmer series II CHNS/O Analyzer 
model 2400. NMR spectra were recorded on a Bruker DPX 300. The temperature was kept 
constant (at 298 K for the characterization of the complexes and at 310 K for the GMP 
reactions) by a variable temperature unit. 1H and 195Pt NMR was measured in DMSO (for the 
characterization of the complexes) and D2O (for the GMP reactions). FTIR spectra were 
obtained on a Perkin Elmer Paragon 1000 FTIR spectrophotometer equipped with a Golden Gate 
ATR device, using the diffuse reflectance technique in the range 4000-300 cm-1 (resolution 4  
cm-1). Mass spectrometry was performed on a Finnigan TQS700 instrument. 
 
4.2.5 X-ray structural determination for complex cMeim 
Single crystals of complex cMeim were obtained directly from the mother solution in 
water at 4 ºC. Reflections were measured on a Nonius KappaCCD diffractometer at a 
temperature of 150(2) K. The structure was solved with automated Patterson methods 
(DIRDIF-9716) and refined with SHELXL-9917 against F2 of all reflections. Hydrogen atoms 
were introduced at calculated positions, after being confirmed in a different map, and refined 
riding on their carrier atom. Molecular illustration, structure checking and all calculations 
were performed with the PLATON package.18,19 The details of the crystal structure 
determination are given in Table 4.3 and the CIF deposited with the Cambridge Structural 
Database with reference number CSD 279490. 
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Table 4.3. Crystal data for complex cis-[PtCl2(iPram)(Meim)] (cMeim). 
 cMeim  cMeim 
Chemical formula [PtCl2C7H15N3] μ [mm-1] 12.359 
Formula weight 407.21 Z 4 
Crystal system Orthorhombic Crystal color Colorless 
Space group P212121 Crystal size [mm-3] 0.10 x 0.15 x 0.20 
a [Å] 8.0479(4) No. refl. measured 21622 
b [Å] 10.3954(3) No. unique refl.. 2680 
c [Å] 14.0445(10) No. Parameters 121 
α = β = γ [deg] 90 No. obs. refl. (I>2σ(I)) 2580 
V [Å3] 1174.98(11) R1 (obs. refl.) 0.0163 
ρcalc [g/cm3] 2.3019(2) R1 (all refl.) 0.0182 
Flack Param.  0.013(7) wR2 (all refl.) 0.0344 
Min/Max Resd. 
dens. (A-3)  
-0.88/1.23 Transmission  0.13-0.29 
 
4.2.6 Cytotoxicity test 
In vitro cytotoxicity test in human tumor cell lines 
The cytotoxicity tests were performed in a variety of human cell lines (WIDR, M19, 
A498, IGROV and H226). These cell lines belong to the currently used anticancer screening 
panel of the National Cancer Institute, USA.20 The experiment was performed at the Dr. 
Daniel den Hoed Kliniek (Rotterdam Cancer Institute), Department of Medical Oncology 
(Rotterdam, The Netherlands). 
A stock solution of both complexes and cisplatin, which contained 1 mg 
compound/200 μl was used. The compounds were dissolved in DMSO. On day 0, 150 μl of 
the trypsinized tumor cells (1500-2000 cells/wells) were plated in 96-well flatbottom 
microtiter plate (Falcon 3072, BD). The plates with the cancer cells were incubated 48 hr at 
310 K, in air with 8.5 % CO2 to allow the cells to attach to the bottom. After this 48 hr, on day 
3, a three-fold dilution sequence of 10 steps was made in full medium, starting with the stocks 
solutions of 1mg compound/200 μl. Every dilution was used in quadruplicate by adding 50 μl 
to a column of four wells. The plates with the complexes were incubated at 310 K, 8.5 % CO2 
for 120 hr. On day 7, the incubation was finished and the cells were fixed with 10 % 
trichloroacetic acid in PBS and placed at 4 ºC for 1 hr. After three washing with tap water, the 
cells were stained for at least 15 min with 0.4 % sulforhodamine B (SRB) dissolved in 1 % 
acetic acid. The unbound stain was removed by washing with 1 % acetic acid. The plates were 
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air-dried and the bound stain was dissolved in 150 μl 10 mM Tris-base. The absorbance was 
measured at 540 nm using a microplate reader (Labsystems Multiskan MS). The IC50 values 
were determined using the microculture SRB test.21   
 
In vitro cytotoxicity test in A2780 cell lines sensitive and resistant to cisplatin 
A2780 and A2780R human ovarian cell lines were obtained from Prof. Dr. Carmen 
Navarro Ranninger’s group (Universidad Autónoma de Madrid, Spain). The cell lines A2780 
and A2780R, i.e. ovarian cancer cell lines derived from untreated patient cells.22 Both cell 
lines were maintained in continuous logarithmic culture Dulbecco’s modified Eagle’s 
Medium (DMEM) (Gibco BRLTM, Invitrogen Corporation, NL) supplemented with 10 % 
Fetal Medium Serum (Perbio Science, Belgium), PenicillinG Sodium (100 units/ml Duchefa 
Biochemie BV, The Netherlands), Streptomycin (100 μg/ml Duchefa Biochemie BV, The 
Netherlands) and Glutammax 100x (Gibco BRLTM, NL).  
For the cytotoxicity evaluation, 2000 cells/well were seeded in 100 μl of complited 
medium in 96-multiwell flatbottom microtiter. The plates were incubated at 310 K, 8.5 % 
CO2 for 48 hr prior to add the drugs to allow cell adhesion. The stock solutions (1 mg/ml 
PBS) of both complexes were used for the dilutions in complete medium. 100 μl of the 
compounds were added in the microwells containing the cell culture at final concentrations of 
0-200 μM. The plates were then incubated at 310 K, 8.5 % CO2 during 48 hr. The evaluation 
of the cell proliferation was performed using the so-called MTT method23 (based on the 
mitochondrial reduction of the tetrazolium salt MTT  colorimetric assay.24 50 μl of an MTT 
solution (5 mg/ml in PBS, Signma Chemical Co.) was added to each well and incubated for 2-
4 hr. Formazan crystals were solubilized in 100 μl of DMSO. Cell survival was evaluated by 
measuring the absorbance at 590 nm, using a BIO-RAD microplate model 550. All 
experiments were performed in triplicate. The IC50 values were calculated from curves 
constructed by plotting cell survival (%) versus compound concentration (μM) by use of 
GraphPad Prism software, version 3.0, 2000. 
  
4.2.7  Reaction of complexes cMeim and cMepz with GMP 
The complexes cMeim and cMepz were reacted with an excess (1:4) of GMP in 250 
μl 0.1 M NaClO4/D2O at 310 K in an NMR tube. Both complexes were first pre-dissolved in 
30 μl of DMF-d7 because of the poor solubility of the complexes in water, followed by the 
addition of 480 μL of NaClO4/D2O. The reactions were left to incubate at 310 K in the dark. 
The reactions were studied by 1H NMR, recording spectra at time intervals of 30 min during 
the overnight reaction, and after every 24 hr, until no further changes were observed. 
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Subsequently at the end of the reactions, 195Pt NMR was recorded from the same solution in 
the same NMR tube and a mass spectrometry analysis was performed. 
 
4.3 Results and discussion 
4.3.1 X-Ray structure of complex cMeim 
The compound cMeim crystallizes in the orthorhombic space group P212121 with Z = 
4. A molecular plot of the structure is presented in Figure 4.3. Selected bond lengths and 
angles are given in Table 4.4. The coordination of the Pt atom is square planar (angles sum 
360.04). The Pt—N distances are in the expected range, with the Pt—N(amine) distances only 
slightly longer (2.048(3) Å) than the Pt—N(azole) distances (2.003(3) Å). The torsion angles 
in this complex, 54.6(3)º and -71.3(3)º for Cl2PtN3C2 and Cl2Pt1N7C8, respectively, are 
quite different from that of its trans analogue. In the case of the cis-Pt(II) the angles show a 
perpendicular disposition respect to the equatorial plane formed by Cl1, Cl2, N3 and N7, 
while in the case of the trans analogues (chapter 3) both ligands, isopropylamine and 1-
methylimidazole, are almost in the equatorial plane, only in the case of residue A the iPram 
ligand shows similar torsion angle as the cis complex. 
 
 
 
Figure 4.3. Molecular structure and of the complex cis-[PtCl2(iPram)(Meim)] (cMeim). 
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Table 4.4. Selected bond distances (Å), angles, and relevant torsion angles (deg) for cis-
[PtCl2(iPram)(Meim)] (cMeim). 
Atoms Distances and angles 
Pt1-N7 2.048(3) 
Pt1-N3 2.003(3) 
Pt1-Cl1 2.296(9) 
Pt1-Cl2 2.315(11) 
N3-Pt1-N7 91.43(13) 
Cl1-Pt1-Cl2 92.07(3) 
N3-Pt1-Cl2 89.59(9) 
N7-Pt1-Cl1 86.95(9) 
N7-Pt1-Cl2 178.00(9) 
N3-Pt1-Cl1 177.92(9) 
Cl2-Pt1-N3-C2 54.6(3) 
Cl1-Pt1-N7-C8 -71.3(3) 
 
The lattice structure consists a zig-zag one-dimensional chain formed in the direction 
of the crystallographic a axis. A plot of the hydrogen-bonding pattern in the chain is displayed 
in Figure 4.4. The details for the hydrogen bonding geometry are given in Table 4.5.  As it 
can be observed, one of the hydrogen bonds, i.e. N7—H7A…Cl2 is quite weak with a Cl…N 
distance of 3.666(3) Å. 
 
 
Figure 4.4. Intramolecular hydrogen bonding between N-H and Cl in cis-[PtCl2(iPram)(Meim)]. C-H 
hydrogen atoms have been omitted for clarity.  
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Table 4.5. Hydrogen bonding parameters for cis-[PtCl2(iPram)(Meim)] (cMeim). Symmetry 
operations: i: -1/2+x, 3/2-y, -z. 
D-H...A D-H [Å] H...A [Å] D...A [Å] D-H...A [deg.] 
N7--H7A...Cl2i 0.92 2.75 3.666(3) 175 
N7--H7B...Cl1i 0.92 2.80 3.300(3) 116 
 
4.3.2 Reactions of complexes cMeim and cMepz with GMP 
The 1H NMR spectra of the reaction of cMeim with an excess of GMP (1:4) and the 
reaction scheme are shown in Figure 4.5 and Scheme 4.2, respectively. While the reaction 
between the platinum complex and the GMP proceeds, new signals appeared, which can be 
assigned to a platinum species binding to GMP. After already 1 hr of reaction the first signal 
appears, at 8.45 ppm. This signal was assigned to the monoadduct product, IV-Cl(GMP)a. The 
intensity of this signal increases with time up to 9 hr of reaction. At 8.57 ppm a small signal 
appeared without increasing much its intensity. This signal disappeared with time and it could 
be assigned also to a monoadduct product, IV-Cl(GMP)b, but the other isomer. In fact, two 
different signals for the H8 protons of the GMPs would be expected in the formation for each 
of the monoadduct species due to the asymmetry of the starting complexes. This asymmetry 
allows GMP to bind to two different positions (cis to the iPram or Meim, see Scheme 4.2). 
However, only one signal is clearly observed; a possible explanation for that observation is 
that the rotation around the Pt—N(iPram) is equally fast as the rotation Pt—N(Meim). Thus, 
the H8 of both GMPs, cis or trans to iPram ligand, do not distinguish the different 
environment they have and they show the same resonance. Alternatively steric bulk on the 
position cis to azole could make this side unfavourable; so only one monoadduct is formed. 
The same effect was observed in the asymmetric cis-platinum complexes with mixed aliphatic 
amines (Chapter 2).  
At 8.34 and 8.50 ppm, two new signals start to appear after 2.5 hr of reaction. Both 
signals simultaneously increase in intensity. They have been assigned to the bisadduct 
product, IV-(GMP)2. The appearance of two peaks, one for each H8 of each GMP, is due to 
the asymmetry of the complex, as explained earlier for the same kind of asymmetric cis-Pt(II) 
complexes.12 195Pt NMR agrees with the formation of this bisadduct product, by the 
appearance of a signal at -2379 ppm. As in its trans analogue (Chapter 3) this value is about 
100 ppm lower than the values commonly observed for the N4 environment of platinum 
complexes.25,26 Mass spectrometry confirms the formation of the bisadduct product by a peak 
at m/z= 531.6 ((IV-(GMP)2)2++H+).  
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Figure 4.5. 1H NMR spectra in the aromatic region on the reaction of the complexes cMeim and 
cMepz with 4 equiv. of GMP in 0.1 M NaClO4/D2O solution measured at 310 K as a function of time. 
The symbols show the H8 signals of GMP ligands in the products: IV, V-(GMP)Cl (●), IV, V-(GMP)2 
(■), free GMP (▲). (*) corresponds to traces of DMF-d7 used to predissolve the complex. 
 
Since the two GMP ligands bound to the platinum are not equivalent, two doublets 
would be expected in the proton NMR for each H1’ of each GMP and this is indeed observed. 
Both H1’ signals of the sugar rings of each GMP are shifted to higher field, confirming the 
stacking interactions.27 The small value for J1’-2’ (5.15 Hz) indicates an increase in the N-type 
population of the sugar puckering of both GMP molecules.27-29 
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 Scheme 4.2. Scheme of the reaction of the compound cMeim with GMP. 
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The 1H NMR spectra of the reaction of complex cMepz with an excess of GMP (1:4) 
are also shown in Figure 4.5. In this case the formation of the monoadduct product is not 
observed as clearly as in the case of complex cMeim. At 8.52 ppm a signal appears after 2 hr. 
However, its intensity does not increase with time, but it gradually disappears. This signal has 
tentatively been assigned to the formation of the monoadduct product, V-Cl(GMP). At 8.33 
and 8.59 ppm two signals start to appear after 3 hr of reaction. Their intensity increases with 
time until the end of the reaction and they were assigned to the bisadduct product, V-(GMP)2. 
195Pt NMR and mass spectrometry have confirmed the formation of these species, by a signal 
at -2375 ppm and a peak at m/z= 532.6 ((V-(GMP)2)2+ + 2H+), respectively. For the H1’ of 
the sugar rings of the GMP, two different doublets are observed in the NMR spectrum. One of 
the doublets overlaps with the H1’ signal of the free GMP, while the other one is shifted to 
higher field. The appearance of these two doublets further confirms the formation of the 
bisadduct product. Two different signals for the H1’ are observed due to the asymmetry of the 
complex, as explained above. The small value of J1’-2’ (5.89 Hz) in the doublets of both H1’, 
just like in cMeim, indicates an increase in the N-type conformer of the sugar puckering of 
both GMP.27-29 
 
4.3.3 Kinetic aspects of complex cMeim in its interaction with excess of GMP 
For the complex cMeim it was possible, as for its trans analogue, to study the kinetics 
of its interaction with an excess of GMP. The study was performed measuring the integrals of 
the signal at 8.34 ppm assigned to one of the GMPs of the bisadduct species, since the other 
signal assigned to the same product overlapped with the monoadduct species in a number of 
some time intervals. 
The kinetics of the reaction for cMeim with an excess of GMP in 0.1 M NaClO4/D2O 
solutions have been followed in detail by 1H NMR. After 11 hr of reaction it was found that 
the monoadduct and bisadduct species coexist in the same proportion, while in the case of 
complex tMeim this was the case after 5 hr. The time of disappearance of 25% (t1/4) of free 
GMP was found to be 6 hr (360 min) and the time of formation ((t1/4) of 25% of IV-(GMP)2 
was found to be 7 hr (420 min). The reaction rate is proportional to the starting material of 
GMP; this indicates that as in the case of complex tMeim the reaction takes place by direct 
substitution of the Cl- ligand by GMP.  
Both isomers, tMeim and cMeim, react completely with GMP within 48 hr, they only 
differ in the formation time of the different intermediate species. They even react through the 
same mechanism, in contrast with cisplatin where the rate-determining step for binding to 
DNA is known to be the hydrolysis of a Pt—Cl bond.30  
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4.3.4 Cytotoxicity properties of complexes cMeim and cMepz  
In vitro cytotoxicity assay in human tumor cell lines 
 In Table 4.6 the cytotoxicity data in a series of human cell lines ((MCF7 and EVSA-T 
(breast cancer), WIDR (colon cancer), IGROV (ovarian cancer), M19 (melanoma), A498 
(renal cancer), and H226 (non-small cell lung cancer)) of the complexes cMeim and cMepz 
are listed and compared to cisplatin. As already defined in Chapter 3, the IC50 value 
represents the minimum amount of drug to inhibit the 50 % of the growth of the cancer cells. 
It can be observed that both cis-platinum(II) complexes are in general in the same micromolar 
range as cisplatin; however, their antitumor activity is significantly lower than cisplatin and 
even lower than their trans analogues. In three of these human tumor cell lines, WIRD, A498 
and H226, the cytotoxicity of both groups of isomers is lower if compared to the rest of cell 
lines. cMepz shows better antitumor activity than cMeim; however, the differences are not 
very large. Only in the cell line EVSA-T complex cMepz shows an IC50 value comparable to 
cisplatin, although it is still 4.5 times less cytotoxic than cisplatin. 
 
Table 4.6. In vitro cytotoxicity assay of the asymmetric cis-Platinum(II) complexes and cisplatin on 
human tumor cell lines (abbreviations: see text). 
IC50 (μM) 
Compounds MCF7 EVSA-T WIDR IGROV M19 A498 H226 
cMeim 71.1 37.4 74 33.2 77.5 >100 >100 
cMepz 57.5 6.5 60.2 15.6 58.7 84.2 67 
Cisplatin 1.42 1.42 1.78 0.43 1.84 5.75 4.53 
 
In vitro cytotoxicity assay on A2780 cell lines sensitive and resistant to cisplatin 
 In Table 4.7 the cytotoxicity data, in cisplatin-sensitive (A2780) and cisplatin-
resistant (A2780R) ovarian cancer cell lines is shown for complexes cMeim and cMepz.  
 
Table 4.7. In vitro cytotoxicity assay of the cis-Platinum(II) complexes and cisplatin on 
A2780 ovarian cancer cell lines sensitive (A2780) and resistant (A2780R) to cisplatin.  
IC50 (μM) 
Test 
compound 
A2780 A2780R RF 
cMeim 15 28 1.86 
cMepz 21 49 2.33 
Cisplatin 3 24 8 
tMeim 21 14 0.66 
tMepz 49 21 0.42 
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In the parental cell line, A2780, both cis complexes show a cytotoxicity comparable to 
cisplatin, in the same active range, albeit 5 and 7 times less cytotoxic than cisplatin. The 
complex cMepz, with 1-methylpyrazole, shows an IC50 value slightly higher than the 
complex cMeim, with 1-methylimidazole. For the trans-Pt(II) analogues a similar behavior 
has been observed (Chapter 3). So, the fact of having a pyrazole or an imidazole ring has a 
small, but visible influence in the cytotoxicity of these complexes. If a comparison is made 
between the cis complex cMepz and the trans compounds tHpz and tMepz, with pyrazole 
and 1-methylpyrazole, respectively, it is observed that the presence of a substituent at the N of 
the pyrazole ring has an influence on the cytotoxic activity of the complexes. When a 
substituent is not present at the non-coordinated N of the pyrazole ring, the antitumor activity 
of the complex is slightly higher. This is clearly seen for complex tHpz,                        
trans-[PtCl2(iPram)(Hpz)], which is the most cytotoxic complex; whether or not the H-bond 
donor function also plays a role cannot be deduced. 
In the cisplatin-resistance cell line, A2780R, both complexes cMeim and cMepz are 
less cytotoxic than cisplatin, although the difference for complex cMeim compared to 
cisplatin is small. The resistance factor (RF = relative ratio of IC50 values in both cell lines 
A2780R/A2780) for the cis complexes in fact is lower than for cisplatin. This fact leads to 
think that initially both cis complexes overcome cisplatin resistance. However, for being 
considered a complex as non-cross resistant a RF < 2 is taken as standard;31 therefore, only 
complex cMeim with a RF value of 1.86 overcomes  cisplatin resistance. In contrast, their 
trans analogues, tMeim and tMepz, were found to overcome cisplatin resistance, with not 
only RF values much lower than that of cisplatin, but also with lower IC50 values in the 
resistant cell line (Chapter 3). So, a cis complex analogue of cisplatin has been found to show 
an acceptable antitumor activity, and what it is more important, that overcomes cisplatin 
resistance, which is still one of the main goals in the search of new antitumor drugs based on 
platinum. 
  
4.4 Concluding remarks 
In this chapter, the GMP interaction and cytotoxicity properties of two new cis-Pt(II) 
complexes is reported and compared to their trans analogues. The crystal structure of the 
complex cMeim has been presented in detail. The crystallographic data are in agreement with 
the square-planar geometry of the platinum complex. The cytotoxicity of these asymmetric 
cis-platinum(II) complexes in several human cell lines was found to be in the same range as 
cisplatin. However, the difference in activity compared to cisplatin and their trans analogues 
is significant. Only the complex cMepz was found to show comparable cytotoxicity to that of 
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cisplatin in the EVSA-T cell line. The cytotoxicity of both complexes was found to be in the 
same range as cisplatin in the cisplatin-sensitive (A2780) and cisplatin-resistant (A2780R) 
cell lines; however, only one of the cis complexes, cMeim, shows no cross-resistance to 
cisplatin as it has a RF value lower than 2. It is also observed that when the azole ligand is 
Mepz instead of Meim, the cytotoxic activity decreases. This behavior is also observed in the 
case of the trans complexes and the cytotoxicity is even higher when the azole is an 
unsubstituted pyrazole. This behavior is probably related to the position of hydrogen bond 
formation. 
Cis- and trans-[PtCl2(iPram)(azole)] interact with GMP at similar rates. In their 
interaction with GMP, the cis complexes behave as bifunctional species. In the case of 
complex cMepz, the monoadduct species was not observed, which means that it immediately 
reacts with a second GMP to give the bisadduct. When the bisadduct product is formed, two 
different signals are observed in the NMR spectrum, for both complexes, as a consequence of 
the non-equivalence of the GMPs due to the asymmetry of the complexes. In conclusion these 
asymmetric cis-Pt(II) complexes show less antitumor activity than their trans analogues but 
do behave as bifunctional species as it was expected. 
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DNA-binding studies of asymmetric trans-platinum(II) 
complexes* 
 
Abstract 
The modification of mammalian and plasmid DNAs by three asymmetric platinum 
complexes, trans-[PtCl2(iPram)(azole)], where azole = pyrazole, 1-methylimidazole or 1-
methylpyrazole, was investigated using different biochemical and biophysical methods. These 
modifications of the DNA were evaluated in the context of the activity of these new 
complexes in several tumor cell lines, including those resistant to cisplatin (Chapter 3). The 
results have shown that the replacement of both amine groups by iPram and an azole-type 
ligand in the clinically ineffective transplatin resulted in a strong enhancement of its activity. 
Importantly, this replacement of ligands also markedly altered the DNA-binding mode of 
these new trans-platinum(II) complexes.  
The analysis of the DNA structural changes caused by these asymmetric trans-
platinum(II) complexes of formula trans-[PtCl2(iPram)(azole)] and the relation of these 
changes to the chemotherapeutical properties of the different complexes, shows that these 
complexes form different lesions in DNA, compared with other trans and cis-Pt(II) analogues. 
Three different experiments have been performed; (1) the unwinding induced for each of the 
complexes in plasmid DNA, (2) the determination of the amount of interstrand cross-links and 
(3) the formation of monofunctional lesions. It has been found that the amount of 
monofunctional lesions is either lower than that formed for other trans-Pt(II) complexes, or 
that these asymmetric complexes form monofunctional lesions different from those formed by 
cisplatin and transplatin.  
 
                                                 
* Most of the experiments described in this chapter were performed during a working visit in the Academic 
Science of Czech Republic, Institute of Biophysics, Brno. 
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5.1 Introduction 
To understand the antitumor activity of trans-platinum(II) compounds, it is required to 
examine their binding modes with DNA and to analyze the differences with the classical 
complexes cis-[PtCl2(amine)2]. Recently, studies of the interaction with DNA of some trans-
platinum(II) complexes, such as trans-[PtCl2(E-iminoether)2],1-3 trans-[PtCl2(Am)2] or trans-
[PtCl2(NH3)(Am)] (Am = pyridine or quinoline),4-6 have been reported. They show major 
differences in DNA-binding modes between these complexes and both classical 
diamminedichloroplatinum(II) isomers (cisplatin and transplatin). For example, the trans-
Pt(II) complex with iminoether ligands binds to DNA preferentially in a monofunctional 
mode,2 while the other two groups of complexes bind preferentially in a bifunctional mode.7 
These differences may help to elucidate the difference in antitumor activity. 
In this Chapter, the study of the interaction with DNA of asymmetric trans-platinum(II) 
complexes (Figure 5.1), with formula trans-[PtCl2(iPram)(azole)], is described. These trans 
complexes (see chapter 3 for their synthesis and structure) do overcome cisplatin resistance in 
the cisplatin-resistant A2780 ovarian carcinoma cell line. It is of interest to study the 
interaction with DNA of these new asymmetric trans-Pt(II) complexes, to improve 
understanding of the type of structures that trans-platinum(II) complexes form with DNA.  
For this study, different experiments have been performed, such as the unwinding that these 
platinum complexes induce in DNA, the determination of the amount of interstrand cross-
links (ICLs) and the amount of monofunctional lesions, using a variety of biophysical and 
biochemical methods. 
 
Pt
H2
NCl
N Cl
NH
Pt
H2
NCl
N Cl
N
Pt
H2
NCl
N Cl
N
tHpz tMeim tMepz  
 
Figure 5.1. Structural formula of the used asymmetric trans-Pt(II) complexes. 
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5.2 Experimental Section 
5.2.1 Materials 
The trans complexes tHpz, tMeim and tMepz were used as prepared in Chapter 3. 
Cisplatin was obtained from Sigma-Aldrich. The stock solutions of the platinum complexes at 
a concentration of 1 x 10-4 M in NaClO4 (10 mM) were prepared at 25 ºC. Calf Thymus DNA 
(CT DNA) (42% G + C, molecular mass about 20 kDa) was prepared and characterized, as 
described in literature.8,9 Plasmid pSP73KB (2464 bp) was isolated according to standard 
procedures and banded twice in CsCl/ethidium bromide (EtBr) equilibrium density 
gradients.10 Ethidium bromide (EtBr), thiourea, agarose and NaCl were used as obtained from 
Merck. The radioactive products were obtained from Amersham. 
 
5.2.2 Platination reactions 
CT DNA was incubated with the platinum complexes in 10 mM NaClO4 at 37 ºC for 
24 hr in the dark. At various time intervals different aliquots of the reaction mixture were 
taken and precipitated by ethanol and redissolved in 10 mM NaClO4 for a later analysis by 
differential pulse polarography (DPP), to determine the amount of platinum that did not react 
with DNA. An aliquot of these samples was used to determine the value of rb (rb is defined as 
the number of molecules of platinum bound per nucleotide residue) for each of the 
complexes.11 
  
5.2.3 Unwinding of negatively supercoiled DNA 
The unwinding of the closed circular supercoiled pSP73 plasmid DNA was studied by 
an agarose gel mobility shift assay.12 The unwinding angle Φ induced per platinum-DNA 
adduct was calculated from the determination of the rb(c) value at which the complete 
transformation of the supercoiled to relaxed form of the plasmid was attained. Samples of 
pSP73KB plasmid were incubated with the tHpz, tMeim and tMepz at 37 ºC in the dark for 
24 hr at different rb values (0.10-0.16 for complex tHpz and 0.01-0.12 for complexes tMeim 
and tMepz). To all samples 1 μl of Tris/acetate/edta buffer (TAE) (0.04 M Tris-acetate, 0.001 
M edta, pH 7.0) and 2 μl of gel-loading buffer (0.25 % bromophenol blue, 40 % (w/v sucrose 
in water)) were added. All samples were subjected to electrophoresis on 1 % agarose gels 
running at 25 ºC with the TAE buffer; the voltage was set at 20 V. The gels were then stained 
with EtBr and read by photography.  
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5.2.4 DNA interstrand cross-links assay 
Complexes tHpz, tMeim and tMepz were incubated, at different rb values, with 0.1 
μg of pSP73KB DNA linearized by EcoRI for 24 hr at 37 ºC in the dark. The linear duplexes 
were first 3’-labeled by means of a Klenow fragment of DNA polymerase I in the presence of 
[α-32P]dATP. To all the samples 0.6 μl of 1 M NaOH and 1,2 μl bromophenol blue (loading 
buffer: 33 mM NaCl, 70 mM Tris-HCl, 1 mM edta, 2 % (w/v) SDS, 0.01 % (w/v) 
bromophenol blue, 10 % glycol, pH 6.8)) were added. The amount of interstrand cross-links 
was analyzed by electrophoresis under denaturing conditions on alkaline agarose gel (1 %). 
After the electrophoresis was complete, the intensities of the bands corresponding to single 
strands of DNA and to interstrand cross-links duplex (ICL) were quantified by the FUJIFILM 
bioimaging analyser, and the radioactivities associated with bands were quantified with the 
AIDA image analyser software.  
The frequency of interstrand cross-links (ICLs), % ICLs/Pt (number of ICLs per 
adduct), was calculated as % (ICL/Pt) = XL/(4928rb) (pSP73KB contained 4928 nucleotide 
residues). XL is the number of ICLs per molecule of the linearized DNA duplex, which was 
calculated assuming a Poisson distribution of the ICLs, as XL = -ln A, where A is the fraction 
of molecules running as a band corresponding to the non-cross-linked DNA. 
 
5.2.5 Thiourea assay, estimation of monofunctional adducts 
Calf thymus DNA (double-stranded, or thermally denatured), at a concentration of 
0.16 mg/ml, was incubated with tHpz, tMeim and tMepz at ri value of 0.1 (ri is defined as the 
molar ratio of free metal complex to nucleotide-phosphates at the onset of the incubation). 
Different aliquots were withdrawn at 10 min, 1, 2, 4, 8, 24 and 48 hr time intervals. Of these 
solutions, 40 μl was added to 40 μl of 20 mM thiourea, and                       
another 40 μl, as a control, was added to 40 μl of 1 M NaCl. After 10 min of incubation at 37 
ºC, 420 μl of 0.5 M NaCl pH 7.0 was added to both aliquots to stop the reaction. The samples 
were stored at 4 ºC until all the samples were incubated. Then the samples were exhaustively 
dialyzed, first twice against 0.5 M NaCl for 1.5 hr and subsequently twice against 10 mM 
NaClO4 (1.5 hr and overnight). After that, the concentration of DNA was determined by UV 
spectroscopy and the concentration of platinum by FAAS. 
 
5.2.6 Fluorescence measurements 
Fluorescence measurements were performed on a Shimadzu RF 40 
spectrofluorophotometer using 1-cm quartz cells. Fluorescence measurements of DNA 
modified by platinum in the presence of EtBr were performed at an excitation wavelength of 
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546 nm, and the emitted fluorescence was analyzed at 590 nm. The fluorescence intensity was 
measured at 25 ºC in 0.4 M NaCl to avoid secondary binding of EtBr to DNA.13 The used 
concentrations were 0.04 mg/ml for DNA and 0.04 mg/ml for EtBr, which correspond to the 
saturation of all intercalation sites of EtBr in DNA.13 The fluorescence intensity was 
measured after equilibrium for 60 min at 25 ºC in the dark. Full details of this measurement 
can be found in the original literature.13 
 
5.2.7 Other physical measurements 
Absorption spectra were measured with a Beckmann DU-7400 spectrophotometer. 
FAAS measurements were carried out on a Unicam 939 AA spectrometer with a graphite 
furnace. DPP curves were recorded with the aid of an EG&C PARC Electrochemical 
Analyzer, Model 384B. Circular dichroism (CD) spectra were recorded at 25 ºC using a 
JASCO spectropolarimeter, Model J720. Fluorescence was measured using a Perkin Elmer 
Luminescence Spectrometer LS50B. The gels were dried and visualized by using the 
FUJIFILM bioimaging analyzer, and the radioactivities associated with bands were quantified 
with the AIDA image analyzer software. 
 
5.3 Results and discussions 
5.3.1 DNA binding 
Solutions of double-helical CT DNA at a concentration of 0.064 mg/ml were 
incubated with tHpz, tMeim and tMepz at the value of ri of 0.01 in 10 mM NaClO4 at 37 ºC 
(ri is defined in section 5.2.5). At various time intervals an aliquot of the reaction mixture was 
taken. The samples were assayed by differential pulse polarography (DPP) for the amount of 
platinum not bound to DNA. In DPP a decrease in the polarographic signal was observed with 
time as a consequence of the decrease in the amount of free platinum complex (Figure 5.2). 
After 24 hr, 45 %, 53 % and 63 % of free platinum was observed for tHpz, tMeim and 
tMepz, respectively. This means that 55 %, 47 % and 37 % of platinum was bound to DNA in 
24 hr for each of the complexes. The amount of platinum bound to DNA was calculated by 
subtracting the amount of free platinum, calculated by DDP from the total amount of platinum 
present in the reaction. After 48 hr no further changes were observed in the DPP signal.  In 
these binding reactions the amount of platinum bound to DNA after 24 hr reaches 50 % only 
in the case of the complex tHpz. For cisplatin, under the same conditions, it was found that 
100 % of platinum is bound to DNA. Other cis-, and trans-platinum complexes show also 
high ranges of binding.14 An aliquot of these samples was used to determine the rb value for 
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each of the complexes, resulting in: 0.003, 0.002 and 0.0018 for tHpz, tMeim and tMepz, 
respectively. 
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Figure 5.2. Dependence of the DPP signal with time. 
 
5.3.2 DNA Unwinding 
  Electrophoresis in a native agarose gel has been used to determine the unwinding 
induced in negatively supercoiled pSP73KB plasmid by monitoring the degree of supercoiling 
(Figure 5.3).12 A compound that unwinds the DNA duplex reduces the number of supercoils 
in closed circular DNA. This reduction, after binding of unwinding agents, causes a decrease 
in the rate of migration through an agarose gel, which makes it possible to quantify the 
average value of unwinding per adduct. 
Figure 5.3 shows the electrophoresis gels from the experiment in which variable 
amounts of the complexes have been bound to a mixture of relaxed and negatively 
supercoiled pSP73KB DNA. The unwinding angle (Φ) is given by Φ = 18 σ/rb(c), where σ is 
the superhelical density of the plasmid DNA and rb(c) is the value of rb at which the 
supercoiled and relaxed forms comigrate.12 Under the present experimental conditions, σ was 
calculated to be -0.05 on the base of the data for cisplatin for which the rb(c) was determined 
in this study and Φ = 13º was assumed.12,15 For tHpz, tMeim and tMepz, rb(c) was found to 
be 0.0825, 0.047 and 0.0444, respectively (Figure 5.3; lines 0.15, 0.1 and 0.12, for tHpz, 
tMeim, tMepz, respectively). For the calculation of the unwinding angles the rb value of each 
complex was multiplied by the percentage of platinum that is bound to DNA in 24 hr, i.e. 
55%, 47% and 37% for tHpz, tMeim and tMepz, respectively. The unwinding angle for the 
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three complexes was calculated in this way, and it was found to be 11º, 19º and 20º for tHpz, 
tMeim and tMepz, respectively. If these values are compared with the unwinding angles for 
cisplatin (13º), transplatin (9º) and [PtCl(dien)]Cl (6º),12 it is observed that only in the case of 
the complex tHpz, the unwinding angle is similar to that of cisplatin. On the other hand, the 
complexes tMeim and tMepz show an unwinding angle larger than cisplatin, transplatin, or 
[PtCl(dien)]Cl. Large unwinding angles could be expected, since the planar ligands present in 
the three complexes may partly intercalate in the DNA and, consequently, would produce a 
larger unwinding angle than cisplatin or transplatin. It seems reasonable to suggest that the 
large additional contribution to unwinding is associated with intercalation of the azole ligand. 
The large unwinding angle produced by tMeim and tMepz is good evidence that the 1-
methylimidazole and 1-methylpyrazole ligands do interact with the duplex of DNA upon 
coordination of platinum. These high values of the unwinding angles are consistent with DNA 
binding that involves a combined intercalation/coordination mode similar to that observed for 
some cationic platinum(II) complexes that carry EtBr as non-leaving group (ethidium is a 
well-known DNA intercalator, which unwinds DNA by 26 º).12 
 
 
 
Figure 5.3. Unwinding process of supercoiled pSP73KB plasmid DNA modified by tHpz, tMeim and 
tMepz at different rb values. 
 
5.3.3 DNA interstrand cross-links 
The experiments were carried out with DNA samples that were modified by the 
platinum complexes for 24 hr at various rb values (0.0001, 0.0002, 0.0005, 0.001, 0.002 and 
0.005) and in comparison with cisplatin at rb = 0.001. Bifunctional platinum compounds that 
bind coordinatively to DNA form different types of interstrand and intrastrand CLs. Several 
evidences suggest the antitumor efficacy of bifunctional platinum compounds to be the result 
of the formation of such lesions, but their relative efficacy remains unknown. Therefore, it 
was decided to quantify the interstrand cross-linking efficiency of all three asymmetric trans-
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Pt(II) complexes in linearized pSP73KB plasmid (4928 bp). This plasmid was linearized by 
EcoRI (EcoRI cuts only once within the pSP73 plasmid)16 and modified platinum complexes. 
The samples were analyzed for ICLs by agarose gel under denaturating conditions.17 After 
electrophoresis, the 3’-end-labeled strands of linearized pSP73KB plasmid containing no 
interstrand cross-links migrate as the 2464-base single strand does, whereas the interstrand 
cross-linked strands migrate more slowly due to their higher molecular mass species (Figure 
5.4). The radioactivity associated with the individual bands in each lane was measured to 
obtain estimations of the fraction of non-cross-linked or cross-linked DNA under each 
condition.  
The frequency of interstrand CLs (% ICL/Pt) was calculated using the Poisson 
distribution from the fraction of non-cross-linked DNA in combination with the rb values and 
the fragment size.17-19 The DNA interstrand cross-linking efficiency of all three complexes 
was found to be independent of rb and to be: 10.7 %, 7.2 % and 6.7 %, for tHpz, tMeim and 
tMepz, respectively. Interstrand cross-linking of these new asymmetric trans-platinum 
complexes was found to be very similar to that of cisplatin (6 %)17-19 for the complexes 
tMeim and tMepz and similar to that of transplatin (12 %)17,19 for complex tHpz. 
 
 
Figure 5.4. The formation of ICLs by complexes tHpz, tMeim and tMepz in linear plasmid DNA 
pSP73KB at different rb values. Autoradiogram of denaturating 1% agarose gels of linerarized DNA, 
3’-labeled. 
 
 
5.3.4 Circular Dichroism Spectroscopy  
CD spectral characteristics were compared for CT DNA modified and non-modified 
by the complexes tHpz, tMeim and tMepz at rb = 0.08 and 0.1 (Figure 5.5).  
After binding of these compounds to CT DNA, the conservative CD spectrum 
normally found for DNA in the canonical B conformation is considerably transformed at 
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wavelengths below 300 nm. A significant decrease in intensity of the band around 280 nm 
was observed. The same behaviour was found for other related trans complexes already 
reported by others.14 From the results obtained in this experiment the alterations induced in 
DNA by the complexes tHpz, tMeim and tMepz appear to correspond to denaturational 
alterations.20 
 
240 260 280 300 320 340
-3
-2
-1
0
1
2
3
 CT DNA
 tMeim
 tHpz
 tMepz
de
lta
 
wavelenght (nm)
 
Figure 5.5. CD spectroscopy of CT DNA and after modification by tHpz, tMeim and tMepz at rb = 
0.1. CD was recorded for DNA in 10 mM NaClO4. 
 
5.3.5 Thiourea assay 
It is known that bifunctional platinum complexes bind to DNA in a two-step process, 
forming first the monofunctional adducts, preferentially to guanine residues, which progress 
to form bifunctional lesions.20-23 So the monofunctional lesions are formed in the early stage 
of the reaction between platinum complexes and DNA. Thiourea is successfully used to 
labilize monofunctionally bound transplatin or analogues from DNA.24 The displacement of 
the trans-Pt(II) complexes takes place via coordination of thiourea trans to the base residue. 
Because of the strong trans effect of sulfur, the nucleobase nitrogen-platinum bond is 
weakened, so it becomes susceptible to further substitution reactions. Consequently, the 
monofunctional DNA adducts of trans-Pt(II) complexes are effectively removed, whereas the 
bifunctional adducts of the trans-Pt(II) complexes are known to be quite resistant to the 
thiourea treatment.24 
This experiment was undertaken with the aim to characterize the DNA adducts that 
the trans complexes tHpz, tMeim and tMepz form by using thiourea as a probe of the 
formation of DNA monofunctional adducts (Figure 5.6).  
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Figure 5.6. Thiourea assay of the trans-Pt(II) complexes tHpz, tMeim and tMepz. Concentration of 
the DNA bound to the platinum complexes versus time. 
 
 In previous studies it has been reported24 that thiourea can displace about 90% of 
transplatin from double-helical DNA at early time intervals (1-5 hr).2 At longer incubation 
times (24-48 hr), thiourea was found less efficient in removing transplatin from DNA, since at 
these time intervals a large amount of monofunctional adducts of transplatin had closed to 
bifunctional lesions, known to be resistant to the treatment with thiourea.24 Thus after 48 hr of 
the reaction only ~35 % of transplatin was displaced from double-stranded DNA, which 
would indicate that up to 65 % of monofunctional adducts had evolved to bifunctional 
adducts.24 In contrast to the behavior of transplatin, thiourea displaced only 11%, 13% and 16 
% of tHpz, tMeim and tMepz from DNA, after 24 hr of incubation, respectively (Figure 
5.6). This observation indicates that as compared with transplatin, complexes tHpz, tMeim 
and tMepz form double-helical DNA adducts, which are resistant to the thiourea treatment 
already at early time intervals. This would imply they form more bifunctional lesions. 
 It is reasonable to assume that these new asymmetric trans-dichloroplatinum(II) 
complexes with planar ligands either form a huge amount of bifunctional lesions, or 
monofunctional adducts different from that formed by transplatin. This new type of 
monofunctional adduct, either would not bind readily to thiourea, or after binding thiourea, 
would be resistant to the trans-labilizing effect of the sulfur-donor ligand. This behavior is 
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likely, since in the treatment with thiourea it is seen that the formed adducts by tHpz, tMeim 
and tMepz are resistant to it. 
 
5.3.6 Fluorescence measurement 
In order to establish a difference between the two eventualities obtained in the 
experiment of the three trans-platinum(II) complexes with thiourea, EtBr has been employed 
as a fluorescence probe. This probe can be used to distinguish between perturbations induced 
in DNA by monofunctional and bifunctional adducts of platinum compounds.13,25 Binding of 
EtBr to DNA by intercalation is blocked in a stoichiometric manner by formation of the 
bifunctional adducts of a series of platinum complexes, including cisplatin and transplatin, 
which results in a loss of fluorescence intensity.25 On the other hand, modification of DNA by 
monofunctional platinum complexes (having only one leaving group) results only in a slight 
decrease of EtBr fluorescence intensity, as compared with the non-platinated DNA-EtBr 
complex.  
Double-helical DNA was first modified by cisplatin, tHpz, tMeim, tMepz and by the 
monofunctional [Pt(dien)Cl]Cl for 24 hr. The levels of the modification corresponded to the 
values of rb in the range between 0.02 and 0.1. Modification of DNA by all platinum 
complexes resulted in a decrease of EtBr fluorescence (Figure 5.7) In results published 
earlier,13,25 monofunctional [Pt(dien)Cl]Cl decreases the fluorescence only to a small extent, 
whereas the decrease induced by the DNA adducts of cisplatin is significantly more 
pronounced. The decrease in the fluorescence signal induced by the formed adducts of tHpz, 
tMeim and tMepz was found markedly less pronounced.  
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Figure 5.7. Dependences of EtBr fluorescence on rb for DNA modified by tHpz, tMeim, tMepz, 
cisplatin and [Pt(dien)Cl]Cl in 10 mM NaClO4 at 37 ºC for 24 hr. I1 represents the DNA-Pt-EtBr 
fluorescence – pure EtBr, and I0 the DNA-EtBr fluorescence – pure EtBr fluorescence. 
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In fact the fluorescence intensity was only slightly lower than the fluorescence 
intensity of the DNA modified by the monofunctional [Pt(dien)Cl]Cl. This result clearly 
shows that the three trans-Pt(II) complexes can form monofunctional adducts, which inhibit 
EtBr fluorescence. Therefore, the fluorescence analysis is consistent with the idea that the 
major DNA adducts of these new asymmetric trans-platinum complexes are monofunctional 
lesions. However, it was observed in the experiments with thiourea that the monofunctional 
lesions formed by these trans-Pt(II) complexes are different to that formed by transplatin, 
since they were more resistant to the treatment with thiourea at short time intervals. 
 
5.4 Concluding remarks 
The goal of the study described in this chapter was to examine the effect of substitution of 
the NH3 in transplatin for iPram and azole ligands on their DNA-binding properties. The 
results obtained here show that the combination of the iPram ligand and azole ligands in one 
complex do not alter the first step of the binding mode of bifunctional platinum complexes to 
DNA, i.e. the formation of the monofunctional adducts at N7 position of guanine residues. 
Importantly, the bulky ligands present in all three complexes result in a greatly reduced rate of 
transition of the monofunctional platinum lesions into the bifunctional lesions. This result 
implies an important difference in the nature and frequency of the DNA adducts of tHpz, 
tMeim and tMepz and the clinically ineffective transplatin. 
Other trans-platinum(II) complexes containing sterically hindered planar ligands instead 
of NH3 groups haven already reported.4,26 As in the case of the complexes reported in this 
chapter, complexes with that type of ligands exhibit a greatly enhanced cytotoxicity in tumor 
cell lines in comparison with transplatin and their cis analogues and in several cases, as 
discussed in chapter 3, their cytotoxicity was found to be comparable to that of the clinically 
used cisplatin. This result changes the standard cis/trans structure-activity relationship 
observed previously for [PtCl2(amine)2] complexes. The presence of bulky planar amine 
ligands has been found to enhance strongly the DNA interstrand cross-linking capability of 
the complexes with trans geometry. It is suggested that this enhanced interstrand cross-
linking efficiency of trans-[PtCl2(amine)2] complexes, along with specific conformational 
changes in DNA, could be relevant to their improved cytotoxicity in tumor cells. 
The asymmetric trans-platinum complexes, tHpz, tMeim and tMepz, also exhibit 
cytotoxicity in tumor cells, which is much more pronounced than that of their cis analogues 
(see chapter 4). However, in contrast with the trans complexes of planar amine ligands and 
transplatin, these new asymmetric trans-platinum complexes appear to form markedly smaller 
amounts of bifunctional DNA adducts. Thus, an important feature for biological activity of 
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these trans-platinum complexes is their capability to form relatively stable monofunctional 
adducts in DNA. The same behavior was found for trans complexes with iminoether ligands.2 
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Possible applications of trans-platinum species in drug 
targeting 
 
Abstract 
 An example of the application of platinum species attached to a common drug, 
pentoxifylline is described. The selected drug, pentoxifylline, is an anti-inflammatory drug, 
which blocks hepatic stellate cells activation independently of phosphodiesterase inhibitory 
activity. This blocking of the hepatic stellate cells is an essential step in hepatic fibrosis. In 
this chapter a new pathway of selective delivery of this drug into the liver, using “drug 
delivery systems”, is presented. New systems are synthesized, characterized and purified with 
this approach as objective. The innovation of this research lies in the use of platinum 
coordination complexes as cleavable linker between the drug (pentoxifylline) and the carrier. 
Aliphatic diamines are used as linkers between the platinum and the carrier, and which are 
modified for a successful binding of the carrier. As a carrier mannose 6-phosphate human 
serum albumin has been selected, since albumin-based carriers have specific receptors in the 
liver, known to lead to a successful targeting of anti-fibrotic drugs. 
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6.1 Introduction    
6.1.1 Introduction to drug targeting  
In general, many synthesized drugs fail to enter the market, because of the difficulty to 
reach therapeutically active concentrations at the target site in the diseased tissue without 
resulting in severe side effects. Cell-specific drug delivery provides an excellent opportunity 
to enhance the effectiveness of drugs and simultaneously prevent their side effects, and for 
some diseases, like liver fibrosis,1 it may represent the only way towards a successful 
pharmacotherapy. 
Since the 1960s, many scientists have studied the development of drug targeting 
strategies for the treatment of diseases. In general, the aim of targeted therapies is to increase 
the efficacy and reduce the undesired toxicity of drugs. The behavior of the carrier molecules 
largely determines the pharmacokinetics and cellular distribution of the drug. Furthermore, 
selective delivery into the target tissue may allow a higher drug concentration at, or in the 
target cells, or even in specific compartments of the target cells, thereby enhancing drug 
efficacy.  
 As a result new chemical entities are generated, which in principle can exert potent 
effects on disease processes, but have a deficient distribution to the areas of disease. 
However, by attaching a carrier molecule to these chemical entities, its whole body and 
cellular disposition can be considered manipulated. For these treatment modalities to become 
a major success, the delivery and/or targeting of these compounds will be an essential 
component.2 
 In comparison with a native drug, a macromolecular prodrug exhibits improved body 
distribution and prolonged blood circulation times, due to the dominant pharmacokinetic 
properties of the macromolecular carrier. The chemical and/or biological stability of the 
linkage between the drug and the macromolecular carrier should be considered, since their 
pharmacological effectiveness requires the release of the drug from the conjugate. The blood 
circulation times increase in this type of macromolecular prodrugs, because the bond between 
the drug and the macromolecular carrier is strong enough to be cleaved at the target site.3  
As stated above, targeting of therapeutics to specific cell populations involved in the 
disease process is a highly relevant technique to improve their safety and clinical application. 
However, there are still many specific problems to be solved, especially with respect to the 
“covalent” coupling of these molecules to suitable carrier molecules for drug delivery 
systems. The most important are: 
1) The major problem of the coupling of the therapeutic proteins (such as anti-
inflammatory cytokines) to carriers is that proteins are complex molecules that can 
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bind to the carrier with more than one functional group. This often leads to the 
formation of several non-defined species, which can cause a corruption of the 
targeting strategies and/or a loss of biological activity of the molecule. This implies 
that extensive purifications methods are required to obtain the desired target 
molecule.4 
2) In some cases, drugs may exert their therapeutic effect outside the target cell. In this 
case, the drug should either be released extracellularly, or it should be still active when 
chemically coupled to the homing device. However, the coupled drug should often 
first be internalised in the target cell and subsequently be released from its targeting 
device, in order to become biologically active. This means that the linkage between 
the drug and the targeting device should be stable in the blood, but should be 
degradated at the target site. The problem is that in most of the systems designed, the 
drugs are prematurely released, as a consequence of the degradation of the linkers.5 
3) Many small organic drugs simply do not have functional groups that can be used for 
the conventional chemical linkage technologies (e.g. the so-called NHS ester linkage) 
to couple the particular drug to a carrier molecule and, therefore, would need 
modification. 
 
So, with no effective drugs available for certain diseases and the unacceptable side 
effect profile of those drugs, many diseases might benefit from the targeting of drugs to cells 
in the diseased tissue. This chapter discusses the possibilities and limitations to use trans-Pt 
compounds for this purpose. 
 
6.1.2 Pentoxifylline 
In this pilot study, pentoxifylline, ptx (Figure 6.1), an anti-fibrotic drug, is used for 
the targeting of hepatic stellate cells (HSCs), which are the main responsible of liver fibrosis. 
There are several ways to interfere with the fibrotic process. One way is the targeting of drugs 
to the sinusoidal endothelial cells (SECs) and the Kupffer cells (KCs) to modulate their 
release of pro-inflammatory mediators. This may arrest the inflammatory process leading to 
cirrhosis. Another approach - and this is the one studied in this project - is the delivery of 
drugs in the HSC, to inhibit the collagen production or to enhance their extracellular matrix 
degrading capabilities.1  
The drug, ptx, is an alkylated xanthine, which is clinically useful for the treatment of 
conditions involving defective regional cirrhosis.6-8 Ptx, a non-specific inhibitor of cyclic 
nucleotide phosphodiesterases,9 inhibits collagen gene expression in dermal fibroblasts.10 
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That property makes it possible to use this drug for the targeting to HSCs, which are the cells 
responsible of the synthesis of collagen in the liver. Moreover, the mechanisms responsible 
for the prevention of hepatic fibrosis by ptx in yellow phosphorus-induced hepatocellular 
necrosis remain to be determined.11  
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Figure 6.1. Structural formula of pentoxifylline (ptx). 
 
 Unfortunately, a standard administration of ptx does not reach a therapeutical 
concentration at the liver and the drug is known to result in several side effects, limiting the 
dosage administered. Therefore, a selective delivery of ptx, or other drugs, may comprise a 
promising new way to improve the treatment of liver fibrosis.  
 
6.1.3 Albumin-based carriers 
Hepatic stellate cells are the key cells involved in the formation of the extracellular 
matrix proteins. This type of cells plays an important role in the development of liver fibrosis, 
since this cell is the major target for anti-fibrotic drugs. Targeting of antifibrotic agents using 
albumin carriers is an option to obtain a selective drug accumulation in activated HSC. Until 
recently, no carriers were available to target drugs to stellate cells. However, more recently 
carriers have been developed that interact with certain membrane receptors on stellate cells 
and which are upregulated after activation of this type of cells.12 
Since a strong upregulation of the mannose 6-phosphate/insulin-like growth factor II 
receptor was reported on the cell membrane of activated stellate cells,1 Meijer et al. have 
modified albumin with mannose 6-phosphate groups (M6Px-HSA) (Figure 6.2) to be used as 
carrier of anti-fibrotic drugs.12 When the number of mannose 6-phosphate groups increases in 
the core protein albumin, an increase in the hepatic stellate cell-specific accumulation in vivo 
in rats with live fibrosis is observed.12 When a low degree of sugar loading is present (x < 10) 
in M6Px-HAS, it will remain in the plasma (>75 % of the administered dose), whereas an 
increase in the molar ratio of M6P-HSA to 28:1 will cause a preferential accumulation in the 
liver (59 ± 9 % of the administered i.v. dose at t = 10 min).12 
Possible applications of trans-platinum species in drug targeting 
117 
Some studies have shown that M6P28-HSA binds to specific receptors on the target 
cells. Furthermore, rapid internalisation of M6P28-HAS was demonstrated to occur via the 
endosomal-lysosomal pathway. Sinusoidal endothelial cells were found responsible for the 
hepatic uptake of M6P28-HAS in normal human livers, whereas hepatic stellate cells 
contributed primarily to the uptake of this neoglycoprotein in cirrhotic human livers.13 So 
M6P28-HAS allows cell-specific delivery of anti-fibrotic agents to hepatic stellate cells. 
Drug carriers may create interesting new opportunities for conventional antifibrotic 
agents that are not effective enough in vivo, or display serious extrahepatic side effects.  
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Figure 6.2. General structural formula of cis-ULS®, modified trans-ULS® systems and the albumin-
based carrier. 
 
6.1.4 ULS® systems as cleavable-bond linkers between the carrier and the drug 
 At present, the existing chemical (covalent) linkage methods are insufficient to 
overcome the problems described above. In the remaining part of this chapter some detailed 
studies will be reported that provide an alternative generic (non-covalent) ULS®-based 
linkage technology to solve these problems (Figure 6.3).14-18 It should be realized beforehand 
that after the release of the drug, the platinum-based linkers might be themselves toxic as 
well, as related compounds (cisplatin) are well-known antitumor drugs. However, for a study 
of the proof of principle, this is less relevant at this stage. The importance of ULS labelling is 
based on the stable (kinetically slow) coordinative binding properties of platinum complexes 
to nucleic acids and proteins. The ULS molecules consist of a platinum complex, a detectable 
molecule and a leaving group, which is displaced upon reaction with the target. This ULS 
molecule forms a coordinative bond, coupling the ULS to the target in a sufficiently stable 
way. 
Several modified ULS® systems have been synthesized with the goal of targeting 
organic drug molecules that cannot be targeted using conventional strategies. In this chapter 
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ptx and mannose 6-phosphate human serum albumin (M6P-HSA) are studied as a drug and 
core protein or carrier, respectively. The general structure of the ULS® system and the 
modified ULS® systems and the M6P-HSA are also represented in and Figure 6.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Structural design of drug targeting system. There are three fragments in the design system. 
Module 1 is the drug payload, Module 2 is the cleavable bond unit, including the linker and Module 3 
is the carrier that recognizes the target tissue. 
 
 The original ULS®19 systems show a cis geometry of the organic drug and the core 
protein or carrier. However, in the present chapter, trans ULS® systems are synthesized 
(Figure 6.4) with the aim to compare the differences in the targeting strategy between the 
different geometries cis and trans and to study the effect of using different lengths of the 
aliphatic linker systems, as shown in Figure 6.5. Differences in relaxation time of the drugs 
and amount of drug that reaches the target cell will be determined at a later stage. In this 
chapter, only synthesis and purification of the trans ULS® systems are presented. 
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Figure 6.4. Trans-ULS® systems, trans-[Pt(NH3)2(ptx)(NH2(CH)nNH2)] (n = 3, 4, 5) and the used 
numbering for the spectroscopy characterization. 
 
For the binding of the carrier to the linker, the modification of the free amine group is 
necessary, after the deprotection of the Boc group. This modification is due to the fact that the 
drug ULS®
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amine group can react with many functional groups of the protein, as mentioned above. The 
amine group will be transformed to an amide functional group; in this way the coordination of 
the carrier to the linker will be more selective. The ultimate goal of this drug delivery research 
is to develop more effective drug-delivery systems, thereby improving the pharmaco-
therapeutic intervention in liver fibrosis and cirrhosis. 
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Figure 6.5. Protected linkers used in the ULS® systems. 
 
6.2  Experimental section 
6.2.1 Materials 
Transplatin and the bromoacetic acid N-hydroxysuccinimide ester were obtained from 
Sigma-Aldrich. Mono-tertbutoxycarbonyl-1,5-diaminopentane was provided by 
Novabiochem (Germany). Mono-tertbutoxycarbonyl-1,3-diaminopropane and mono-
tertbutoxycarbonyl-1,4-diaminobutane were synthesized as described in literature.20 
Triethylamine was provided by Fisher Scientific Nederland B.V. Pentoxifylline was obtained 
from Sigma-Aldrich. 
 
6.2.2 Synthesis and characterization of the trans-ULS® systems, trans-
[Pt(NH3)2(ptx)(NH2(CH)nNH2)] 
The synthesis of the used ULS® systems was performed in five steps (see also Scheme 6.1). 
Cis-[PtCl(ONO2)(NH3)2]  
Transplatin (0.1 g, 0.333 mmol) in 4 ml of dimethylformamide (DMF) was treated 
with 0.9 equiv. of AgNO3 (0.051 g, 0.3 mmol). The reaction mixture was stirred overnight, in 
the dark. After this time, AgCl was filtered off and the yellow solution, containing cis-
[PtCl(ONO2)(NH3)2], was checked by 195Pt NMR. A single peak was observed at -1775 ppm, 
which agrees with the ClON2 environment around the platinum center.21,22 
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Cis-[PtCl(NH3)2(Boc1,n)]+ (n = 3, 4, 5)  
Cis-[PtCl(ONO2)(NH3)2] in DMF was treated with 0.8 equiv. of Boc1,n (n= 3 (0.046 
g, 0.266 mmol), 4 (0.050 g, 0.266 mmol), 5 (0.099 g, 0.266 mmol)) and 0.8 equiv. of 
triethylamine (Et3N). The reaction mixture was reacted overnight at room temperature. The 
formation of cis-[PtCl(NH3)2(Boc1,n)]+ was checked by 195Pt NMR, directly from the reaction 
solution. A single signal was observed at -2399 ppm, which was assigned to a ClN3 
environment around the platinum.21,22 The same signal was observed, at the same chemical 
shift, for the three used linkers Boc1,3; Boc1,4 and Boc1,5. 
 
Pt
NH3Cl
H3N Cl
+ 0.9  AgNO3
DMF
overnight,
in the dark
Pt
NH3Cl
H3N ONO2
0.8 Boc1,n
0.8 Et3N
Pt
NH3Cl
H3N NH2
NHBocn
+
+0.9  AgNO3Pt
NH3O2NO
H3N NH2
NHBocn
+
DMF
overnight,
in the dark
0.8 ptx
overnight 
75 ºC
Pt
NH3ptx
H3N NH2
NHBocn
2+
HCl 0.1N
65 ºC
overnight
Pt
NH3ptx
H3N NH2
NH2n
2+
n= 3, 4, 5  
Scheme 6.1. Reaction scheme of the modified ULS® systems trans-
[Pt(NH3)2(ptx)(NH2(CH)nNH2)] (n = number of C atoms in the aliphatic chain of the linkers). 
 
Cis-[Pt(ONO2)(NH3)2(Boc1,n)]+ (n = 3, 4, 5)  
Cis-[Pt(Cl)(NH3)2(Boc1,n)]+ was treated with 0.9 equiv. of AgNO3 (0.051 g, 0.3 
mmol) in DMF. The reaction mixture was stirred overnight, in the dark. After this time, AgCl 
was filtered off and the yellow solution, containing cis-[Pt(ONO2)(NH3)2(Boc1,n)]+, was 
checked by 195Pt NMR. A single signal was observed at -2133 ppm. This signal agrees with 
the ON3 environment around the platinum.21,22 The same chemical shift value was observed 
for the three used linkers. 
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Cis-[Pt(ptx)(NH3)2(Boc1,n)]2+ (n = 3, 4, 5) 
Cis-[Pt(ONO2)(NH3)2(Boc1,n)]+ was treated with 0.8 equiv. of ptx (0.074 g, 0.266 
mmol) at 75 ºC, overnight in the dark. After overnight the formation of the desired species 
were checked by 195Pt NMR. A signal was observed at -2487, -2484 and -2492 ppm for 
complexes RBo1,3, RBoc1,4 and RBoc1,5, respectively. These values are in agreement with a 
N4 environment around the platinum center.21,22 
 
Deprotection of the Boc group. 
The deprotection of the amine group in the final step takes places by the overnight 
treatment with 0.1 M HCl of each of the complexes RBoc1,3, RBoc1,4 and RBoc1,5 at 50 ºC, 
in the dark. 1H NMR proved the successful deprotection by the disappearance of the signal 
assigned to the tert-butyl group at 1.34 ppm (Figure 6.6).   
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. 1H NMR spectra recorded before and after the Boc  
deprotection reaction for complex R1,5 (for R1,3 and R1,4 a  
similar effect is observed). 
 
6.2.3 Purification of the trans-ULS® systems by HPLC 
Purification for all three trans-ULS® systems had to be performed, as a mixture of 
different species was initially formed. 
 A variety of conditions were tried for a successful separation of the different species; 
the proper conditions finally selected were as follows: 
 Buffer A: 10% acetonitrile 90% 100 mM triethylammonium acetate (TEAA) pH 5. 
 Buffer B: 70% acetonitrile 30% 100 mM TEAA pH 5. 
 Flow = 4 ml/min. 
For all the complexes the purification was successful, as checked by MS and in 1H-
NMR. The characterization of the pure ULS® systems is presented in section 6.3.1. 
 
Boc 
Boc deprotection
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6.2.4 Modification of the NH2 group of the linker 
As said in section 6.1.1, one of the problems of these new systems in drug targeting is 
the coupling of the therapeutic proteins to suitable carriers, since proteins can bind to the 
carrier, with more than one functional group. This may lead to the formation of many 
different species, which may interfere in the drug targeting. Therefore, a modification at the 
NH2 group of the linker is required.  
For the modification of the amine group, the ULS® systems have been dissolved in 
water and the pH is adjusted between 8-9 with 1M NaOH. After the pH is adjusted, 1.5 equiv. 
of bromoacetic acid N-hydroxysuccinimide ester is added to the solution. The reaction is 
stirred at room temperature for 7 hr. It is important to maintain the pH of the reaction mixture 
between 8 and 9 during the complete reaction (Scheme 6.2), to allow the reaction between the 
amine group and the ester.  
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Scheme 6.2. Reaction scheme of the modification of the NH2 group of the linker. 
 
The progress of the reaction was followed by LCMS. Every 2 hr an aliquot was 
withdrawn and checked by LCMS. It was observed that the peak corresponding to the 
modified complexes was gradually increasing its intensity with time as is depicted in Figure 
6.7. After 7 hr of reaction no further changes were observed in the chromatogram. The mass 
of the desired species were found to be 701.08, 715.05, 729.08 for the modified complexes 
R1,3, R1,4 and R1,5, respectively (Figure 6.8). 
Purification of the modified complexes was required. It was performed by HPLC, with 
the same conditions as used for the purification of the non-modified complexes (section 
6.2.3). Although the purification was successful in all cases, all three complexes appear to be 
unstable after the purification, gradually generating decomposition products during or after 
freeze-drying the samples. No clearly identified decomposition products could be detected, 
unfortunately. 
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Figure 6.7. LC for the reaction modification of complex R1,3 connected with MS (for complexes 
R1,4 and R1,5 the same behavior was observed). 
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Figure 6.8. Structural formula of the modified ULS® systems. 
  
6.3 Results and discussion 
6.3.1 Synthesis and purification of the UL S® systems 
The synthesis takes place in five steps as has been schematically depicted in scheme 
6.1. Preparation of the ULS® systems involves the subsequent activation of the two Pt—Cl 
bonds with AgNO3, for the binding of the linker and the drug ptx. In all three cases R1,3, 
R1,4 and R1,5 (Figure 6.4) the purification, by HPLC, was needed due to the formation of 
different species. The purified complexes were characterized by 1H and 195Pt NMR and MS 
(Table 6.1).  
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Table 6.1. 1H and 195Pt NMR and MS data for the ULS® systems trans-
[Pt(NH3)2(Boc1,n)(ptx)] (n = 3, 4 and 5). For the used atom numbering see Figure 6.4. 
Atoms R1,3 R1,4 R1,5 
H1 3.04 3.84 3.42 
H2 2.87 1.78 1.69 
H3 2.05 1.42 1.45 
H4  2.66 1.69 
H5   2.59 
H1’ 2.18 2.18 2.18 
H3’ 2.77 2.77 2.77 
H4’ 1.56 1.56 1.56 
H5’ 1.56 1.56 1.56 
H6’ 3.00 3.00 3.00 
H10’ 4.45 4.45 4.45 
H11’ 8.51 8.48 8.49 
H14’ 3.95 2.37 2.37 
Boc 1.34 1.34 1.34 
195Pt (δ, ppm) -2487 -2484 -2492 
MS (m/z) 580.19 595.32 608.31 
 
6.3.2 Modification of the NH2 of the ULS® systems 
After purification of complexes R1,3, R1,4 and R1,5 the modification of the NH2 of 
the linker was performed by treatment of the complexes with bromoacetic acid N-
hydroxysuccinimide ester. The modification consists in the transformation of the amine group 
into an amide functional group, to allow a better reaction with the carrier to the ULS® 
systems. The formation of the modified complexes was checked by MS. A peak at 703.26, 
755.3 and 727.5 was observed and assigned to the complexes MR1,3, MR1,4 and MR1,5, 
respectively. Purification by HPLC was also required for the modified complexes. However, 
after purification the complexes appeared to be unstable, during or after freeze-drying, as 
deduced from the fact that when 195Pt NMR was measured overnight no signal was observed. 
The identification of the different decomposition products by other methods was not studied.  
 
6.4 Concluding remarks 
The goal of the research presented in this chapter has been the synthesis and 
characterization of new platinum systems, based on ULS®, that join the drug and the carrier. 
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Platinum complexes with trans geometry were successfully synthesized and characterized 
containing ptx as a drug. 
As mentioned above, ptx is used as an anti-fibrotic in the treatment of liver fibrosis; 
however, the therapeutic concentration by standard administration it is not high enough for 
the treatment of this disease and the side effects are serious. The selective delivery, “drug 
targeting”, of ptx may lead to an improved method for the treatment of this disease. For the 
selective delivery of ptx in the liver, a specific carrier is needed. Albumin-based linkers seem 
to be most suitable carrier for the target of anti-fibrotic drugs to the liver, since they have 
specific receptors in the stellate cells,8 which are the cells responsible of fibrosis. Apparently 
a rapid internalization of the systems takes place with this type of carriers, what makes their 
use potentially more successful for the delivery of ptx into the liver. 
Modifications in the diamines linker of the modified ULS® systems are required to 
bind efficiently with the carrier; however, the modified systems synthesized so far were found 
not stable enough after purification by HPLC. Different modifications in the amine group of 
the linkers need to be tried for a successful synthesis of such new systems. The first steps, 
however, are important enough to further investigate these systems as potential drug carriers. 
Results obtained in other labs on the PTX - Pt - HAS system confirm this expectation.23 
It is important to point out that in this case platinum complexes are not primarily 
synthesized as new antitumor agents, but it is logical to consider that these complexes, once 
released the drug, themselves could be toxic. To explore that possibility, preliminary studies 
have been performed to evaluate the possible toxic effects of the cis-ULS® systems in HSC 
and kidney cells. It was found that neither cis-ULS species nor cis-ULS-carrier species were 
killing cells, or at least significantly less than cisplatin (positive control).[24] However, the 
most important feature of using platinum complexes in drug delivery derives from the fact 
that the strength bond Pt-drug is stable enough - and not covalent - to reach the target and to 
release the drug in the target tissue. 
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General discussion and future prospects 
 
7.1 General discussion 
7.1.1 Introduction 
This thesis deals with a variety of asymmetric cis- and trans-platinum(II) complexes. 
The major aim of this research has been the design of complexes with high antitumor activity 
that may overcome cisplatin resistance, and to establish a comparison between complexes in 
both cis and trans geometries. 
The general introduction (Chapter 1) comments the discovery of cisplatin, its 
mechanism of action and the problems found for cisplatin in chemotherapy treatment. 
Cisplatin binds to DNA preferentially through the N7 position of two adjacent guanines, 
producing a distortion in the structure of DNA, which prevents replication and transcription, 
eventually driving the cell to death. The major problem of cisplatin treatment is its intrinsic or 
acquired resistance, as well as its toxicity.  
Platinum anti-cancer research has been ongoing for four decades now, and the 
gradually increased understanding of the mechanisms of platinum drugs has facilitated a shift 
from the pure trial-and-error to a more rational approach. The growing number of platinum 
complexes, including the ones presented in this thesis, shows that the synthetic possibilities 
are far from being exhausted. However, the behavior of many new platinum complexes is still 
rather unpredictable.  
Therefore, it was decided to design and investigate a new group of new “asymmetric” 
cis- and trans-platinum(II) complexes, containing in all cases the iPram ligand and in addition 
aliphatic amines or azole ligands. However, a strong emphasis on asymmetric trans-
platinum(II) complexes with azole ligands is presented in this thesis.  
 
7.1.2 Asymmetric cis- and trans-platinum(II) complexes with aliphatic amines 
In Chapter 2, the synthesis, characterization, interaction with GMP and cytotoxicity 
of new asymmetric cis-platinum(II) complexes with general formula cis-
[PtCl2(iPram)(amine)] (amine = methylamine, dimethylamine, propylamine and butylamine), 
as well as the comparison of their antitumor activity with their trans analogues, are reported. 
These cis-platinum(II) complexes were primarily synthesized to provide antitumor drugs 
endowed with better antitumor activity than their trans analogues, which already  showed   an  
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improved cytotoxicity in several tumor cell lines in comparison with cisplatin. The interaction 
of both groups of isomers cis and trans with DNA model bases was studied for a better 
understanding of the differences in the DNA binding of these complexes. The model base 
studied was guanosine 5’-monophosphate (GMP). The interaction of these asymmetric 
complexes with GMP was found to be similar for all studied complexes, producing the 
formation of bisadduct species within 24 hr, which implies that both groups of isomers 
behave as bifunctional species, with two GMP molecules binding to the platinum center.  
The results of cytotoxicity tests showed that these asymmetric cis-platinum(II) 
complexes are less cytotoxic than their trans analogues and than cisplatin. Only one of the cis 
complexes, where the amine is butylamine, was found to be active in the same range as 
CDDP in only one of the studied cisplatin-sensitive cell lines (CH1); but this activity was 
found still 2.9 times lower than for CDDP. Therefore, it was concluded that the complexes 
with trans geometry show a higher cytotoxicity than their cis analogues, apparently violating 
the classical structure-activity relationship rules, for the development of new antitumor drugs. 
 
7.1.3  Asymmetric cis- and trans-platinum(II) complexes with iPram and azole ligands 
In Chapters 3 and 4, the synthesis, characterization, crystal structures, cytotoxicity 
and interaction with GMP of the asymmetric cis-, trans-platinum(II) complexes with general 
formula cis-, trans-[PtCl2(iPram)(azole)] (azole = Hpz, Meim and Mepz) have been reported. 
The X-ray data show that all trans complexes crystallize in the monoclinic system, with bond 
distances Pt—N(azole) slightly shorter than the bond distances Pt—N(iPram). Moreover, it 
was found that in the case of complexes tMeim and tMepz two different orientations for the 
iPram ligand were observed, and in the case of tMeim it results in two independent molecules 
in the asymmetric residue. The complex cMeim crystallizes in the orthorhombic system, with 
only one orientation of the iPram ligand in contrast with its trans analogue. The same effect 
was found for the bond distances of Pt—N(azole) and iPram. In all four complexes the bond 
distances Pt—Cl were found within the expected range for such trans-dichlorideplatinum(II) 
species. 
 Each complex reacts with GMP in a bifunctional way to form the 1:2 complexes. All 
the complexes react with GMP with comparable rates, and in the case of complexes tHpz and 
tMepz the second hydrolysis-intermediate species have been observed. This leads to the 
conclusion that both complexes follow the same mechanism as cisplatin in their interaction 
with GMP. The mechanism proposed for complexes tMeim, cMeim and cMepz was a direct 
substitution of the Cl ligands by the GMP, since intermediate-hydrolyzed species were not 
observed during the reaction. For the complexes tMeim and cMeim a kinetic analysis was 
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performed and it was confirmed that the interaction of both complexes with GMP seems to 
proceed via a direct substitution of the Cl- ligand by the N7 of GMP. It is interesting to 
remark on complex cMepz, the step from the monofunctional adduct to the bifunctional 
adduct is so fast that the first species can hardly be observed during the reaction.  
The results of cytotoxicity show that the trans complexes have a higher cytotoxicity 
than their cis analogues in some of the human tumor cell lines tested. Furthermore, it was 
found that the trans complexes, tHpz, tMeim and tMepz, overcome cisplatin resistance, 
while only one of the cis analogues cMeim overcome it, but still with a RF value 2.8 times 
higher than the corresponding trans analogue. A relationship between the ligand in the 
complexes and the activity was deduced. It was proven that the most cytotoxic complex in 
either the cisplatin-sensitive or the cisplatin-resistant cell lines is the trans complex with the 
Hpz ligand, followed by the complex with the Meim ligand. Complex tMepz, with the Mepz 
ligand, was found to be cytotoxic only in the micromolar range compared to CDDP. 
However, it did not show a marked activity in comparison with the other trans complexes 
studied. As already said, the cis complexes did show less activity in all the used cell lines; 
nevertheless, also a relationship was found between the activity and the azole ligand present 
in the platinum compound, and the cis complex with the Meim ligand was found more active 
than the complex with the Mepz ligand. The most important and interesting result obtained 
for the cytotoxicity studies appeared to be that the trans complexes overcome cisplatin 
resistance, but it is even more important that the cis complex, cMeim, also overcomes 
cisplatin resistance and although its activity is lower than the trans analogue, it may show less 
side effects. This is a highly relevant observation in the search for antitumor complexes 
endowed with better antitumor properties than CDDP.  
With the aim of finding a possible explanation for the different activity shown by 
these new asymmetric cis and trans platinum complexes and taking in account that in general 
complexes with trans geometry have been less studied than their cis isomers, a study of the 
DNA-binding of the asymmetric trans-platinum(II) complexes was performed (Chapter 5). 
Different biochemical and biophysical techniques were used, such as electrophoresis, 
differential pulse polarography, UV spectroscopy, fluorescence spectroscopy and circular 
dichroism. The experiments carried out for that study were: unwinding induced by each of the 
complexes in plasmid DNA, determination of the amount of interstrand cross-links and 
monofunctional lesions. Only the complex tHpz can induce an unwinding angle similar to 
that of CDDP, which is coincident with the fact that it is the most cytotoxic complex of the 
three trans complexes studied. The other two complexes, tMeim and tMepz, induce 
unwinding angles larger than cisplatin, transplatin and [PtCl(dien)]Cl. This observation is in 
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agreement with the presence of planar ligands, which may intercalate in the double helical 
structure of DNA, producing higher unwinding angles than cisplatin or its analogues. 
The amount of interstrand cross-links formed by the tHpz complex is similar to that 
formed by transplatin, while the amount of these lesions formed by tMeim and tMepz was 
found similar to that of CDDP. The results obtained on the study with thiourea showed that 
these asymmetric trans-platinum(II) complexes form adducts that are resistant at early time 
intervals. So, it is reasonable to assume that these trans complexes could form either 
bifunctional lesions, or monofunctional adducts different from that formed by transplatin. 
However, from the thiourea and EtBr experiments it was proven that these trans-platinum(II) 
complexes form relatively stable monofunctional adducts. This finding is important from the 
biological point of view, to understand the enhanced antitumor activity that these new 
asymmetric trans-platinum(II) complexes show. 
 
7.1.4  Platinum complexes as systems for drug delivery 
In the study presented in Chapter 6, platinum complexes were synthesized and 
characterized, not as antitumor agents, but aimed for drug delivery systems, analogous to 
trans-ULS®. In this case the ULS-platinum species are used as cleavable linkers between the 
drug and the carrier. A different area of research, “drug delivery”, is studied in which there is 
a direct delivery of the drug into the tissue that develops the tumor. With this approach, 
toxicity and acquired resistance problems of the different antitumor drugs used in 
chemotherapy may be overcome. Perhaps more importantly, diseases that until now do not 
have a successful therapy may be treated in this way. As a model drug pentoxifylline (ptx) 
was selected. So, platinum complexes containing ptx, a drug known for treatment of liver 
fibrosis, and different hydrophobic linkers have been synthesized and purified. Ptx is an anti-
inflammatory drug, which blocks the hepatic stellate cells from the liver, responsible for the 
liver fibrosis. As a carrier M6-HSA has been used, which has specific receptors in the liver, 
allowing a possible successful delivery of ptx into that organ. Platinum species have been 
selected with this aim, because the bond formed by Pt and ptx is of medium strength and 
likely to remain intact until the whole trans-ULS® system reaches the liver, allowing the 
possible release of the drug at the target. In a related system, cis-ULS®, studies (not published 
yet) to investigate whether these systems are toxic themselves were performed, since it is 
known that platinum compounds present some toxicity. In these studies, cisplatin was used as 
a positive control. It was found that cisplatin was killing more cells than these cis-ULS or cis-
ULS-carrier species. Similar tests for trans-ULS systems have to be performed to prove that 
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these platinum systems after release of the drug do not have any effect in the process of 
killing the target cells. 
 
7.2 General discussion and future prospects 
This thesis is focused on the study of the biological properties of new asymmetric cis- 
and trans platinum complexes. Two different synthetic methods were applied for the 
synthesis of the cis and trans compounds. In all the complexes studied in Chapter 2, 3 and 4, 
the isopropylamine ligand is present and the other ligand can be either an aliphatic amine, or 
an azole ligand. These changes in the structure of the complexes were made to find a better 
relation between structure and antitumor activity of platinum complexes.  
The recent discoveries that trans-Pt(II) complexes not only show an antitumor activity 
in the same range as their cis analogues, but more importantly overcome cisplatin resistance 
in most of the tumors turns towards the interest in platinum complexes with trans geometry. 
Farrell et al. have reported1-3  a number of trans-Pt(II) complexes with planar ligands showing 
an enhanced cytotoxicity, in comparison with their cis analogues and cisplatin. These ligands 
make the complexes less reactive towards sulfur-containing molecules, which is one of the 
main causes for the resistance of CDDP.1-3 This property appears to be a general feature of 
complexes with planar ligands with formula trans-[PtCl2(L)(L’)] ((1) L = L’ = pyridine or 
thiazole, (2) L = quinoline, L’ = R’R’’SO, R’= Me, R’’ = Me, CH2Ph, Ph, (3) L= quinoline, 
L’ = NH3)).2 Moreover, the presence of sterically demanding amines in the trans structure 
clearly has a dramatic effect on the biological activity of these complexes. Platinum 
complexes with this type of ligands also show less reactivity towards sulfur-containing 
molecules, resulting from the steric effects of the ligands.4-6 In the case of cis-platinum 
complexes the amine non-leaving groups are replaced by these sulfur-donor ligands, giving 
rise to polymeric species. However, in the case of trans-platinum complexes with planar 
ligands and ligands imposing steric hindrance, the replacement of the non-leaving groups is 
not observed. Furthermore, the monofunctional lesions formed by transplatin are longer lived 
than those from its cisplatin analogue and may react with sulfur-containing ligands, thereby 
preventing closure to a bifunctional lesion.7,8 How the closure to a bifunctional lesion is 
affected by the presence of sterically more demanding planar ligand is not fully understood 
and still under investigation. So, in this research planar ligands and ligands that enforce steric 
hindrance have been combined for the search of new trans platinum complexes as antitumor 
agents with better antitumor properties and less side effects than CDDP, or other platinum 
drugs known at this moment. Moreover, the use of other planar ligands with more demanding 
steric hindrance than the ligands used in this work could be used for the design of other 
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platinum antitumor drugs. The same type of ligands, but introducing OH groups to improve 
the water solubility of the complexes, could be also used to explore a more general relation 
between structure and antitumor activity of the platinum complexes with trans geometry and 
to find better antitumor drugs based on platinum. 
The new class of asymmetric trans-platinum(II) complexes introduced in this thesis are 
highly potent candidates for new anticancer drugs. Especially the complexes with azole 
ligands are promising, as they show remarkable cytotoxicity in several human tumor cell lines 
and most importantly they overcome cisplatin resistance. This result is important, since the 
resistant cell line used possesses the four main mechanisms of resistance to cisplatin (i.e. 
decreased uptake, enhanced DNA repair, increased DNA damage tolerance, and elevated 
glutathione (GSH) levels)9,10 It seems that trans platinum complexes with planar ligands 
result in an enhanced uptake in the cell, while the steric effects of the ligands affect binding of 
bulky thiol or thioether groups to platinum.11 However, it could be of interest to study the 
cytotoxicity in other cell lines that only show one of each of the resistance mechanisms to 
cisplatin and to establish which of them are the responsible of the non cross-resistance of the 
asymmetric trans-platinum(II) complexes, shown in this research.   
All these trans complexes, even though derivatives from transplatin, seem to form 
primarily monofunctional lesions with DNA, which are structurally different from those 
formed by cisplatin, transplatin or [PtCl(dien)]Cl; since they are resistant to the treatment of 
thiourea. The importance of the trans geometry is shown again, since the cis analogues, which 
have been also synthesized, characterized and tested in the same cell lines, do not only show 
less cytotoxicity, but they do also not overcome cisplatin resistance.  
At this point, it is of crucial importance to study whether the formation of those 
monofunctional lesions is responsible for the facility of these trans complexes to overcome 
cisplatin resistance. When platinum complexes are bound to DNA, local conformational 
changes take place.  That change might be the major determinant of the recognition by DNA 
repair mechanisms. In the case of cisplatin a strong conformational change in the double 
helical structure of DNA is produced. This change is recognized by HMG proteins that 
probably shield the lesion in the DNA repair.12 In the case of transplatin the bend produced in 
the structure of the DNA is not strong enough and therefore the HMG proteins may not 
recognize the damage. Summarizing, if a platinum complex, which binds to DNA, does not 
produce a strong conformational change in the structure of DNA, then this change could 
escape from repair. Two of the asymmetric trans-platinum complexes studied, tMeim and 
tMepz, show unwinding angles of high magnitude, 19º and 20º, respectively; this is an effect 
of intercalation/monofunctional covalent binding mode as observed for the linkage isomers of 
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the cation trans-[PtCl(NH3)2(EtBr)]+ (EtBr = ethidium bromide).2,13 However, it has not been 
proven yet whether or not those lesions are responsible for the cytotoxic effect of the 
complexes. In the trans-platinum(II) complexes presented in this  thesis, the presence of 
planar ligands in the structure may lead to an intercalation effect of the ligands in the DNA, 
making a slight conformational change in the structure of DNA; they are not recognized by 
the different repair mechanisms known. 
It is important to obtain information of the cytotoxicity or toxicity of the complexes, not 
only the type of Pt-DNA adducts, but also kinetic aspects have to be taken in account. In the 
reaction with GMP, all the complexes studied show a fast reaction. However, a clear 
relationship between the kinetics of the reaction and cytotoxicity cannot be made. A 
qualitative kinetic study has shown that the complex tMepz is the slowest one in its reaction 
with GMP, and also the complex that less bind to DNA (37 %). A more exhaustive kinetic 
study would help to detect a better relation between the cytotoxicity of complexes and their 
capability to overcome cisplatin resistance. 
The formation of monofunctional lesions by the asymmetric trans-platinum(II) 
complexes, which are resistant to treatment with thiourea, leads to the idea that these lesions 
are structurally different from that formed by cisplatin or transplatin. These structural changes 
could be responsible for either the good antitumor activity of these new trans species, or their 
ability to overcome cisplatin resistance. However, to understand this observation a deeper 
study in the structure of these lesions is of essential importance. For that, the study of the 
interaction of the trans complexes with sulfur-containing ligands could be relevant, and to 
establish a comparison with cisplatin, transplatin or other trans-Pt(II) analogues. If interesting 
results would be obtained in these studies, then it would be worthwhile to study the toxicity 
that these complexes show in healthy cells. Furthermore, if their toxicity is lower, or in the 
range of cisplatin, then experiments in vivo could be planned for these new asymmetric trans 
complexes. 
It has been shown in this thesis that the asymmetric cis analogues show lower 
cytotoxicity than their trans analogues. The study of their interaction with cellular DNA and 
the knowledge of the main adducts formed by these complexes could help in the 
understanding of why these complexes, structurally analogues to cisplatin, are less antitumor 
active.  
With the study made with these new cis and trans-platinum(II) complexes proves once 
more that the original structure-activity relationship rules are violated by the discovery of a 
number of new asymmetric trans-platinum(II) endowed with better antitumor properties than 
Chapter 7 
134 
cisplatin or other platinum complexes having a cis geometry. So, with the study presented in 
this PhD thesis, updated rules could be formulated: 
i) Complexes with trans geometry may show better antitumor activity than their cis 
analogues and cisplatin, depending on the used amines (see below). 
ii) Normally complexes with trans geometry overcome cisplatin resistance, while their cis 
analogues do not show the same property.  
iii) Complexes with trans geometry and azole-based ligands show an improved 
cytotoxicity. Especially when next to the donor atom of the azole ligand there is a 
source of hydrogen-bond donor. This is the case for the complex tHpz, which was 
found to be the most cytotoxic complex of all. However, when next to the donor atom a 
bulky group is presented, the cytotoxicity in considerable reduced, as observed for the 
complex tMepz. For the cis complexes this behavior has also been observed. 
iv) It seems, that the use of mixed ligands (aliphatic amines and azole ligands) improves the 
activity of the trans-Pt(II) complexes. The aliphatic amine requires the NH moiety for 
the formation of hydrogen bonds with the O6 of the guanosine residue, forming more 
stable Pt-DNA adducts, while the azole planar ligand may intercalate into the helix of 
the DNA. The combination of both effects seems to enhance the cytotoxicity of the 
complexes. 
 
Using the experience of the present platinum compounds, in a parallel project, platinum 
complexes were synthesized as drug delivery systems that link a drug and a carrier. In this 
way, a drug is transported specifically to a target tissue and it is not distributed through all the 
body like the systemic antitumor agents. Although the study so far has been preliminary, a 
further search towards synthetic conditions may lead to a cleaner synthesis and higher yields 
of these new systems. Further studies, e.g. with hepatic stellate cells will be required to find 
out the possible application of such species. The challenge of these experiments will be to see 
how the drug, ptx, attached to the platinum is selectively delivered into the liver, to stop the 
process of fibrosis in that tissue.  
Finally, no relationship has been obtained yet between the experiments in vitro an in 
vivo. Only few antitumor drugs are known, which show the same spectrum of activity in 
experiments in vitro and in vivo, what complicates the search of new antitumor drugs. 
However, with the potential properties of the asymmetric trans-Pt(II) complexes presented in 
this thesis, an evaluation of their in vivo properties is highly interesting and important. 
 
 
General discussion and future prospects 
135 
7.3 References 
1 N. Farrell, T. T. B. Ha, J. P. Souchard, F. L. Wimmer, S. Cros, and N. P. Johnson, J. 
Med. Chem., 1989, 32, 2240. 
2 N. Farrell, in 'Current status of Structure-Activity Relationship of Platinum Anticancer 
Drugs: Activation of the Trans Geometry.' ed. H. Sigel, A. Sigel, New York, 1996, pp. 
603. 
3 V. Brabec, K. Neplechova, J. Kasparkova, and N. Farrell, J. Biol. Inorg. Chem., 2000, 5, 
364. 
4 J. Holford, S. Y. Sharp, B. A. Murrer, M. Abrams, and L. R. Kelland, Br. J. Cancer, 
1998, 77, 366. 
5 J. Holford, P. J. Beale, F. E. Boxall, S. Y. Sharp, and L. R. Kelland, Eur. J. Cancer, 
2000, 36, 1984. 
6 P. Rogers, F. E. Boxall, C. P. Allott, T. C. Stephens, and L. R. Kelland, Eur. J. Cancer, 
2002, 38, 1653. 
7 A. Eastman and M. A. Barry, Biochemistry, 1987, 26, 3303. 
8 D. P. Bancroft, C. A. Lepre, and S. J. Lippard, J. Am. Chem. Soc., 1990, 112, 6860. 
9 Y. Najajreh, J. M. Pérez, C. Navarro-Ranninger, and D. Gibson, J. Med. Chem., 2002, 
45, 5189. 
10 M. A. Fuertes, C. Alonso, and J. M. Pérez, 2003, 103, 645. 
11 N. Farrell, L. R. Kelland, J. D. Roberts, and M. van Beusichem, Cancer Res., 1992, 52, 
5065. 
12 E. R. Jamieson and S. J. Lippard, Chem. Rev., 1999, 99, 2467. 
13 M. V. Keck and S. J. Lippard, J. Am. Chem. Soc., 1992, 114, 3386. 
 
 
 
 
136 
Summary 
 
This thesis describes a variety of asymmetric cis- and trans-platinum(II) complexes. 
The major aim of this research has been the design of complexes with high antitumor activity 
that may overcome cisplatin resistance, and to establish a comparison between complexes 
with both geometries. These new type of asymmetric platinum complexes contain in all cases 
the iPram ligand and in addition either aliphatic amines or azole ligands. Furthermore, a 
strong emphasis on asymmetric trans-Pt(II) complexes with azole ligands is presented in this 
research. 
In chapter 1, an introduction about the discovery of cisplatin, its mechanism of action 
and the encountered chemotherapy problems are described. Moreover, the evolution in the 
search of antitumor drugs based on platinum is presented. 
In chapter 2, asymmetric cis-Pt(II) complexes with aliphatic amines are introduced. 
Synthesis, characterization, cytotoxicity tests and interaction with GMP were performed. In 
addition, a comparison with their trans analogues was also carried out. The results of this 
work show that both groups of complexes, cis and trans, react with GMP with the same rate 
and in both cases the formation of bisadduct species was observed. However, it was found 
that complexes with cis geometry possess less antitumor activity than their trans analogues. 
This fact leads to the study of the comparison of other groups of complexes to see whether or 
not a relationship in the cytotoxicity between cis- and trans-Pt(II) complexes can be made. 
In chapter 3, the synthesis, characterization, interaction with GMP and study of the 
antitumor properties of new asymmetric trans-Pt(II) complexes with iPram and azole ligands 
are presented. All studied complexes were found to behave as bifunctional species, yielding 
bisadduct products within 24 hr in their interaction with GMP. The cytotoxicity tests show 
that all three complexes possess an antitumor activity similar to that of cisplatin and, even 
more important, these new asymmetric trans-Pt(II) complexes have an improved cytotoxicity 
in a cisplatin-resistant cell line, thereby overcoming cisplatin resistance.  This is a relevant 
observation in the search for antitumor complexes endowed with better antitumor properties 
than cisplatin. 
In chapter 4, the analogues cis-Pt(II) complexes with iPram and azole ligands are 
presented. A comparison is made between these cis and trans complexes. It was found that 
the cis complexes react with GMP with the same rate, resulting in the formation of bisadduct 
species within 24 hr, just like their trans isomers. However, small differences were found in 
their cytotoxicity studies. Both cis-platinum complexes showed less cytotoxicity than their 
trans isomers, and only one of the studied cis complexes was found non-cross resistant to 
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cisplatin, but still with a resistant factor (RF) value 2.8 times higher than that of its trans 
analogue. 
To find an explanation in the different activity shown by these cis- and trans-Pt(II) 
complexes, and due to the fact that in general complexes with trans geometry are less studied 
than their cis analogues, it was decided to study the DNA-binding of the trans compounds. 
This study is presented in chapter 5. The results described in this chapter show that these new 
asymmetric trans-platinum(II) complexes form monofunctional lesions, initially structurally 
different from those formed by cisplatin and transplatin, since they are resistant to the 
treatment with thiourea. This may be an important feature to understand the enhanced 
antitumor activity that these trans complexes show. 
In chapter 6, new drug delivery systems based on platinum are presented. With this 
approach the intention is to decrease the side effects that the systemic drugs have in the 
treatment of some diseases. Synthesis, characterization and purification were performed. In 
this case platinum complexes are used as a cleavable linker between a drug and a carrier, 
which will transport the drug into a target tissue. 
A general discussion of the research presented in this thesis and future prospects are 
elaborated in chapter 7. Three new asymmetric trans-Pt(II) complexes and one cis-Pt(II) 
complex have been found to show antitumor properties quite comparable to those of cisplatin, 
and all of them with a really important characteristic: they overcome cisplatin resistance. Due 
to this fact, the new complexes synthesized are highly potent antitumor drugs and in vivo 
experiments should be planned to know whether or not these new complexes are less toxic 
than cisplatin. 
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Samenvatting 
 
In dit proefschrift wordt een aantal verschillende asymmetrische cis- and trans-
platinum(II)-complexen beschreven. Het belangrijkste doel hierbij is de zoektocht naar 
complexen die een hoge antitumoractiviteit kunnen combineren met het vermijden van 
cisplatina-resistentie. Eveneens wordt een vergelijking tussen de cis- en de trans-geometrie 
gemaakt. De complexen beschreven in dit proefschrift hebben alle een isopropylamineligand 
naast een alifatische amine of een azole-amine. Een sterke nadruk in dit werk ligt op de 
transplatina-complexen met azoolliganden.  
Hoofdstuk 1 geeft een introductie betreffende de ontdekking van cisplatina, het 
werkingsmechanisme van de stof en de problemen ondervonden tijdens platinachemotherapie. 
Verder wordt een historisch overzicht van de verschillende op platina gebaseerde cytostatica 
gegeven.  
In hoofdstuk 2 worden cis-platina(II)-complexen met alifatische amines beschreven. 
Naast de synthese en karakterisering worden de cytotoxiciteit en de reactiviteit met GMP 
onderzocht. De resultaten hiervan worden vergeleken met resultaten verkregen voor de     
trans-analoga van deze complexen. Hieruit blijkt terwijl zowel de cis- als de trans-isomeren 
met een vergelijkbare reactiesnelheid met GMP reageren om een bisadduct te vormen. 
Tegelijkertijd blijkt dat de trans-isomeren hogere antikankeractiviteit tonen dan hun cis-
analoga. Dit resultaat heeft geleid tot verdere vergelijkende onderzoeken tussen cis- en    
trans-isomeren in de volgende hoofdstukken van dit proefschrift om te zien of er een 
duidelijke relatie tussen geometrie en activiteit gevonden kan worden. 
In hoofdstuk 3 wordt de synthese, karakterisering, interactie met GMP en de 
antikankeractiviteit van een serie nieuwe asymmetrische trans-Pt(II)-complexen met een 
isopropylamine en een azoolligand gepresenteerd. Hieruit blijkt duidelijk dat alle stoffen 
bifunctioneel reageren, en binnen 24 uur bisadduct-producten vormen in hun reactie met 
overmaat GMP. Tijdens de cytotoxiciteitstest blijkt dat deze complexen een hoge activiteit in 
verschillende kankercellijnen tonen, en nog belangrijker, activiteit behouden in voor 
cisplatina resistente cellijnen. De complexen omzeilen dus grotendeels cisplatina-resistentie, 
wat van groot belang is voor de ontwikkeling van platinacomplexen met verbeterde 
antikankereigenschappen in vergelijking met cisplatina. 
Hoofdstuk 4 is gewijd aan de cis-analoga van de in hoofdstuk 3 beschreven stoffen. 
Hiermee kan vervolgens een vergelijking tinssen de cis en trans complexen gemaakt worden. 
Opnieuw blijkt dat de stoffen met een vergelijkbare reactiesnelheid bisadducten vormen 
tijdens de reactie met GMP. Verschillen worden echter gevonden tijdens de 
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cytotoxiciteitsstudies. Beide cis-platinacomplexen zijn minder actief dan hun trans-analoga in 
de voor cisplatina gevoelige cellijnen, terwijl slechts een complex cisplatinaresistentie deels 
overkomt. En zelfs dit relatief meest actieve cis-isomeer is nog altijd 2.8 keer minder actief 
dan zijn trans-analoog. 
Om een reden te vinden voor het geconstateerde verschil in activiteit tussen de cis- en 
trans-isomeren uit hoofdstukken 3 en 4, en omdat er minder bekend is over de interactie van 
trans-platina(II)-complexen met DNA, is in hoofdstuk 5 de DNA-binding van de trans 
complexen nader bestudeerd. Dit onderzoek laat zien dat de complexen monofunctioneel aan 
DNA binden. Zij doen dit op een andere manier dan zowel cisplatina als transplatina, wat 
blijkt uit de ongevoeligheid van de adducten voor thioureum. Dit kan een belangrijk verschil 
zijn, dat aan de hoge antikankeractiviteit van deze stoffen kan meewerken 
In hoofdstuk 6 wordt een nieuw geneesmiddelafgiftesysteem gebaseerd op platina 
gepresenteerd. Het doel van dit systeem is om de bijwerkingen van ongestuurde 
geneesmiddelen te verminderen door een brug tussen een geneesmiddel en een sturend ligand 
te vormen. In dit hoofdstuk worden synthese, zuivering en karakterisering van de 
doelverbindingen beschreven.  
Hoofdstuk 7 geeft een algemeen overzicht van de verkregen resultaten en richtingen 
waar dit onderzoek op zou kunnen gaan. 
 
Resumen 
  
1. Cáncer 
El cáncer consiste en el crecimiento descontrolado de células anormales en el organismo, 
las cuales se propagan, invaden y dañan tejidos y órganos. El cáncer es la principal causa de 
muerte en todo el mundo. Actualmente se están llevando a cabo numerosos estudios para una 
mejor compresión de los procesos molecular, celular y genético del cáncer; sin embargo, los 
resultados de estos estudios no se han traducido, hasta el momento, en tratamientos efectivos 
para curar esta enfermedad.1 Los principales tratamientos contra el cáncer se pueden dividir 
en cuatro grupos: cirugía, radioterapia, quimioterapia e inmunoterapia. No obstante, tanto 
avances en el diagnóstico; así como en los distintos tratamientos para mejorar la cura del 
cáncer, siguen siendo necesarios. 
 Esta tesis doctoral está basada en el estudio del tratamiento del cáncer mediante 
quimioterapia, la cual fue definida por Paul Ehrlich (Premio Novel en Medicina en 1908) 
como “el uso de drogas para dañar a un organismo invasor sin dañar al huésped”. 
Actualmente, se utilizan para el tratamiento del cáncer diferentes drogas antitumorales con 
diferente espectro de actividad. La investigación de esta tesis doctoral ha sido dirigida hacia el 
diseño de nuevas drogas antitumorales basadas en el cisplatino y sus análogos.  
 
2. Breve historia del cisplatino 
El cisplatino, cis-diaminodicloroplatino(II) o CDDP (Figura 1), fue químicamente 
descrito por Peyrone en 1844,2 pero sus propiedades antitumorales fueron descubiertas 
accidentalmente por Rosenberg en 1965,3,4 mientras investigaba la influencia de un campo 
eléctrico en el crecimiento de las bacterias Escherichia coli, utilizando dos electrodos de 
platino. Rosenberg encontró que no había división de células, sino la formación de grandes 
filamentos. Este fenómeno parecía estar relacionado con la presencia de pequeñas cantidades 
de compuestos de platino, cis-[PtCl4(NH3)2] y cis-[PtCl2(NH3)2], formados mediante lenta 
solvatación de los electrodos de platino en cloruro de amonio. Se encontró que sólo 
compuestos de platino con geometría cis poseían actividad antitumoral. De hecho, el isómero 
trans del CDDP, transplatino (Figura 1), no mostraba actividad antitumoral.  
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NH3
NH3
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NH3
Cl
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Figura 1. Estructura del cisplatino y de su inactivo isómero trans (transplatino). 
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El CDDP entró satisfactoriamente en ensayos clínicos en 1971,5 y en la actualidad se usa 
de forma rutinaria en clínica y parece ser el agente antitumoral más eficaz en el tratamiento de 
cáncer de ovario y de testículo. El porcentaje de respuesta en otros tumores sólidos malignos 
(cabeza, cuello, pulmón, esófago) puede ser mejorado con el tratamiento con CDDP, aunque 
el efecto del mismo parece ser temporal.6  
A pesar del éxito que el CDDP muestra en el tratamiento del cáncer de ovario y testículo 
presenta, sin embargo, importantes limitaciones en su uso, debido a los efectos tóxicos que 
produce  tales como nefrotoxicidad, ototoxicidad y neuropatía periférica.7-9 Además, la 
resistencia adquirida por ciertos tumores al CDDP también limita la eficacia terapéutica del 
mismo. Estos efectos secundarios tóxicos del CDDP limitan la dosis que puede ser 
administrada a los pacientes; típicas dosis son de 100 mg/día una vez al día durante 3 semanas 
consecutivas, seguido de una semana de descanso, si bien hay distintas formas de 
administración de la droga, dependiendo del tipo de tumor.10 
El conocimiento de los efectos secundarios del CDDP nos lleva a la búsqueda de análogos 
del mismo que sigan uno o todos los siguientes criterios: 
1. Mayor selectividad, presentando un espectro más amplio de actividad y, 
especialmente, actividad en tumores resistentes al cisplatino, pero con menos 
efectos tóxicos. 
2. Modificación del índice terapéutico, es decir, una mayor eficacia clínica para 
reducir la toxicidad, con actividad al menos en el mismo rango que el CDDP. 
3. Modificación de las propiedades farmacológicas, tales como solubilidad, que 
podrían resultar en otras formas de administración. 
 
Todas estas drogas cumplen una serie de reglas donde estructura y actividad están 
relacionadas. Así (i) la geometría cis es requerida para que los compuestos presenten 
actividad, (ii) los grupos salientes deben tener fortalezas de enlace medias (Cl-, SO42-, 
caboxilatos) y (iii) los grupos no salientes deben al menos tener una unidad NH, necesaria 
para la formación de enlaces de hidrógeno con el ADN. 
Así surgen nuevas drogas de platino, tales como carboplatino,11 nedaplatino12 y 
oxaliplatino,13,14 conocidas también como drogas de “segunda generación”. Todas ellas 
presentan menos efectos secundarios que el CDDP y una actividad antitumoral similar a la del 
mismo. Sin embargo, solamente el oxaliplatino vence la resistencia al cisplatino, es decir, es 
activo en células resistentes al CDDP.15 
El CDDP y todas las drogas de segunda generación son administradas por infusión 
intravenosa. La capacidad de administrar la droga oralmente daría mayor flexibilidad en la 
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dosis administrada y aumentaría el potencial para el uso de las drogas de platino, 
especialmente en el tratamiento paliativo.  
Se han descubierto compuestos que no cumplen las reglas estructura-actividad y sin 
embargo presentan activad antitumoral. Son llamados compuestos de platino “no clásicos”:  
(i) Compuestos de Pt(IV) surgen como consecuencia de la búsqueda de 
compuestos más solubles que el CDDP y por lo tanto se baraja la posibilidad de 
ser administrados oralmente. El más satisfactorio de los compuestos de Pt(IV) es 
el satraplatin o bis(acetato)aminodicloro(ciclohexilamina)platino(IV);16 
(ii) Compuestos impedidos estéricamente. El más conocido es cis-aminodicloro(2-
metilpiridina)platino(II) (ZD0473),17 el cual no presenta resistencia al cisplatino 
ya que su impedimento estérico le hace menos reactivo frente a moléculas que 
contienen azufre, que es una de las causas de los efectos secundarios del 
cisplatino;  
(iii) Compuestos polinucleares.18-20 Este tipo de compuestos forma aductos con el 
ADN estructuralmente diferentes a aquellos formados por el cisplatino u otros 
análogos mononucleares; y  
(iv) Compuestos con geometría trans.21-25 Estos compuestos rompen las reglas que 
relacionan la estructura y la actividad de los compuestos de platino. La mayoría 
de estos compuestos de platino con geometría trans presentan una actividad 
antitumoral mejor que la de sus análogos cis y son activos en células resistentes 
al cisplatino, lo cuál abre un amplio abanico de posibilidades en el tratamiento 
del cáncer. 
 
3.  Mecanismo de acción del cisplatino  
¿Cómo llega a la célula? Aunque hay una gran variedad de condiciones fisiológicas de 
algunos sistemas transportadores que influyen en la acumulación celular del CDDP, no hay 
suficientes evidencias del mecanismo activo de transporte del mismo a la célula.1 Debido a 
que la acumulación de CDDP no es ni saturable ni inhibida competitivamente por análogos 
estructurales, se sugiere que la droga entra en la célula a través de una difusión pasiva.26-2 La 
difusión de alta capacidad facilitada a través de los canales de entrada a la célula también ha 
sido sugerida como mecanismo de entrada,30 pero debido al tamaño del cisplatino la entrada a 
través de la mayoría de los canales bien caracterizados se ve dificultada. Recientemente se ha 
publicado que el transportador de cobre Ctr1 está implicado en la absorción del CDDP, ya que 
ha sido demostrado que la eliminación de su gen homólogo, el cuál codifica a un 
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transportador de cobre de alta afinidad, da lugar a un aumento en la resistencia del CDDP y 
reduce la acumulación intracelular del mismo.31,32 
Una vez que el CDDP ha entrado en la célula, donde la concentración de cloruro es mucho 
más baja que en el plasma sanguíneo (~ 4 mM), se hidroliza para formar especies activas 
cargadas positivamente para la consecuente reacción con componentes celulares.16 La diana 
del CDDP dentro de la célula es el  ADN. El modo exacto de interacción entre el CDDP y el 
ADN así como su distribución celular no se conoce todavía de forma exacta. Sin embargo, 
dentro de la célula hay otros componentes (proteínas, aminoácidos, péptidos, polifosfatos) que 
compiten por el CDDP. Se cree que la unión Pt-proteína juega un papel importante en la 
toxicidad y mecanismo de resistencia del CDDP. 
 
4.  Unión al ADN 
Hay distintas posiciones donde el CDDP se une en el ADN. Sin embargo, la posición 
preferente de unión es el N7 de la guanina. Esta tendencia resulta de la gran basicidad que 
esta posición presenta, por la posibilidad de formación de enlaces de hidrógeno entre los 
protones del grupo amino del CDDP con el O6 de la guanina, así como por su accesibilidad 
para los compuestos de platino. 
La reacción del CDDP con el ADN conduce a la formación de seis diferentes estructuras. 
En mayor proporción los aductos formados son 1,2-intracatenarios con dos guaninas 
adyacentes, seguidos de los aductos 1,2-intracatenarios entre una adenina y una guanina y 
aductos 1,3-intracatenarios y 1,4-intracatenarios entre guaninas separadas por una o dos bases, 
respectivamente. Un porcentaje muy pequeño del CDDP está involucrado en la formación de 
aductos intercatenarios, entre las dos hebras de ADN, o monoaductos con una única guanina o 
aductos proteína-ADN, donde el CDDP se une a una proteína y a una base nitrogenada 
(Figure 2).33-38 
Aducto intercatenario           Aducto intracatenario         Aducto ADN-proteína  
Figure 2. Aductos formados por el cisplatino. 
Resumen 
145 
5. Resistencia 
 El uso clínico del CDDP se ve limitado por la resistencia que determinados tumores 
presentan a esta droga. La resistencia puede ser intrínseca de las células o adquirida como 
consecuencia de una prolongada exposición al compuesto. Algunos de los tumores presentan 
resistencia inherente al CDDP y no responden al tratamiento; otros tumores, como el de 
ovario, pueden responder inicialmente al tratamiento y, sin embargo, volverse luego 
resistentes a la droga. 
El mecanismo de resistencia al CDDP se ha estudiado extensamente y se han encontrado 
diferentes mecanismos de resistencia como: 
(i) disminución de la acumulación de platino,  
(ii) niveles elevados de proteínas como glutation o metalotionina, que pueden unirse 
al CDDP antes de que éste alcance su diana farmacológica 
(iii) aumento de la capacidad de reparación para eliminar las lesiones Pt-ADN,  
(iv) alteración de los tipos de lesiones formadas, y quizás  
(v) modificaciones en la secuencia de ADN en regiones reguladoras ricas en residuos 
de guanina. 
 
6.  Apoptosis 
 La apoptosis, o muerte celular programada, se caracteriza por la reducción del volumen 
celular, condensación de la cromatina y formación de cuerpos apoptóticos con la activación 
de una endonucleasa endógena, reconocida por células fagocíticas.39 Se considera a la 
apoptosis un mecanismo fisiológico (inherente al desarrollo celular) que se desencadena por 
diversas señales las cuales pueden ser fisiológicas, o por estimulaciones exógenas 
ambientales. Esos cambios fisiológicos sirven para determinar si la célula muere por 
apoptosis o necrosis (se produce la lisis de la célula como consecuencia de un desbalance 
osmótico). El primer cambio en las células que sufren apoptosis se observa en la membrana 
plasmática de la superficie celular. 
 
7. Objetivos de esta tesis doctoral 
 En los últimos 30 años se ha producido un gran avance en el entendimiento del 
mecanismo molecular y genético del comportamiento antitumoral del CDDP. A partir de ahí, 
surge la búsqueda de compuestos análogos al mismo, en busca de ampliar su actividad 
antitumoral frente a distintos tumores y superar sus limitaciones intrínsecas (sólo activo frente 
a determinados tumores) así como extrínsecas (derivadas de la capacidad de reparación de la 
propia célula como respuesta al daño inducido por la droga). 
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 En esta tesis doctoral, por lo tanto, se han diseñado nuevas drogas de platino con 
geometrías cis y trans con el objetivo de disminuir los efectos secundarios del CDDP. En los 
últimos años se ha abierto un área nueva de investigación relacionada con compuestos de 
geometría trans, como se ha descrito en la sección 1.8.5, no estudiados hasta hace pocos años 
debido a la inactividad del transplatino hizo pensar que los derivados de éste tampoco serían 
activos. 
 Los compuestos que se han diseñado y estudiado en esta tesis doctoral son compuestos 
asimétricos de platino con geometría trans, cuya fórmula general es trans-
[PtCl2(isopropilamina)(azol)], con el fin de encontrar nuevas drogas antitumorales dotadas 
con mejor citotoxicidad que el CDDP y menos efectos secundarios.  Estos nuevos compuestos 
de geometría trans sortean la resistencia al CDDP. Así mismo, se describe un estudio 
comparativo con sus análogos cis, estudiando sus propiedades antitumorales así como su 
interacción con bases nitrogenadas del ADN. 
 
8. Resumen de los diferentes capítulos 
 En el Capítulo 2, titulado “Nuevos compuestos cis-[PtCl2(isopropilamina)(amina’)]: 
Comparación con sus isómeros trans de la actividad citotóxica y reacción con GMP”,25 se 
presenta la síntesis, caracterización, interacción con GMP y citotoxicidad de nuevos 
compuestos cis-Pt(II) así como la comparación con sus isómeros trans. Amina’ representa 
distintas aminas alifáticas, tal como dimetilamina, metilamina, propilamina y butilamina. 
Estos compuestos con geometría cis (Figure 2.2, pág. 47) fueron inicialmente sintetizados 
para proporcionar drogas antitumorales con mejor actividad antitumoral que sus isómeros 
trans, los cuales ya mostraban una mejorada citotoxicidad en comparación con el CDDP, en 
varias líneas de células cancerígenas, sensibles (CH1 y Pam212) y resistentes (CH1cisR, 
Pam212ras) al CDDP. Se estudió la interacción de ambas series de isómeros con bases 
nitrogenadas del ADN, para un mejor entendimiento de las diferentes formas de unión con el 
ADN que presentan los distintos compuestos con geometría cis y trans. La base nitrogenada 
estudiada fue la guanosina 5’-monofosfato (GMP). La interacción con GMP no muestra 
grandes diferencias cuando comparamos compuestos cis y trans de Pt(II). Se observó el 
mismo comportamiento para ambas series de isómeros, produciéndose la formación de 
bisaductos en 24 hr, es decir, ambos grupos de compuestos se comportan como especies 
bifuncionales, uniéndose dos moléculas de GMP al platino.  
 Los resultados de citotoxicidad obtenidos muestran que los compuestos con geometría cis 
son menos citotóxicos que sus análogos trans y que el CDDP. Solamente uno de los 
compuestos cis, cuando amina’ es butilamina mostró actividad antitumoral en el rango del 
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CDDP, en una de líneas celulares estudiadas; sin embargo, esa actividad es 2.9 veces más que 
pequeña que la del CDDP. Por lo tanto, se probó que los compuestos con geometría trans 
presentaban mayor citotoxicidad que sus análogos cis, violando las reglas que relacionan la 
estructura y la actividad, lo cuál es una importante característica para el desarrollo de nuevas 
drogas antitumorales. 
 En los Capítulos 3 y 4, titulados respectivamente “Nuevos compuestos asimétricos trans 
de Pt(II) que superan la resistencia al cisplatino” y “Comparación de la actividad tumoral e 
interacción con bases nitrógenadas del ADN de los compuestos cis-
[PtCl2(isopropilamina)(azol)] con sus análogos trans”,40,41 se muestra la síntesis, 
caracterización, estructuras cristalográficas, citotoxicidad e interacción con GMP de 
compuestos asimétricos de platino cis y trans con ligandos planos. Azol representa a dichos 
ligandos planos que pueden ser pirazol (Hpz), 1-metilimidazol (Meim) y 1-metilpirazol 
(Mepz). En las Figure 3.1 (pág. 59) y Figure 4.1 (pág. 82) se representan las fórmulas 
estructurales de los compuestos trans y cis, respectivamente. Todos los compuestos trans 
cristalizan en el sistema monoclínico, con distancias de enlace Pt—N(azol) ligeramente más 
cortas que las distancias de enlace Pt—N(iPram). Además, se observaron dos orientaciones 
distintas para el ligando iPram en los compuestos tMeim y tMepz, y en el caso del 
compuesto se observaron dos moléculas independientes en la unidad asimétrica. El compuesto 
cis, cMeim, cristaliza en el sistema ortorrómbico, con una sola molécula en la unidad 
asimétrica a diferencia de su isómero trans, que presenta dos. Se encontró el mismo efecto en 
las distancias de enlace      Pt—N(azol) e iPram. En los cuatros compuestos, tHpz, tMeim, 
tMepz y cMeim, las distancias de enlace Pt—Cl se encontraron en el rango esperado para 
compuestos trans-, cis-dicloroplatinato(II). 
 De cada uno de los compuestos se estudió la interacción con GMP. Los resultados indican 
que todos los compuestos muestran un comportamiento bifuncional en su interacción con la 
GMP, es decir, dos moléculas de GMP se unen al platino. Todos los compuestos con 
geometría trans reaccionan a la misma velocidad con GMP, y en el caso de los compuestos 
tHpz y tMepz, también se observaron las especies intermedias hidrolizadas, siguiendo el 
mismo mecanismo de reacción que el cisplatino; sin embargo, el compuesto tMeim no mostró 
dichas especies en el transcurso de su reacción, siguiendo un mecanismo de sustitución 
directa de los ligandos cloro por GMP. Para los compuestos tMeim y cMeim, el estudio 
cinético de su reacción con GMP muestra que la sustitución de los ligandos Cl- por GMP tiene 
lugar de forma directa. Es interesante resaltar que para el compuesto cMeim, los monoaductos 
(sólo una  molécula de GMP está unida al platino) prácticamente no son detectados, siendo el 
paso a bisaducto muy rápido. 
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 Los resultados de citotoxicidad mostraron que los compuestos con geometría trans 
poseían una citotoxicidad mayor que la de sus análogos cis en varias líneas de células 
tumorales humanas (sensibles (WIDR, M19, A498, IGROV, H226, EVSA-T, MCF7 y 
A2780), y resistentes (A2780R) al CDDP). Se encontró relación entre la estructura y 
actividad de ambos grupos de compuestos. Así, se comprobó que el compuesto trans con 
mayor actividad, no sólo en líneas celulares sensibles al CDDP sino también en la línea 
celular resistente al mismo, fue el que poseía Hpz en su estructura, seguido del compuesto con 
Meim. En el caso del compuesto trans con Mepz se encontró que aún estando en el rango 
activo del CDDP, no poseía marcada citotoxicidad en ninguna de las líneas celulares 
estudiadas. Los compuestos con geometría cis mostraban menor citotoxicidad que los 
compuestos trans en todas las líneas celulares, sólo el compuesto cis con 1-metilimidazol, 
cMeim, vencía la resistencia al cisplatino. El compuesto cMepz, con 1-metilpirazol, aunque 
con un factor de resistencia (FR) menor que el cisplatino, sin embargo, no se consideró que 
vencía la resistencia al cisplatino ya que se requiere un valor FR menor de 2 para poseer tal 
propiedad.42 Pero también exhibían el mismo comportamiento según el ligando azol utilizado. 
Por lo tanto, el resultado más importante obtenido de este estudio de citotoxicidad fue que los 
tres compuestos presentados con geometría trans vencen la resistencia al cisplatino, mientras 
que sólo uno de los compuestos con geometría cis, cMeim, muestran el mismo efecto en los 
ensayos realizados. Ésto supone un gran avance en la dura tarea de diseñar y encontrar 
compuestos antitumorales dotados con mejores propiedades que el CDDP no solo con 
geometría cis sino también trans.  
 Para un mejor entendimiento en la diferencia de citotoxicidad de ambos grupos de 
isómeros cis y trans, en el Capítulo 5, titulado “Estudios de unión al ADN de compuestos 
asimétricos trans de platino(II)” se muestra el estudio de la interacción con ADN de los 
compuestos trans, descritos en el capítulo 3. Para dicho estudio se utilizaron diferentes 
técnicas bioquímicas y biofísicas como electroforesis, polarografía de pulso diferencial, 
espectroscopía visible, espectroscopía de fluorescencia y dicroísmo circular. Los 
experimentos llevados a cabo para dicho estudio fueron: desenrollamiento inducido por los 
compuestos en un plásmido de ADN, la cantidad de aductos intercatenarios y la cantidad de 
monoaductos. Se encontró que solamente el compuesto tHpz inducía un ángulo de 
desenrollamiento similar al del CDDP, siendo coincidente con ser el compuesto más activo, 
mientras que los compuestos tMeim y tMepz  inducían un ángulo de desenrollamiento mayor 
que el del CDDP, transplatino o [PtCl(dien)]Cl. Estos valores están de acuerdo con la 
presencia de ligandos planos en la estructura de los compuestos ya que pueden intercalar con 
el ADN, produciendo, por lo tanto, un desenrollamiento mayor que el CDDP o transplatino.   
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 Se encontró que la cantidad de aductos intercatenarios formados por los compuestos 
tMeim y tMepz era similar a la cantidad formada por el CDDP, mientras que la del 
compuesto tHpz era similar a la del transplatino. Los resultados obtenidos en el experimento 
con tiuorea muestran que los compuestos asimétricos con geometría trans de Pt(II) forman 
aductos resistentes al tratamiento con la misma a tiempos de incubación cortos. Por lo tanto, 
es razonable pensar que estos compuestos trans de Pt(II) forman lesiones bifuncionales o 
monofuncionales diferentes de aquellas formadas por el transplatino. Con los experimentos 
realizados con tiourea y bromuro de etidio se probó que estos compuestos forman 
monoaductos relativamente estables. Estos resultados son un importante avance desde el 
punto de vista biológico, para una mejor comprensión en la mejorada actividad antitumoral 
que estos compuestos muestran. 
 El Capítulo 6 titulado “Aplicaciones de compuestos de platino en el transporte específico 
de drogas antitumorales” da un nuevo enfoque a especies de platino, siendo éstas utilizadas 
como punto de unión entre una determinada droga y un transportador. Se introduce una 
novedosa área de investigación, donde se produce el reparto directo de drogas en el órgano 
que desarrolla el tumor. Ésto implica un avance importante en el tratamiento de ciertos 
tumores, ya que se vencen los problemas de toxicidad que muestran la mayoría de las drogas 
utilizadas en quimioterapia, la resistencia adquirida por diferentes tumores, y se hace viable el 
tratamiento de ciertas enfermedades que hasta ahora no tienen ninguna terapia eficaz, como es 
la fibrosis del hígado. Así, se sintetizan y caracterizan compuestos de platino que contiene 
pentoxifilina. La pentoxifilina es una droga antiinflamatoria que bloquea la activación de las 
células estrelladas del hígado, una de las causas responsables de la fibrosis del hígado. Como 
transportador específico se utiliza albúmina de suero normal humano modificada con la 
manosa 6-fosfato (M6-HSA). Este transportador es utilizado porque tiene receptores 
específicos en el hígado, haciendo posible un transporte específico de la pentoxifilina al 
hígado. Los nuevos sistemas de platino diseñados y sintetizados tienen unidos en posición 
trans a la pentoxifilina y un linker al cuál se le unirá más tarde la M6-HSA. El uso de platino 
es debido a la fortaleza media de enlace platino-ptx, de manera que se liberará una vez llega al 
órgano diana. Por lo tanto, los compuestos de platino se sintetizan no como drogas 
antitumorales sino como sistemas que reparten drogas directamente en el órgano que tiene el 
tumor. En sistemas parecidos, cis-ULS®, se han realizado estudios (todavía no publicados) 
para determinar si esos sistemas eran tóxicos, ya que se sabe que las especies de platino 
muestran cierta toxicidad (El cisplatino se utilizó como control positivo). Los resultados 
mostraron que el cisplatino mataba mas células que los sistemas cis-ULS o cis-ULS-
transportador. Estudios similares se llevarán a cabo para los sistemas trans-ULS, para probar 
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que los sistemas de platino después de la liberación de la droga no ejercen ningún efecto en el 
proceso de matar a las células diana, dando lugar a la muerte de la célula. 
 
9. Discusión general y planes futuros 
 Esta tesis doctoral está enfocada en el estudio de las propiedades biológicas de nuevos 
compuestos asimétricos cis y trans de Pt(II). Se han utilizado dos métodos diferentes de 
síntesis para obtener compuestos con distintas geometrías cis y trans (Capítulos 2, 3 y 4). En 
todos los casos se mantiene el ligando isopropilamina mientras que el otro ligando puede ser o 
una amina alifática o bien un ligando plano (azol). Estos cambios en la estructura de los 
compuestos se llevaron a cabo para encontrar una mejor relación entre la estructura y la 
actividad que presentan los compuestos de platino. 
El interés por el estudio del comportamiento de los compuestos de platino con geometría 
trans reside en los recientes descubrimientos sobre compuestos de dicha geometría, ya que no 
sólo se ha encontrado que poseen propiedades antitumorales similares a las de sus análogos 
cis, sino que vencen la resistencia al cisplatino en la mayoría de los tumores. Farrell y 
colaboradores han publicado un número de compuestos trans de platino con ligandos planos 
que muestran propiedades antitumorales mejores que las de sus análogos cis, y el cisplatino. 
Estos ligandos hacen que los compuestos presenten una reducida reactividad con moléculas 
que contienen azufre, la cuál parece jugar un papel importante en el mecanismo de resistencia 
de los compuestos de platino. Esta propiedad parece ser una característica general en 
compuestos con fórmula trans-[PtCl2(L)(L’)] ((1) L = L’ = piridina o tiazol, (2) L = quinolina, 
L’ = R’R’’SO, R’ = Me, R’’ = Me, CH2Ph, Ph, (3) L = quinolina, L’ = NH3).43 También se 
encontró que la presencia de ligandos amina que presentan impedimento estérico en la 
estructura de los compuestos trans, tiene un marcado efecto en la actividad biológica de estos 
compuestos. Los compuestos de platino con este tipo de ligandos también muestran una 
menor reactividad hacia moléculas que contienen ligandos azufre, como consecuencia del 
efecto estérico de los ligandos.17,44,45 En el caso de los compuestos cis de platino los grupos 
amino no salientes son sustituidos por ligandos con azufre, dando lugar a especies 
poliméricas. Sin embargo, esta sustitución no se observa en el caso de compuestos trans de 
platino con ligandos planos y ligandos que presentan impedimento estérico. Además, los 
monoaductos formados por el transplatino tienen un tiempo de vida medio más largo que 
aquellos formados por el cisplatino, pudiendo reaccionar con ligandos que contienen azufre e 
inhibiendo la formación de aductos bicatenarios.46  Cómo se ve afectada la evolución a la 
formación de aductos bicatenarios por ligandos planos que presentan impedimento estérico no 
se comprende completamente, y sigue todavía bajo estudio. Por lo tanto, en esta investigación 
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ligandos planos y ligandos con impedimento estérico han sido combinados para la búsqueda 
de nuevos compuestos trans de platino con mejores propiedades antitumorales y menos 
efectos secundarios que el cisplatino u otras drogas conocidas hasta ahora. Sin embargo, el 
uso de otros ligandos planos con mayor impedimento estérico que los estudiados en esta tesis 
doctoral y ligandos con grupos hidroxilo, OH, para mejorar la solubilidad de los compuestos 
en agua, podrían establecer una relación más clara entre la estructura y la actividad de los 
compuestos de platino con geometría trans, además de mejorar la actividad biológica de los 
mismos. 
 La nueva clase de compuestos asimétricos trans de platino introducidos en esta tesis 
son candidatos potenciales a nuevas drogas antitumorales. Especialmente los compuestos con 
ligandos azoles, los cuales muestran una marcada citotoxicidad en varias líneas celulares de 
tumores humanos y, más importante, que vencen la resistencia al cisplatino. Este resultado es 
importante, ya que la línea resistente al cisplatino utilizada, muestra los cuatro principales 
mecanismos de resistencia al cisplatino ((1) disminución de la acumulación de platino, (2) 
aumento en la capacidad de reparación del ADN, (3) aumento en el daño de ADN y alteración 
en los tipos de lesiones formadas y (4) elevados niveles de glutationa o metalotionina).47,48 La 
presencia de ligandos planos en compuestos trans de platino parece que da lugar a un 
aumento de la acumulación de los compuestos en la célula, mientras que ligandos con 
impedimento estérico dificultan la reacción de los compuestos de platino con moléculas que 
contienen azufre.21 Sin embargo, sería interesante estudiar la citotoxicidad de estos 
compuestos en otras líneas de células tumorales resistentes al cisplatino que muestren un 
único mecanismo de resistencia para así poder establecer cual de ellos es el responsable de 
que los compuestos asimétricos trans de platino, mostrados en esta tesis, venzan la resistencia 
al cisplatino. 
 Todos estos compuestos trans de platino, aunque derivados del transplatino, parece 
que inicialmente forman monoaductos con el ADN, los cuales son estructuralmente diferentes 
a aquellos formados por el cisplatino, transplatino y [PtCl(dien)]Cl. Esta conclusión deriva del 
hecho de que las lesiones monofuncionales formadas por los compuestos asimétricos trans 
son resistentes al tratamiento con tiourea. Por lo tanto, la importancia del estudio de 
compuestos de platino con geometría trans se muestra de nuevo, ya que sólo uno de los 
análogos cis, cMeim, vence la resistencia al cisplatino. Sin embargo, ambos compuestos cis 
presentan valores de IC50 más bajos que sus trans análogos en la línea celular resistente al 
cisplatino, A2780R. 
 Llegados a este punto, es de crucial importancia estudiar si la formación de esos 
monoaductos es la responsable de la facilidad que estos compuestos trans presentan para  
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vencer la resistencia al cisplatino. Cuando los compuestos de platino se unen al ADN, tienen 
lugar cambios conformacionales. Estos cambios podrían ser esenciales para ser reconocidos 
por los mecanismos de reparación del ADN. En el caso del cisplatino se produce un fuerte 
cambio conformacional en la doble hélice del ADN. Este cambio es reconocido por las 
proteínas HMG que probablemente protegen la lesión de los mecanismos de reparación.49 En 
el caso del transplatino, la doblez producida en la estructura del ADN no es lo suficientemente 
grande y por lo tanto las proteínas HMG no reconocen el daño. Resumiendo, si un compuesto 
de platino, el cuál se une al ADN, no produce cambios conformacionales suficientemente 
grandes, pueden escapar a la reparación. Dos de los compuestos asimétricos trans de platino 
estudiados, tMeim y tMepz, muestran un ángulo de desenrollamiento de gran magnitud, 19º 
y 20º, respectivamente; esto se traduce en un efecto de intercalación/enlace monofuncional 
covalente, observado también en la unión de isómeros del catión [PtCl(NH3)2(EtBr)]+ (EtBr= 
bromuro de etidio).43,50 Sin embargo, no se ha probado todavía si esas lesiones son las 
responsables del efecto citotóxico de los compuestos estudiados. En los compuestos trans de 
platino presentados en esta tesis, la presencia de ligandos planos en la estructura podría dar 
lugar a un efecto de intercalación en la doble hélice del ADN, dando lugar a un cambio 
conformacional pequeño y por lo tanto no siendo reconocidos por los mecanismos de 
reparación del ADN. 
 No sólo el tipo de aducto formado, Pt-ADN, es importante para obtener información 
sobre la actividad antitumoral de los compuestos, también los efectos cinéticos deben tenerse 
en cuenta. En el estudio de la interacción con GMP, todos los compuestos estudiados 
muestran una cinética rápida. Sin embargo,  no se puede establecer una relación clara entre la 
cinética de reacción y la citotoxicidad que los compuestos presentan. El estudio cinético 
cualitativo, realizado por RMN, nos muestra que el compuesto tMepz es el más lento de 
todos en su interacción con GMP y además coincide con el hecho de que es el compuesto que 
menos reacciona con el ADN (37 %). Un estudio cinético más detallado nos ayudaría a 
realizar una mejor relación entre la actividad antitumoral y la capacidad de los compuestos 
para vencer la resistencia al cisplatino. 
 La formación de monoaductos por los compuestos asimétricos trans de platino, los 
cuales son resistentes al tratamiento con tiourea, nos lleva a pensar que estas lesiones son 
estructuralmente diferentes a aquellas formadas por el cisplatino o transplatino. Estos cambios 
estructurales podrían ser los responsables tanto de la buena actividad antitumoral como de la 
habilidad para vencer la resistencia al cisplatino. Sin embargo, se podría realizar un estudio 
más profundo de la estructura de estas lesiones, para mejorar el entendimiento de las 
características que los muestran compuestos. Para ello, el estudio de la interacción de estos 
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compuestos con ligandos que contienen azufre podría ser relevante. Si se obtuviesen 
resultados interesantes en estos estudios, sería interesante estudiar la toxicidad de estos 
compuestos en células sanas. Además, si su toxicidad es menor o en el mismo rango que la 
que presenta el cisplatino, experimentos in vivo podrían ser planeados para estos compuestos 
asimétricos trans de platino. 
 En esta tesis doctoral se ha mostrado que los compuestos asimétricos cis de platino 
muestran una citotoxicidad menor que la de sus análogos trans y que solo uno de los 
compuestos cis, cMeim, vence la resistencia al cisplatino. El estudio de la interacción de 
dichos compuestos con ADN celular y el estudio del tipo de aductos que forman estos 
compuestos, estructuralmente análogos entre ellos y con el cisplatino, podría ayudar a 
entender porqué sólo el compuesto cMeim vence la resistencia la cisplatino, mientras que el 
compuesto cMepz y cisplatino no muestran el mismo efecto. 
 El estudio realizado con estos nuevos compuestos asimétricos cis y trans de platino(II) 
prueba, una vez más, que las reglas que relacionan la estructura y la actividad de los 
compuestos son violadas, por el descubrimiento de un nuevo número de compuestos con 
geometría trans dotados con mejores propiedades antitumorales que el cisplatino u otros 
compuestos de platino con geometría cis. Por lo tanto, con el estudio presentado en esta tesis 
doctoral, las reglas estructura actividad pueden actualizarse: 
i) Compuestos con geometría trans muestran mayor actividad antitumoral que sus 
análogos cis y que el cisplatino, dependiendo de los ligando utilizados (ver más abajo). 
ii) Normalmente los compuesto trans de platino superan la resistencia al cisplatino, 
mientras que el mismo efecto no se observa en los análogos cis.  
iii) Compuestos con geometría trans que contienen ligandos azol (planos) muestran una 
mejor citotoxicidad, especialmente cuando al lado del átomo dador del ligando azol hay 
una fuente de formación de enlaces de hidrógeno. Este es el caso del compuesto tHpz, 
el cuál se encontró que era el más activo de todos los compuestos estudiados. Sin 
embargo, cuando al lado del átomo dador hay un grupo que presenta impedimento 
estérico, la citotoxicidad se ve reducida, como se observa en el compuesto tMepz. Para 
los compuestos con geometría cis se observa el mismo comportamiento. 
iv) Se observa un aumento en la actividad antitumoral cuando en el diseño de drogas 
antitumorales de platino(II) se combinan aminas alifáticas y ligandos azol. Ésto podría 
ser debido a que la amina alifática presenta la unidad NH necesaria para la formación de 
enlaces de hidrógeno con el O6 de la guanosina, dando lugar a la formación de aductos 
Pt-ADN más estables; mientras que los ligandos azol podría intercalar con la doble 
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hélice del ADN. La combinación de ambos efectos parece aumentar la citotoxicidad de 
los compuestos de platino. 
 Utilizando la experiencia sobre los compuestos de platino, en un proyecto paralelo, se 
sintetizaron compuestos de platino como sistemas que depositan drogas de forma directa en el 
órgano a tratar. Estos sistemas unen una droga y un transportador. De esta forma, una droga 
se transporta de forma específica en el tejido diana y no es distribuida  por todo el cuerpo 
como ocurre con los agentes antitumorales sistémicos. Aunque el estudio hasta ahora es 
preliminar, la búsqueda de nuevas condiciones sintéticas para obtener sistemas más puros y 
con mayor rendimiento puede ser llevada a cabo. Otros estudios, por ejemplo, con células 
estrelladas del hígado son requeridos para encontrar aplicaciones de estos nuevos sistemas de 
platino. El desafío de estos experimentos será ver como la droga, unida al platino 
pentoxifilina, en nuestro caso se libera de forma selectiva en el hígado, para parar el proceso 
de fibrosis en este órgano. 
 Finalmente, no se han obtenido todavía relación entre experimentos in vitro e in vivo 
en la mayoría de los compuestos estudiados. Hay pocas drogas antitumorales que muestren el 
mismo espectro de actividad in vitro e in vivo, lo que hace más difícil la búsqueda de nuevas 
drogas. Sin embargo, con las propiedades potenciales que muestran los compuestos 
asimétricos trans de platino presentados en esta tesis, una evaluación de su actividad in vivo 
podría ser de alto interés. 
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